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Abstract 
 
The aim of the present study was twofold: pharmacologically characterize novel ligands and set-
up and validate novel in vitro assays for nociceptin/orphanin FQ (N/OFQ) peptide (NOP) and 
classical opioid receptors. NOP and opioid receptors are 7TM receptors coupled with inhibitory 
G proteins; receptor activation leads to the inhibition of cAMP formation and calcium currents, 
and opening of potassium channels. Via these cellular inhibitory mechanisms, the N/OFQ – NOP 
receptor and classical opioid systems regulate a variety of biological functions both in the central 
nervous system and in the periphery.  
The calcium mobilization assay has been and still is broadly used as primary screening for novel 
molecules in academic and industrial in vitro pharmacology laboratories. The use of chimeric G 
proteins allows to extend the calcium mobilization assay to virtually all types of G protein 
coupled receptors. This approach was  previously used in our laboratories for characterizing NOP 
receptor ligands. In the frame of the present study, the calcium mobilization assay has been 
extended and validated for classical opioid receptors using a panel of standard opioid receptor 
agonists and antagonist. This test was used for investigating the pharmacological profile of novel 
opioid ligands including a series of morphine and oxymorphone analogues and novel cyclic 
endomorphin-2 derivatives. Calcium mobilization studies together with classical in vitro assays 
such as receptor binding, [
35S]GTPγS binding and bioassays with isolated organs were applied to 
novel NOP receptor ligands including i) 3 different series of spiroxatrine derivatives; ii) the 
antagonist NiK-21273; iii) [X
5
]N/OFQ(1-13)-NH2 derivatives; iv) three tetrabranched derivatives 
of N/OFQ generated with an innovative chemical approach named peptide welding technology.  
Recent data demonstrated that biased agonists, i.e. receptor ligands able to select which signaling 
pathways become activated upon binding to the receptor, may display advantages over unbiased 
ligands. In particular, in the field of opioids, G-protein (vs arrestin)  biased agonists for the mu 
receptor displayed an increased therapeutic index associated to reduced tolerance liability. No 
data are yet available about biased agonism in the NOP receptor field. Therefore a novel 
bioluminescence resonance energy transfer (BRET) based assay was set-up for the NOP receptor. 
This method that allows to study both NOP/G-protein and NOP/β-arrestin interactions has been 
validated using a large panel of NOP ligands encompassing full and partial agonist as well as 
antagonist activity. The comparison of data achieved investigating NOP/G-protein and NOP/β-
arrestin interaction allowed us to perform the very first study of biased agonism in the NOP 
receptor field.  
In summary the studies performed in the frame of my PhD project extend our knowledge on the 
pharmacological profile of NOP and classical opioid receptors, provided to the scientific 
community novel compounds, pharmacologically characterized in detail, to be used as research 
tools and possibly as drug prototypes, and made available novel pharmacological assays useful 
for selecting fully innovative drugs such NOP receptor biased agonists.  
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1. Introduction 
 
 
1.1 G-protein coupled receptors 
 
G protein-coupled receptors (GPCRs) are the largest and most diverse group of membrane 
receptors in eukaryotes. GPCRs recognize a wide number of different extracellular stimuli, 
including photons, ions, small molecules, peptides and proteins, and transmit the resulting 
extracellular signals to elicit intracellular responses. With their common architecture of seven 
transmembrane (7TM) helices (Figure 1), GPCRs represent the largest protein family in the 
human proteome (> 800 human GPCRs). These receptors can be classified into major classes (i.e. 
secretin, adhesion, glutamate, frizzled/taste2, rhodopsin, and other 7TM receptors families) and 
further divided into subfamilies based on sequence similarities (e.g. opioid receptors belong to 
the SOG cluster of γ-group/rhodopsin family of GPCRs, (Fredriksson et al., 2003)). Signal 
transmission occurs through the interaction between receptors and different intracellular proteins 
(e.g., heterotrimeric G-proteins, kinases, and arrestins (Rajagopal et al., 2010)), which then 
activate downstream effectors and trigger cascades of cellular and physiological responses. 
GPCRs signaling have been related to numerous diseases, and these receptors are targeted by 30-
40% of all drugs currently available (Wise et al., 2002). Consequently, understanding the 
pharmacology of these receptors is of two-fold interest, for the basic science community 
interested to uncover the processes regulated by these receptors and their details at a molecular 
level, and for the applied science community devoted to discover more efficacious and better 
tolerated drugs.  
 
Introduction 
2 
 
 
Figure 1. General architecture and modularity of GPCRs. N-terminal extracellular domains (top side), C-
terminal intracellular domains (bottom side). Image taken from (Katritch et al., 2012) 
 
 
Structural data, ranging from NMR to X-ray 3D structures of active and inactive GPCRs, and site 
by site mutation analysis of GPCRs sequence/function, are now abundantly available; however 
the mechanisms by which drugs that bind GPCRs are able to evoke their effect through these 
receptors have not yet fully understood. It is possible to generalize the modes of GPCR activation 
processes in two models. In the classical model for GPCR activity, agonist binding to the GPCR 
causes the receptor to adopt a conformation that results in the activation of associated 
heterotrimeric G proteins. This activation involves the exchange of bound guanosine diphosphate 
(GDP) for guanosine-5'-triphosphate (GTP) by the Gα subunit of the G protein, leading to 
dissociation of the heterotrimeric protein complex into Gα and Gβγ subunits. This dissociation 
then promotes the production of and consequent signalling by second messenger systems, such as 
those involving cyclic AMP, diacylglycerol and calcium. Signalling by the activated 
conformation of the GPCR is terminated by phosphorylation of the cytoplasmic loops and tail of 
the GPCR, which is catalyzed predominantly by GPCR kinases (GRKs). This results in the 
binding of arrestins (i.e. β-arrestin 1 and 2) and consequent desensitization followed by 
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internalization into clathrin-coated pits (Lefkowitz & Shenoy, 2005). Thus, in the classical 
model, heterotrimeric G proteins mediate signal transduction and β-arrestins mediate receptor 
desensitization and internalization. Despite this simplification is widely accepted, it is now 
known that β-arrestins act not only as regulators of GPCR desensitization, but also as adaptor 
proteins that carry the GPCR signaling through multiple mediators such as mitogen-activated 
protein kinases, proto-oncogene tyrosine-protein kinase SRC, nuclear factor-κB and 
phosphoinositide 3-kinase. Moreover, biochemical data suggest that the signaling mediated by β-
arrestins has distinct functional and physiological consequences from that mediated by G proteins 
(Lefkowitz & Shenoy, 2005; Rajagopal et al., 2010) (Figure 2). 
 
 
Figure 2. Signal transduction by seven transmembrane receptors. (A) Classical paradigm. The active form of 
the receptor (R*) stimulates heterotrimeric G proteins and is rapidly phosphorylated by G protein–coupled 
receptor kinases (GRKs), which leads to β-arrestin recruitment. The receptor is thereby desensitized, and the 
signaling is stalled. (B) New paradigm. β-arrestins not only mediate desensitization of G protein–signaling but 
also act as signal transducers themselves. Image taken from (Lefkowitz & Shenoy, 2005). 
 
 
The biological role of arrestins within the classical opioid receptor field was demonstrated in vivo 
using mice lacking the β-arrestin 2 gene that displayed a remarkable potentiation and 
prolongation of the analgesic effect of morphine (Bohn et al., 1999) and reduced tolerance 
liability (Bohn et al., 2002) compared to their wild type littermates. It is also known that some 
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GPCR ligands may act as biased agonists i.e. ligands able to bind a single receptor and 
differentially activate some of its pathways over others, for example G-protein over arrestin or 
vice versa. Based on these findings it has been proposed that opioid receptor biased agonists able 
to promote receptor/G-protein better than receptor/arrestin interaction may display in vivo higher 
efficacy and/or better tolerability (Violin et al., 2014). 
 
 
1.2. N/OFQ - NOP system 
 
Nociceptin/Orphanin FQ (N/OFQ) is a neuropeptide of 17 amino-acids 
(FGGFTGARKSARKLANQ) that binds with high affinity the N/OFQ peptide (NOP) receptor 
(Meunier et al., 1995; Reinscheid et al., 1996). N/OFQ is cleaved from a peptide precursor 
preproN/OFQ (ppN/OFQ). This precursor is composed by 176 amino acids in humans, 181 in rats, 
and 187 in mice, sharing an high degree of conservation. Moreover, the ppN/OFQ gene both in term 
of structural similarity and of organizational characteristics resembles those of the opioid peptide 
precursors, in particular preproenkephalin and preprodynorphin, suggesting a common ancestor for 
these peptide precursors (Mollereau et al., 1996). It is worth mentioning that N/OFQ is the first 
ligand that was discovered by reversed pharmacology. Before molecular biology techniques 
became common, firstly, ligands had been discovered and, then, their receptors found by classical 
pharmacology approaches. Nowadays, most GPCRs are identified on the basis of their DNA 
sequences and thus are initially unmatched to known natural ligands and classified as orphan 
GPCRs. For discovering the endogenous ligand of NOP receptor, the orphan receptor was cloned 
by homology cloning and transfected in mammalian cells; tissue extracts were prepared from the 
brain, purified, and fractionated following a number of rounds of fractionation. The extracts were 
then subsequently tested for their ability to modify cAMP levels in cells expressing the NOP 
receptor, N/OFQ was then isolated and characterized (Meunier et al., 1995; Reinscheid et al., 
1996). 
NOP is a G-protein coupled receptor (GPCR) whose activation leads to the inhibition of both 
cAMP levels and calcium channels, and to the stimulation of potassium currents; these cellular 
effects are due to the activation of pertussis toxin (PTX)-sensitive G-proteins (Gi/o) (Lambert, 
2008). Like many other GPCRs it is known that the NOP receptor may interact (and signal) not 
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only with G-proteins but also with other proteins, such as GRKs and arrestins (Soergel et al., 
2014).  
NOP receptor shares high degree of structural similarities with opioid receptors. Furthermore, 
N/OFQ sequence is similar to that of dynorphin A, an endogenous opioid peptide. Despite such 
similarities, N/OFQ does not bind opioid receptors and NOP does not interact with opioid 
neuropeptides. Thus, the NOP receptor was defined as opioid-related rather than opioid 
(Alexander et al., 2013). Recently, the crystal structure of the human NOP receptor was solved in 
complex with the antagonist compound-24 (C-24) (Thompson et al., 2012) revealing some 
substantial differences in the binding pockets of NOP and classical opioid receptors (Filizola & 
Devi, 2013; Thompson et al., 2012) (Figure 3).  
 
 
Figure 3. Overlay of the crystallized opioid ligands in a representative opioid receptor crystal structure along 
with schema of their interaction modes in each crystal structure. The central panel shows an overlay of β-
funaltrexamine (red), naltrindole (cyan), JDTic (magenta), and compound 24 (green) in the MOP receptor 
crystal structure, which is partially shown in a grey cartoon representation. Interaction schema for β-
funaltrexamine, naltrindole, JDTic, and compound 24 in the mu opioid (MOP), delta opioid (DOP), kappa 
opioid (KOP), and NOP receptor crystal structures are shown in the left, right, upper, and lower panels, 
respectively. Identical residues in all four receptors are shown in blue. Identical resides in MOP, DOP, and 
KOP but unique to NOP are shown in cyan. Divergent residues in all four opioid receptors are shown in red. 
Divergent residues in MOP, DOP, and KOP but not NOP are shown in brown. Unique residues to either 
MOP, DOP, or KOP are shown in orange. Image taken from (Filizola & Devi, 2013). 
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The N/OFQ-NOP system has been deeply investigated by academic and industrial researchers 
leading to the discovery of a variety of selective NOP receptor ligands (Calo & Guerrini, 2013; 
Mustazza & Bastanzio, 2011). Using such compounds the role of this system in physiology and 
pathology has been, at least partially, elucidated. N/OFQ and the NOP receptor are involved in 
the regulation of different biological functions at both central and peripheral levels including 
pain, mood and anxiety, food intake, learning and memory, locomotion, cough and micturition 
reflexes, cardiovascular homeostasis, intestinal motility and immune responses (Lambert, 2008) 
(Figure 4).  
 
Figure 4. Pleiotropic effects of nociceptin/orphanin FQ (N/OFQ) on major organ systems. Potential clinical 
indications are noted in bold. Image taken from (Lambert, 2008). 
 
 
The role of N/OFQ in pain regulation has been clear since the earliest studies performed in 
rodents. The administration of N/OFQ has been shown to cause hyperalgesia, allodynia and 
analgesia. N/OFQ is able to increase pain sensitivity in mice and rats when administered 
supraspinally (Meunier et al., 1995; Reinscheid et al., 1995). Such hyperalgesic effects of N/OFQ 
was only seen after intracerebroventricular (i.c.v.), rather than after intrathecal (i.t.) 
administration. It has been demonstrated that most prominent role of N/OFQ in supraspinal pain 
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modulation is a “functional opioid antagonism” directed against many different opioid receptor 
agonists (Mogil & Pasternak, 2001). The anti-opioid role of N/OFQ has been corroborated by 
results obtained in vary assays/conditions, firstly N/OFQ counteracts the analgesic effects of 
endogenous opioids (Tian et al., 1997), of morphine (Bertorelli et al., 1999; Calo et al., 1998; 
Grisel et al., 1996; Zhu et al., 1997), and of a panel of selective opioid receptor agonists (King et 
al., 1998). These anti-opioid effects of N/OFQ are subjected to tolerance liability (Lutfy et al., 
1999). 
 
Since NOP and classical opioid receptors largely share similar transduction mechanisms, it is 
probably that their opposite effects on pain threshold are due to distinct localisations of these 
endogenous agonists and respective receptors on the neuronal networks involved in pain 
transmission at the supraspinal level. A cellular model explaining the anti-opioidergic action of 
supraspinal N/OFQ focalizes on brain stem, in particular of the nucleus raphe magnus (NRM), 
the major site of supraspinal N/OFQ effects on pain processing. In this brain region, different 
type of neurons, named ON and OFF cells, can be distinguished. ON cells firing occurs 
immediately before the nociceptive reaction, while OFF cells are inhibited by the GABA release 
due to ON cells firing. When OFF cells are activated, these cells induce a spinal antinociceptive 
effect via descending tracts. MOP opioids inhibit ON cells and thereby cause a subsequent 
disinhibition of the antinociceptive OFF cells. By contrast, N/OFQ inhibits nearly all cell types in 
the RVM. Via a direct inhibition of OFF cells, N/OFQ counteracts the disinhibitory effects of 
MOP agonists on these cells and thereby reverses opioid-induced supraspinal analgesia. The 
same mechanism may also account for the apparent hyperalgesic effect of N/OFQ, providing a 
cellular basis for the reversal of stress-induced analgesia by N/OFQ. These studies demonstrate 
that the net effects of N/OFQ on nociception at supraspinal sites strongly depend on the 
activation state (resting versus sensitized) of pain controlling neuronal circuits, see for a review 
(Zeilhofer & Calo, 2003).  
 
N/OFQ was shown to block morphine-induced place preference (Ciccocioppo et al., 2000) an 
effect that was later extended to other drugs of abuse influencing the dopaminergic 
mesocorticolimbic pathway, such as alcohol, amphetamine and cocaine (Zaveri, 2011). One 
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mechanism whereby N/OFQ attenuates reward elicited by drugs of abuse is by directly inhibiting 
NOP expressing dopaminergic mesocorticolimbic neurons (Murphy et al., 1996). 
 
The peptide N/OFQ is involved in learning and memory, being able to inhibit long-term 
potentiation in rat hippocampal slices (Yu et al., 1997). These observations received strong 
support from the observation that knockout mice for NOP receptor not only displayed greater 
learning ability and have better memory than wild type animals, but also showed increased long-
term potentiation in the hippocampal CA1 region (Manabe et al., 1998). However systematic 
studies on the possible cognitive enhancing properties of selective NOP antagonists have not yet 
been performed. 
 
NOP antagonists are able to elicit antidepressant like effects in the forced swimming test in mice 
(Redrobe et al., 2002). This finding was later confirmed and extended in other studies with other 
antagonists. Clinical studies suggest that N/OFQ levels are increased in depressed patients. 
Mechanisms of action involved in the antidepressant effects of NOP antagonists are still 
unknown. However, it has been reported that N/OFQ is able to inhibit noradrenaline and 
serotonin release from  the cerebral cortex as well as neuronal firing in the dorsal raphe and locus 
coeruleus. Assuming that chronic stress/despair conditions stimulate the release of N/OFQ, the 
peptide may reduce monoaminergic signaling acting both at presynaptic and postsynaptic sites. 
By preventing such effects of N/OFQ, NOP antagonists may restore normal levels of 
noradrenaline and serotonin at their respective synaptic clefts. Thus, NOP receptor antagonists, 
by acting at different levels and with different mechanisms, may achieve a similar endpoint to 
that of classical antidepressants, i.e., an increase in cortical synaptic concentrations of 
monoamines (Gavioli & Calo, 2013). Furthermore, N/OFQ also affects the brain response to 
stress and anxiety; indeed one of the most intensively studied actions of N/OFQ is its ability to 
counteract stress related behaviors and promote anxiolytic like effects. The mechanisms by which 
N/OFQ exerts its anxiolytic effects are not fully understood but there is evidence for the 
involvement of GABA A receptor signaling. However CRFergic and serotonergic pathways 
might be also implicated. 
 
The endogenous peptide N/OFQ has been demonstrated to inhibit the spontaneous locomotor 
activity, this effect is evident both in mice and rats, this inhibitory effect of N/OFQ is abolished 
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in the presence of NOP antagonists and NOP knock out mice. Despite these findings, the N/OFQ-
NOP receptor system does not tonically control spontaneous locomotion since NOP antagonists 
do not modify per se this behavior and knockout animals do not show phenotypes a this level. 
Worth of mention, intranigral injection of the selective NOP antagonist of peptide nature UFP-
101, dose-dependently improved rat performance in the drag and rotarod tests (Marti et al., 
2004), in addition the NOP knockout mice outperformed wild type animals in the same assays. 
These results suggest that endogenous N/OFQ may indeed exert an inhibitory influence over 
motor activity that becomes relevant during exercise. Other findings obtained in models of 
Parkinson’s disease suggest that NOP receptor blockade may represent a new strategy for treating 
hypokinetic disorders and proposed NOP receptor antagonists as drugs for treating Parkinson. 
Clinical evaluations on cerebrospinal fluids from parkinsonian patients showed 3.5 fold higher 
levels of N/OFQ compared to that of healthy subjects. 
 
N/OFQ-NOP receptor system is also involved in food intake control, in fact it has been shown 
that supraspinal N/OFQ (1–10 nmol) administration increases food intake in satiated rats. This 
effect is mimicked by a variety of NOP synthetic agonists. Moreover the involvement of the NOP 
receptor in this action has been confirmed in receptor antagonists and knockout studies. 
 
The value of the N/OFQ-NOP receptor system as target for the development of innovative drugs 
has been demonstrated in several studies, for instance NOP receptor agonists might be used as 
novel  analgesics particularly for neuropathic pain, as anxiolytic agents, as novel agents to treat 
drug dependence, and for the treatment of cough and urinary incontinence. On the other hand, 
NOP receptor antagonists can be worthy of development for treating, major depression and 
Parkinson’s disease and possibly some inflammatory diseases (Lambert, 2008). 
 
 
1.3. Classical opioid receptor system 
 
The history of classical opioid receptors is longer than that of the NOP receptor. Beckett and 
Casy in 1954 proposed the existence of receptors for opiate drugs (Beckett & Casy, 1954) based 
on their studies of structure activity relationships for antinociceptive activity in a series of 
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synthetic opiates. These receptors are called opioid since the discovery of endogenous peptides 
with effects similar to those of opiate drugs. Portoghese and colleagues (1965) through structure 
activity relationship studies, proposed that more than one opioid receptor type or that multiple 
modes of interaction of ligands with opioid receptors were possible. Endogenous opioid systems 
play a critical role in modulating a large number of sensory, motivational, emotional, and 
cognitive functions. As inhibitory neuropeptide transmitters, they fine-tune neurotransmission 
across a wide range of neuronal circuits, setting thresholds or upper limits. Earliest direct 
demonstrations of opioid receptors binding sites were obtained by receptor binding studies with 
radiolabelled naloxone and etorphine molecules (Pert & Snyder, 1973; Simon et al., 1973; 
Terenius, 1973). The first definitive evidence that these receptors did not form a homogeneous 
population was presented in 1976 (Martin et al., 1976). The proposed receptor forms were named 
after the prototypic drugs used in these studies, i.e. the mu, for morphine receptor and the kappa, 
for ketocyclazocine receptor. Pharmacological analysis of opioid peptide effects in guinea-pig 
ileum and mouse vas deferens led to the discovery of a third opioid receptor named the delta, for 
deferens receptor (Lord et al., 1977). The three opioid receptors, MOP, DOP, and KOP have been 
cloned and the recombinant receptors shown to have binding and functional characteristics 
consistent with their endogenous counterparts (Evans et al., 1992; Kieffer, 1995; Kieffer et al., 
1992; Satoh & Minami, 1995).  
 
As far as endogenous opioid peptides are concerned, three families of opioid peptides have been 
identified: enkephalins, endorphins, and dynorphins. Each family derives from a distinct 
precursor protein, prepro-opiomelanocortin (POMC), prepro-enkephalin, and prepro-dynorphin, 
respectively. These precursors are encoded by distinct genes and are subjected to complex 
cleavages and posttranslational modifications resulting in the synthesis of multiple active 
peptides. The opioid peptides share a common amino terminal sequence of Tyr-Gly-Gly-Phe 
(followed by Leu or Met), the opioid message domain. This motif is followed by carboxy 
terminal extensions yielding peptides ranging from 5 to 31 residues. β-endorphin (which derives 
from cleavage of POMC) is also processed into nonopioid peptides such as adrenocorticotropic 
hormone, melanocyte stimulating hormone, and β-lipotropin. Proenkephalin contains multiple 
copies of met-enkephalin, as well as a single copy of leu-enkephalin. Prodynorphin contains three 
peptides of differing lengths that all begin with the leu-enkephalin sequence: dynorphin A, 
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dynorphin B, and neoendorphin (Brunton et al., 2011). A comparison of peptide sequences is 
shown in Table 1.  
Other important opioid peptides are endomorphin 1 (EM-1) that was identified in 1997 in the 
bovine brain (Zadina et al., 1997) and endomorphin-2 (EM-2) found together with EM-1 in the 
human brain cortex (Hackler et al., 1997). The sequences of these peptides are Tyr-Pro-Trp-Phe-
NH2 and Tyr-Pro-Phe-Phe-NH2, for EM-1 and EM-2, respectively (Table 1). EM-1 and EM-2 
peptides showed high affinity for the mu opioid receptor with Ki values being 1.1 and 1.3 nM, 
respectively (Hackler et al., 1997), and more than 4000 fold selectivity for mu over the other 
opioid receptors. Radioimmunological and immunocytochemical analysis revealed that 
endomorphins are distributed throughout the human, bovine, and rodent central nervous system. 
EM-1 is widely distributed in the brain and upper brainstem being particularly abundant in the 
nucleus accumbens, the cortex, the amygdala, the thalamus, the hypothalamus, the striatum, and 
the dorsal root ganglia. In contrast, EM-2 is more prevalent in the spinal cord and lower 
brainstem, hypothalamus, the nucleus of the solitary tract, less abundant EM-2 distribution is in 
the nucleus accumbens, the stubstantia nigra, the nucleus raphe magnus, the ventral tegmental 
area, pontine nuclei and the amigdala. However, endomorphins precursors or processing 
pathways still remains unidentified. The effects elicited by exogenous administration of EM-1 
and EM-2 are similar to that of other mu selective opioid peptides, for the physiological role 
played by these peptides see the review (Fichna et al., 2007). 
 
Opioid receptors are coupled, via Gi proteins, to the inhibition of adenylyl cyclase activity, the 
activation of potassium currents, and the suppression of voltage gated calcium currents; this is 
typical of both opioid and NOP receptors. These receptors are then coupled to an array of second-
messenger systems, e.g. MAP kinases and phospholipase C mediated cascades. Systems as GRKs 
and β-arrestins are also involved in the opioid receptors regulation and cascade. Prolonged 
exposure to opioids results in adaptations at multiple levels within these signaling cascades that 
may relate to effects such as tolerance, sensitization, and withdrawal (Brunton et al., 2011). It has 
been demonstrated that the β-arrestin 2 gene plays a pivotal role in morphine induced analgesia, 
knockout mice for β-arrestin 2 resulted in the potentiation and prolongation of the analgesic 
effect of morphine and reduced liability compared to their wild type littermates (Bohn et al., 
2002; Bohn et al., 1999).  
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Table 1. Amino acid sequence of opioid peptides. 
 
Peptide amino acidic sequence 
Enkephalins YGGFM 
YGGFL 
Dynorphins YGGFLRRIRPKLKWDNQ 
YGGFLRRQFVVT 
YGGFLRKYPK 
Endorphin YGGFMTSEKSQTPLVTLKNAIIKNAYKKGE 
Endomorphin 1 YPWF 
Endomorphin 2 YPFF 
N/OFQ FGGFTGARKSARKLANQ 
 
 
1.4. NOP and OP ligands 
 
The discovery of selective receptor ligands played a fundamental role for identifying the 
biological roles played by NOP and OP receptors systems. Opioid receptors are bound by a 
plethora of different synthetic ligands in terms of pharmacological activity. Radiolabelled 
compounds have allowed the definition of ligand binding characteristics for the three receptor 
subtype and the determination of anatomical distribution of the receptors using autoradiographic 
techniques showing receptor specific anatomical distribution in brain, spinal cord, and the 
periphery.  
Naloxone is a universal opioid antagonist, while CTOP, naltrindole, and nor-binaltorphimine 
(nor-BNI) are selective antagonists for the MOP, DOP, and KOP receptors, respectively. 
Synthetic selective agonists are DAMGO, DPDPE, and U-69,593 for MOP, DOP, and KOP, 
respectively.  
As far as selective NOP receptor ligands, N/OFQ(1-13)-NH2 (Guerrini et al., 1997), UFP-112 
(Rizzi et al., 2007), [Arg
14
Lys
15
]N/OFQ (Okada et al., 2000), Ro 65-6570 (Wichmann et al., 
1999), and SCH 221510 (Varty et al., 2008) are selective full agonists, while [Phe
1ψ(CH2-
NH)Gly
2
]N/OFQ(1-13)-NH2 ([F/G]N/OFQ(1-13)-NH2) (Calo et al., 1998), UFP-113 (Arduin et 
al., 2007), Ac-RYYRIK-NH2 (Dooley et al., 1997) are described in literature as partial agonists, 
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and [Nphe
1
]N/OFQ(1-13)-NH2 (Calo et al., 2000b), UFP-101 (Calo et al., 2002), J-113397 
(Kawamoto et al., 1999), SB-612111 (Zaratin et al., 2004), C-24 (Goto et al., 2006) as selective 
antagonists for the NOP receptor. 
 
Opioid therapeutics are of common use for the treatment of pain, e.g. morphine, buprenorphine, 
methadone, fentanyl, tapentadol, etc. Although the widespread use of opiates, opioid analgesics 
share typical disadvantages such as constipation, respiratory depression, tolerance liability, and 
drug abuse. Much efforts have been spent for developing more effective and well tolerated drugs, 
this research is still ongoing and innovative drug candidates are now being discovered in research 
laboratories, examples of these compounds under clinical evaluation are: i) cebranopadol, a 
mixed NOP/opioid receptor agonist by Grünenthal, candidate for chronic, severe and neuropathic 
pain (Linz et al., 2014; Schunk et al., 2014); ii) TRV130 by Trevena Inc, candidate for treating 
postoperative pain, it is a MOP receptor agonist able to promote G-protein signaling but not to 
recruit β-arrestins, TRV130 is more effective than morphine with less side effects (Hackler et al., 
1997; Soergel et al., 2014).  
 
 
1.5. In vitro pharmacological assays for inhibitory-G protein-coupled 
receptors 
 
An assay is a well-defined analytical method that contains the measurement procedure and how 
the measurement should be interpreted to obtain the properties of a system or object. Assays are 
very important tools in the pharmaceutical industry and in the medical diagnostics industry. The 
characterization of a substance requires the determination of its physiochemical properties by 
physiochemical assays and the determination of its biological activities by bioassays. The 
physiochemical properties of a drug substances include its chemical composition, chemical 
structure, solubility, particle size, crystal property, purity, etc.. through physical and chemical 
techniques, such as high-performance liquid chromatography (HPLC), mass spectrum, nuclear 
magnetic resonance (NMR), X-ray crystallography, amino acid sequencing, and so forth. In 
contrast, the biological activity of a substance by definition is the effect of the substance on a 
biological test system. Thus, the biological activity of a substance cannot be measured by 
Introduction 
14 
 
studying the drug substance alone, it requires a biological test system. The biological test system 
can be biochemical, such as the activity of an enzyme or the ability to bind to a predefined 
protein; cell based, such as isolated primary cells or transformed cell lines; tissue or organ based; 
and animal based (Wu, 2010). 
 
 
Figure 5. Tissue chambers for isolated tissues assays (left panel), FLIPR instrumentation (right panel). 
 
Historically, in vitro studies for assessing the pharmacological profile of new molecules were  
performed by using in vitro bioassays on isolated tissues, at least until ’70. Such techniques 
maintain the advantage of studying the receptor in a physiological environment constituted by the 
tissue/organ. Bioassays on isolated tissues are functional assays and have the ability to estimate 
both the potency and the efficacy of new ligands. On the other hand bioassay techniques are 
difficult and time consuming, and can only be employed for studying receptors expressed by the 
experimental animals. This method is still playing an important role in the characterization of 
novel opioid ligands, and concurred at the characterization of the major part of available NOP 
receptor ligands and drugs (Figure 5, left panel). 
Conversely, another in vitro approach, which for many years has been the most widely used 
method to screen new molecules, is the receptor binding. This approach involves the use of cell 
membranes, both isolated from native tissues and from cells expressing recombinant receptors, 
and the use of labeled ligands. Ligands are often labeled with a radioactive isotope (usually 
3
H or 
125
I) that allows to measure through the specific radioactivity the amount of molecule that bound 
the receptors, less commonly are linked to moieties of fluorescence properties. These type of 
measurements led to the determination of the onset of interaction and dissociation, the affinity, 
and the receptor levels into the membrane preparation. The disadvantage of this method is that 
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does not allow to evaluate the efficacy of a compound, this type of information can be obtained 
only using functional assays. An assay used to measure the potency and efficacy of a ligand to an 
active Gi receptor is the stimulation of the [
35S]GTPγS binding in activated G proteins. This 
technique is widely used, but requires a purification of the components of the membranes, the use 
of radioisotopes and lack of amplification of the signal. Another technique for the measurement 
of the signal of G proteins is the measurement of stimulation or, in the case of Gi, inhibition of 
the forskolin induced accumulation of cAMP, this latter method suffers from vary limitations, 
e.g. the inhibition rarely exceeds 60% of the stimulation, and also, this assay is high expensive 
both in term of costs and time. 
The modern drug-discovery processes, based on the use of big library of compounds have 
required the development of High Throughput Screening (HTS) methods. These methods allow 
the rapid determination of the effects of a large number of new ligands. The development of a 
panel of calcium-sensitive fluorescent dyes and proteins revolutionized the ability to visualize 
calcium as important second messenger and its complex signaling characteristics. In fact, the 
major part of the HTS methods are capable to measure fluorescence and the most used is the 
measurement of fluorescence in response to mobilization of intracellular calcium. The classic tool 
dedicated to this activity is the Fluorimetric Imaging Plate Reader (FLIPR, Molecular Devices) 
(Figure 5, right panel) able to screen new compounds in microplates 96/384 wells seeded with 
transfected cells. In these methods radioactive substances are not needed and it is possible to test 
several compounds simultaneously. This approach is costly and it is not suitable to test ligands 
for those receptors not coupled to calcium signaling.  
Others methods for studying Gi coupled GPCRs that are also based on fluorescence 
measurements employ dyes sensitive to perturbation of cell membrane potential (e.g. (Knapman 
& Connor, 2015)), recently other methods based on Förster/Fluorescence Resonance Energy 
Transfer (FRET), or Bioluminescence Resonance Energy Transfer (BRET) are increasing their 
support to pharmacological assays because genetic engineering is getting fairly common and 
using these type of “proximity” assays it is possible to test a wide spectrum of receptor/effector 
or receptor/receptor interactions (Salahpour et al., 2012). Other methods named “label free” are  
able to follow GPCR activation by an “holistic” point of view without the needing to use any type 
of radioactive or dye compound, e.g. measuring changes in impedance of cells and the dynamic 
mass redistributions following receptor activation (Grundmann & Kostenis, 2015; Ke et al., 
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2015), nowadays the high costs of instruments and particularly consumables for these type of 
experiments limit the use of these assay to industrial laboratories. 
 
 
1.5.1. Chimeric G proteins and calcium mobilization assay 
 
The use of calcium mobilization assays  was limited to Gq coupled receptors whose activation 
stimulates phospholipase C-β, which catalyzes the cleavage of membrane-bound 
phosphatidylinositol 4,5-biphosphate into the second messengers inositol (1,4,5) trisphosphate 
(IP3) and diacylglycerol. IP3 acts on IP3 receptors in the endoplasmic reticulum membrane to 
elicit calcium release from the reticulum.  
The introduction of chimeric G proteins capable to force receptors to signal toward the 
mobilization of calcium enabled to applay this assay to virtually all GPCR. Several biochemical 
studies showed that within the Gα structure there are sequences capable of regulating the 
selectivity of interaction of G proteins and  GPCRs. In particular, the C-terminal region of Gα 
plays a key role in determining the specificity of Gα/GPCR interaction. Furthermore, the 
replacement of at least three amino acid residues at the Gαq C-terminal (Gq proteins are coupled 
to calcium signaling) with the corresponding residues of Gαi generated a chimeric G protein able 
to cause a switch in the coupling of several Gi coupled GPCR to the calcium signaling, e.g. α2 
adrenergic receptors, adenosine A1 and D2 dopaminergic receptor, the substitution of five amino 
acids was demonstrated being the most efficient (Gαqi5) (Conklin et al., 1993). The seminal 
results by Conklin were then extended to an higher number of GPCRs and also used for the 
process of GPCR deorphanization (Kostenis et al., 2005b). Subsequent studies have clarified that 
other regions of G proteins are important to determine the specificity of Gα/GPCR interactions. 
In particular, the G66 residue of the linker region I is involved in this process, it has been shown 
that by point mutating the glycine residue into an aspartic, the GαqG66D protein is less selective 
when tested for the interaction with GPCRs, allowing GPCRs normally coupled to Gαi or Gαs to 
stimulate calcium mobilization. The proposed mechanism for this increase in promiscuity of the 
G protein/GPCR coupling event is the following i) the mutational replacement of glycine by 
other amino acids reduces the conformational freedom of a linker region and might thus yield a 
Gα in an inactive state with a slightly opened nucleotide binding cleft, ii) this in turn might lower 
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the activation energy for a GPCR to induce nucleotide exchange on Gα, enabling GPCRs from all 
coupling classes to facilitate the Gα-activation event (Kostenis et al., 2005b). This mutation 
cooperatively interacts with the replacement of the 5 residues at the C terminal (Gαqi5 and Gαqs5) 
in reducing the receptor/effector specificity. This has been demonstrated for a large number of 
receptors by performing experiments in which potency and/or maximal effects of reference 
agonists were always higher in cells expressing the double mutated protein (GαqG66Di5) compared 
to cell lines expressing either one of the single mutated proteins or native G proteins (Kostenis et 
al., 2005a) (Figure 6). 
 
 
Figure 6. Structure of a heterotrimeric G protein. A highly conserved glycine residue in the linker I region 
that connects the GTPase domain with the helical domain is highlighted in green. The guanine nucleotide 
GDP is buried in a cleft between the helical domain and the GTPase domain of the Gα subunit (Kostenis et 
al., 2005b). 
 
 
In our laboratories the calcium mobilization assay with chimeric G proteins was successfully 
setup and validated for the NOP receptor using a large panel of ligands of different activity and 
applying classical pharmacological criteria (Camarda et al., 2009). This study demonstrated that 
the overall pharmacological profile of the human NOP receptor evaluated with the calcium 
mobilization assay, is not affected by the application of chimeric G protein technology. 
This study also underlined some limitations of the calcium mobilization assay.. Similar to other 
assays that measure second messengers,  the high level of amplification generated a high 
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efficiency of the stimulus/response coupling. Under these experimental conditions ligand efficacy 
is overestimated and for instance partial agonists may display similar maximal effects as full 
agonists.. Moreover the rapid and transient nature of the calcium peak (i.e. rapid calcium release 
and subsequent ions sequestration) may produce two different  artifacts: for agonist ligands, a 
possible underestimation of potencies for slow interacting ligands; for antagonist ligands, the 
evaluation of the type of antagonism (competitive vs non competitive) can be difficult due to 
hemi equilibrium condition that is typical of this assay. For a review see (Charlton & Vauquelin, 
2010).  
 
 
1.5.2. Bioluminescence Resonance Energy Transfer pharmacological assays 
 
Green Fluorescent Proteins (GFP) and other recombinant modified peptides are useful tools for 
investigating the network of macromolecular interactions occurring in living cells. These 
proteins, together with an increasing number of chemical fluorescent probes are designed for 
arranging a wide spectrum of subcellular, cellular, tissue, and organ occurring phenomena. 
Protein biochemists have extensively adopted techniques based on Resonance Energy Transfer 
(RET) between a donor/acceptor couple of chromophores linked to different proteins to 
investigate molecular interactions. Fluorescence RET (FRET) is one of the most common 
methods applied both at cell biology and at in vitro GPCR pharmacology. Examples of this use in 
pharmacology are: protein biosensors for measuring cAMP (Mathiesen et al., 2013), calcium 
levels (Roelse et al., 2013), and also methods for studying GPCRs oligomerization (Ciruela et al., 
2014). Without entering in details the application of Homogenous Time-Resolved FRET (HTRF), 
that is based on the long lasting fluorescent emission of lanthanide metals, enhances the quality 
of FRET measurements by diminishing the background noise that is very common when studying 
fluorescence in cells (Norskov-Lauritsen et al., 2014). TR-FRET was successfully applied to 
monitoring those mechanisms in which low background levels is a fundamental requirement, 
such as receptor binding (Emami-Nemini et al., 2013) and receptor/effector interactions (Ayoub 
et al., 2010). Bioluminescence RET (BRET) is a recently introduced variation that exploits 
energy transfer occurring between a luciferase-bound donor, able to produce light by 
metabolizing a chemical substrate (e.g. luciferine, coelenterazine), and a compatible fluorescent 
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protein acceptor. BRET has two advantages over conventional FRET. First, it does not require 
incident light, which can damage subcellular structures. Second, it may lead to assays with a 
better signal-to-noise ratio, because endogenous luminescence is negligible when compared to 
autofluorescence, at least in mammalian cells (Pfleger & Eidne, 2006) (Figure 8). For these 
reasons BRET was successfully applied both to monitor second messenger levels with biosensors 
(e.g. cAMP, IP3, calcium) but also to evaluate the proximity of proteins and peptides (e.g. GPCR 
to different types of G proteins and/or arrestins), see for a review (Salahpour et al., 2012). 
 
 
Figure 8. Light emission spectra of Donor/Acceptor couple (panel A). FRET, BRET, and HTRF mechanisms 
are summarized in B, C, and D panels. 
 
In the present study we setup and validate a BRET-based assay useful for investigating ligand 
induced  NOP/G-protein and NOP/β-arrestin 2 interactions. Methodological setup and validation 
of linked donor and acceptor couple have been previously made for demonstrating that 
complementation-induced BRET allows detection of the GPCR/β-arrestin interaction with high 
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signal-to-noise ratio, good dynamic range and rapid response (Molinari et al., 2008). This assay 
was then pharmacologically validated for MOP and DOP opioid receptors (Molinari et al., 2010), 
and for the β2-adrenergic receptor (Casella et al., 2011). 
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1.6. Aim of the Study 
 
The aims of the present study were to set-up and validate two assays, the calcium mobilization 
assay for performing pharmacological studies at classical opioid receptors and a BRET-based 
assay for characterizing novel ligands by studying  NOP/G-protein and NOP/β-arrestin 2 
interactions . This study was also aimed to evaluate, using different  in vitro pharmacological 
methods, the pharmacological profile of novel ligands at classical opioid and NOP receptors. In 
particular we investigated compounds generated in the frame of SAR studies of morphine and 
oxymorphone derivatives, and of endomorphin-2 cyclic pentapeptide derivatives. Similarly SAR 
studies were performed with both non peptide (spiroxatrine derivatives) and peptide 
(nociceptin/orphanin FQ(1-13)-NH2 derivatives modified in position 5). Finally innovative 
ligands were characterized pharmacologically in details such as the NOP antagonist NiK-21273 
and N/OFQ tetrabranched derivatives .  
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2. Material and Methods 
 
 
2.1. Receptor binding and stimulation of [
35S]GTPγS binding  
 
CHO cells stably expressing human classical opioid receptors (MOP, KOP, and DOP receptors) 
were maintained in Nutrient F12 containing 10% FBS; CHO cells expressing human NOP 
receptors were maintained in DMEM/Nutrient F12 (50/50) with 5% FBS; all media were further 
supplemented with penicillin (100 IU/mL), streptomycin (100 μg/mL) and fungizone (2.5 
μg/mL). Stock cultures additionally contained geneticin (G418) (200 μg/mL) for CHOMOP, 
CHODOP, and CHOKOP, or G418 (200 μg/mL) and hygromycin B (200 μg/mL) for CHONOP cells.  
For assessing receptor binding, CHONOP membranes (40 μg) were incubated in 0.5 mL of buffer 
consisting of Tris (50 mM), BSA (0.5%), ∼0.8 nM [3H]UFP-101 and increasing concentrations 
(1 pM - 10 μM) of ligands. Non-specific binding was determined in the presence of 1 μM 
N/OFQ. CHOMOP , CHODOP, and CHOKOP membranes were used at a concentration of 50 μg and 
incubated in 0.5 mL buffer consisting of Tris (50 mM), BSA (0.5%), ∼0.8 nM [3H]-
diprenorphine and a range of concentrations of ligands. Non-specific binding was determined in 
the presence of 10 μM naloxone. For both displacement assays, reactions were incubated at room 
temperature for 1 h and terminated by vacuum filtration through polyethylenimine (0.5%)-soaked 
Whatman GF/B filters (Fisher Scientific, Loughborough, UK), using a Brandel harvester. 
Radioactivity was determined following an 8 h extraction of filters in ScintiSafe Gel using liquid 
scintillation spectroscopy. 
For studying the stimulation of [
35S]GTPyS binding, 40 μg of membranes taken from CHONOP 
cells were incubated in 0.5 mL buffer containing Tris (50 mM), EGTA (0.2 mM), MgCl2 (1 
mM), NaCl (100 mM), BSA (0.1%), bacitracin (0.15 mM), GDP (100 mM) and ∼150 pM 
[
35
S]GTPyS. NOP ligands were included in varying concentrations, and non-specific binding was 
determined in the presence of 10 μM GTPγS. Reactions were incubated for 1 h at 30°C with 
gentle shaking and terminated by vacuum filtration through dry Whatman GF/B filters. 
Radioactivity was determined following an 8 h extraction of filters in ScintiSafe Gel using liquid 
scintillation spectroscopy.  
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2.2. Calcium mobilization assay 
 
Cell lines permanently co-expressing the NOP, MOP,  or KOP receptors and the C-terminally 
modified Gαqi5, and cells co-expressing DOP and GαqG66Di5 were all prepared by infecting the 
CHONOP, CHOMOP, CHODOP, and CHOKOP lines with a recombinant retrovirus expressing the 
chimeric α subunit and the hygromycin resistance gene. Polyclonal cell lines were generated 
using the pantropic retroviral expression system from BD-Clontech, as described previously 
(Molinari et al. 2008). Stable lines were selected under hygromycin B (100 μg/ml) and geneticin 
(600 μg/ml active drug) for 2–3 weeks after the infection. These cell lines were maintained in 
Dulbecco Minimum Essential Medium (DMEM) and Ham F-12 (1:1), 2 mM L-glutamine, 200 
μg/ml geneticin, 100 μg/ml hygromicin B and cultured at 37°C in 5% CO2 humidified air.  
Cells were seeded at a density of 50,000 cells/well into 96-well black, clear bottom plates. After 
24 h incubation, the cells were loaded with medium supplemented with 2.5 mM probenecid, 3 
μM of the calcium sensitive fluorescent dye Fluo-4 AM and 0.01% pluronic acid, for 30 min at 
37°C. Afterwards, the loading solution was aspirated and 100 μl/well of assay buffer: Hank’s 
balanced salt solution (HBSS) supplemented with 20 mM HEPES, 2.5 mM probenecid, and 500 
μM Brilliant Black (Aldrich) was added. Concentrated solutions of ligands were made in distilled 
water (1 mM, peptide ligands) or dimethyl sulfoxide (10 mM, non-peptide ligands) and kept at 
−20°C. Serial dilutions were made in HBSS/HEPES (20 mM) buffer containing 0.02% BSA. Cell 
plate and compound plate are placed into the automatized fluorescence reader FlexStation II 
(Molecular Device, Union City, CA, US), and fluorescence changes were measured at 37°C. 
Online additions were carried out in a volume of 50 μl/well. Antagonists were incubated 15 min 
before the addition of the agonist. Maximum change in fluorescence, expressed in percent of 
baseline fluorescence, was used to determine agonist response.  
 
 
2.3. BRET assay 
 
Plasmids - Human NOP Rluc-tagged fusion proteins were made by replacing stop codons with a 
sequence encoding a 10-mer linker peptide (GPGIPPARAT) and cloned into pRluc-N1 
(PerkinElmer, Waltham, MA, USA). NOP-Rluc inserts were then transferred into the retroviral 
expression vector pQIXN (Clontech, Los Baños, Philippines). Bovine Gβ1 N-terminal-tagged 
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with RGFP (Prolume, Pinetop, USA) was built by linking the RGFP sequence without its stop 
codon to Ser
2
 of Gβ1 through a 21-mer linker peptide (EEQKLISEEDLGILDGGSGSG) and 
cloned into the retroviral expression vector pQIXH. The N terminus of human β-arrestin 2 after 
removal of the start codon was tethered to the C terminus of RGFP through a 13-mer linker 
peptide (EEQKLISEEDLRT) and sub-cloned in pQIXH (Molinari et al., 2010).  
Cell and Membrane Preparation - Human Embryonic Kidney (HEK293) cells were grown in 
Dulbecco’s modified Eagle’s medium, supplemented with 10% (v/v) fetal calf serum, 100 
units/ml penicillin G, and 100 ng/ml streptomycin sulfate, in a humidified atmosphere of 5% CO2 
at 37 °C. Cell lines permanently co-expressing the different pairs of fusion proteins, i.e. NOP-
RLuc/Gβ1-RGFP and NOP-RLuc/β-arrestin 2-RGFP, were prepared using the pantropic retroviral 
expression system by Clontech as described previously (Molinari et al., 2008). For G-protein 
experiments enriched plasma membrane aliquots from transfected cells were prepared by 
differential centrifugation; cells were detached with PBS / EDTA solution (1 mM, pH 7.4 NaOH) 
then, after 5 min 500 g centrifugation, Dounce-homogenized (30 strokes) in cold homogenization 
buffer (TRIS 5 mM, EGTA 1 mM, DTT 1 mM, pH 7.4 HCl) in presence of sucrose (0.32 M). 
Three following centrifugations were performed at 1000 g (4°C) and supernatants kept. Two 
25,000 g (4°C) subsequent centrifugations (the second in the absence of sucrose) were performed 
for separating enriched membranes that after discarding the supernatant were kept in ultrapure 
water at -80°C (Vachon et al., 1987). The protein concentration in membranes was determined 
using the QPRO - BCA kit (Cyanagen Srl, Bologna, IT) and the spectrophotometer Beckman DU 
520 (Brea, CA, USA). 
Compound interaction with luciferase activity - For assessing whether compounds affect 
luciferase activity all the ligands were assayed at 1 and 10 μM employing cell membranes 
obtained from HEK293 expressing the human NOP-RLuc and β-arrestin 2-RGFP. 5 μM of 
coelenterazine were added together with membranes 15 min before readings and compounds 5 
min before readings. Data were expressed as mean CPS values in 4 readings (~ 60 s delayed) 
using the 460(25) filter with the microplate luminometer Victor 2030 (PerkinElmer, Waltham, 
MA, USA). 
Receptor levels - The levels of NOP fusion proteins expressed in transfected cells were 
determined by measuring RLuc luminescence activity. Dilutions of cell membranes (0.1 - 4 μg) 
made in duplicate were counted in the Victor 2030 (PerkinElmer, Waltham, MA, USA) 
luminometer to detect RLuc emission; 5 μM coelenterazine was automatically injected to each 
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sample, and, after a delay of 2 s, total light emission was counted at 0.5 s intervals for 5 s. 
Integrated photon counts were plotted as a function of membrane protein concentration and the 
linear regression of the data has been analyzed.  
Receptor-transducer interaction - In whole cells luminescence was recorded in 96-well sterile 
poly-D-lysine-coated white opaque microplates, while in membranes it was recorded in 96-well 
untreated white opaque microplates (PerkinElmer, Waltham, MA, USA). For the determination 
of NOP/β-arrestin 2 interactions, cells co-expressing NOP-Rluc and β-arrestin 2-RGFP were 
plated 24 h before the experiment (100,000 cells / well). The cells were prepared for the 
experiment substituting the medium with Dulbecco’s phosphate buffered saline (DPBS) with 0.5 
mM MgCl2 and 0.9 mM CaCl2. For the determination of NOP/G-protein interaction, membranes 
(3 μg of protein) prepared from cells co-expressing NOP-Rluc and Gβ1-RGFP were added to 
wells in DPBS. Coelenterazine at a final concentration of 5 μM was always injected 10 minutes 
prior reading the cell plate. The receptor / G-protein interaction was measured in cell membranes 
to exclude the involvement of other cellular processes (i.e. arrestin recruitment, internalization). 
Next, different concentrations of ligands in 20 μL of PBS - BSA 0.01 % (Bovine Serum 
Albumin, Sigma Chemical Co. (Poole, UK)) were added and incubated for an additional 5 min 
before reading luminescence. Signals were collected using a Victor 2030 luminometer 
(PerkinElmer, Waltham, MA, USA), emissions were selected using a 460(25) and a 510(10) 
bandpass filters for Rluc and RGFP, respectively. All the experiments were performed at room 
temperature. All the experiments were performed at room temperature.  
Kinetic evaluations – The effects of 100 nM N/OFQ were evaluated after 5, 10, and 15 min of 
incubation in cell membranes (NOP/RLuc and Gβ1/RGFP) and living cells (NOP/RLuc and β-
arrestin 2/RGFP).  
Assessment of antagonist potency - Compounds that do not display agonist activity were further 
evaluated as antagonists. Three types of experiments were performed i) concentration-response 
curves to N/OFQ in absence and in presence of a fixed concentration of antagonist, ii) 
concentration-response curves to N/OFQ in absence and in presence of increasing concentrations 
of SB-612111 (Schild analysis), iii) inhibition-response curves to SB-612111 against a fixed 
concentration of N/OFQ approximately corresponding to its EC80.  
In pilot experiments performed in cell membranes, 15 min pre-incubation with SB-612111 100 
nM, C-24 10 nM, and UFP-101 1 µM were challenged against N/OFQ by measuring BRET ratio 
5 min after agonist injection. Concentration response curves to N/OFQ were rightward shifted in 
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the presence of all antagonists, the agonist maximal effect in presence of UFP-101 was not 
significantly different than control while in the presence of SB-612111 or C-24 the agonist 
maximal effect was strongly depressed. These experiments were then repeated by increasing to 
15 min the time between agonist injection and the measure of BRET ratio. Under these 
experimental conditions all antagonists produced a rightward shift of the concentration response 
curve to N/OFQ without modifying agonist maximal effect. Therefore this protocol was adopted 
for all subsequent antagonist experiments.  
 
 
2.4. Electrically Stimulated mouse Vas Deferens 
 
Experimental procedures - Mouse vas deferens (mVD) tissues were taken from Male CD-1 mice 
(Harlan, San Pietro in Natisone, Udine, Italy) which were handled according to guidelines 
published in the European Communities Council directives (86/609/EEC), National regulation 
(D.L 116/92). They were housed in 425 x 266 x 155 mm cages (Techniplast, Milan, Italy), fifteen 
animals/cage, under standard conditions (22ºC, 55 % humidity, 12-h light/dark cycle, light on at 
7:00 am) with food and water available ad libitum. 
On the day of the experiments the animals were killed by a lethal injection of urethane. From the 
mouse the prostatic portion of the vas deferens was isolated, and prepared according to (Hughes 
et al., 1975). The tissues were suspended in 5 ml organ baths containing heated Krebs solution, 
composition in mM: NaCl 118.5, KCl 4.7, KH2PO4 1.2, NaHCO3 25, glucose 10 and CaCl2 2.5. 
The solution was oxygenated with 95% O2 and 5% CO2 (pH 7.4) and the temperature set at 33 
°C. 
Tissues were continuously stimulated through two platinum ring electrodes with supramaximal 
voltage rectangular pulses of 1 ms duration and 0.05 Hz frequency, with an applied resting 
tension of 0.3 g. The electrically evoked contractions (twitches) were measured isotonically with 
a strain gauge transducer (Basile 7006; Ugo Basile s.r.l., Varese, Italy). Following an 
equilibration period of 60 min, the contractions induced by electrical field stimulation were 
stable. At this time, cumulative concentration-response curves were performed by sub 
sequentially addition of increasing concentrations of the ligand to the same buffer, stabilization of 
each concentration-mediated effect was allowed prior the injection of the following higher 
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concentration. Antagonists were evaluated against the concentration-response curve to the agonist 
following 15 min of pre-incubation.  
Instruments - For bioassays two chamber-glass bathes for isolated organs were utilized. The outer 
chamber contains water heated at 33, while the inner chamber contains 5 ml of oxygenated Krebs 
solution. One end of the tissue is fixed to the bottom side of the inner chamber and the other end 
is linked to a force transducer by a surgery thread. The role of the transducer is to convert the 
mechanical signal in electrical signal, then amplified and recorded with a PC-based acquisition 
system Power Lab 4/25 (model ML845, ADInstruments, USA). 
 
 
2.5. Data analysis and terminology 
 
All data are expressed as the mean ± standard error of the mean (SEM) of n experiments. For 
potency values 95% confidence limits were indicated. Data have been statistically analyzed with 
one way ANOVA followed by the Dunnett’s test for multiple comparisons; p values less than 
0.05 were considered to be significant. 
Receptor binding data are expressed as % displacement. Stimulation of [
35S]GTPγS binding data 
are expressed as stimulation factor that is the ratio between specific agonist stimulated 
[
35S]GTPγS binding and basal specific binding. In calcium mobilization experiments, maximum 
change in fluorescence, expressed as percent over the baseline fluorescence, was used to 
determine agonist response. BRET data are computed as stimulated BRET ratio units, i.e. the 
ratio between CPS from RGFP and RLuc in the presence of ligands, followed by baseline 
subtraction, i.e. the BRET value in the absence of ligand. Maximal agonist effects (Emax) were 
expressed as fraction of the N/OFQ Emax which was determined in every assay plate and reported 
in the graphs as E / Emax. BRET ratio are obtained between CPS measured for the RGFP and 
RLuc light emitted using 460(25) and 510(10) filters (PerkinElmer, Waltham, MA, USA), 
respectively. Electrically stimulated tissues data are expressed as % of the control twitch induced 
by electrical field stimulation.  
Affinity values are showed as pKi calculated using the Cheng-Prusoff equation: 
pKi = log{IC50 / (1 + [L]/KD)} 
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Where IC50 is the concentration of antagonist that produces 50% inhibition of the agonist 
response, [L] is the concentration of free radioligand, and KD is the dissociation constant of the 
radioligand for the receptor. 
Agonist potencies are given as pEC50 i.e. the negative logarithm to base 10 of the molar 
concentration of an agonist that produces 50% of the maximal effect of that agonist. Maximal 
effects elicited by the agonists are expressed as intrinsic activity α using N/OFQ as standard full 
agonist. Concentration-response curves to agonists were fitted to the classical four-parameter 
logistic nonlinear regression model: 
Effect = Baseline + (Emax - Baseline) / (1+10^((LogEC50 – Log[compound]) HillSlope)) 
Curves fitting were performed using PRISM 5.0 (GraphPad Software In., San Diego, USA). 
EC50 is the concentration of agonist producing a 50% maximal response and n is the Hill 
coefficient of the concentration-response curve to the agonist. 
 
Antagonist potencies were derived in functional experiments in inhibition response experiments 
as pKB, which was calculated as the negative logarithm to base 10 of the KB from the following 
equation: 
KB = IC50 / ([2 + ([A] / EC50)
n
]
1/n
 – 1),  
where IC50 is the concentration of antagonist that produces 50% inhibition of the agonist 
response, [A] is the concentration of agonist, EC50 is the concentration of agonist producing a 
50% maximal response and n is the slope coefficient of the concentration-response curve to the 
agonist (Kenakin, 2014). When antagonists were assayed at a single concentration against the 
concentration-response curve to the agonist their pKB was derived with the following equation:  
pKB = log(CR - 1) - log[A]  
where CR is the ratio between agonist potency (expressed as EC50) in the presence and absence 
of antagonist and [A] is the molar concentration of antagonist. The type of antagonism exerted by 
antagonists was assayed by using the classical Schild analysis. The Schild plot was analyzed by 
linear regression to derive the pA2 value of the antagonist. 
To quantify the differences of agonist efficacies for G protein and arrestin interactions the Bias 
factors were calculated by choosing the endogenous NOP ligand N/OFQ as standard unbiased 
ligand. For this analysis, the Emax and EC50 of the agonist were derived using a 3-parameters 
logistic model with unitary slope values. In fact, although several agonist curves displayed slope 
values different from 1, on refitting the curves with the parameter fixed to unity did not produce a 
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statistically significant reduction of the goodness of fit (extra-sum of squares principle (DeLean 
et al., 1978)). Under such conditions, the relative ratio (Emax/EC50)lig / (Emax/EC50)N/OFQ is 
equivalent to the relative (/K)lig/(/K)N/OFQ ratio as defined by the operational model (Black & 
Leff, 1983; Griffin et al., 2007), and represents the ratio of both intrinsic efficacy (i.e.,  as 
defined in (Furchgott, 1966)) and binding affinity of the ligands with respect to the reference 
agonist (Kenakin & Beek, 1982; Onaran et al., 2014). By taking ratios of these values between G 
protein and arrestin can cancel the common K and yield the ratio of ligand intrinsic efficacy 
across the two transduction proteins. Thus, the following formula was used for calculating 
agonist bias factors in log10 units: 
Bias factor =    
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3. Results 
 
3.1. Novel assays 
 
 
3.1.1. Pharmacological studies on classical opioid receptors coupled with calcium signaling 
via chimeric G proteins. 
 
In order to extent the use of the calcium mobilization assay performed on cells expressing 
chimeric G proteins from the NOP receptor (Camarda et al., 2009) to classical opioid receptors, a 
panel of standard opioid ligands has been assessed. The results obtained with these compounds 
were compared to those described in literature with classical assays for Gi coupled receptors. The 
overall aim of these series of experiments was to set up and validate experimental conditions in 
order to use this assay for the pharmacological characterization of novel opioid receptor ligands. 
 
MOP receptor - Concentration-response curves to dermorphin and endomorphin-1 (EM-1) were 
performed in CHO cells stably co-expressing the human MOP receptor and the Gαqi5 chimeric G 
protein. Dermorphin and EM-1 exhibited similar maximal effects (Emax ≈ 200 % over the basal) 
and pEC50 values (8.19 (8.11-8.27) and 8.00 (7.92-8.09), respectively (Figure 9).  
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Figure 9. Concentration-response curve to dermorphin and EM-1 in calcium mobilization experiments 
performed on CHOMOP cells stably expressing the Gαqi5 protein. Agonist effects were expressed as % over the 
baseline. Data are the mean of 4 separate experiments performed in duplicate. 
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In a parallel experiments, DPDPE did not stimulate calcium mobilization up to 1 µM while 
dynorphin A produced a stimulatory effect only at micromolar concentrations (Table 2). 
In a separated series of experiments a fixed concentration of dermorphin (30 nM) was challenged 
against increasing concentrations (10 pM - 10 μM) of naloxone and selective opioid receptor 
antagonists. Naloxone and CTOP were able to concentration dependently inhibits the stimulatory 
effect of dermorphin giving pIC50 values of 7.47 and 6.63, respectively (Figure 10); from these 
data pKB values of 8.45 (8.11-8.79) and 7.91 (7.36-8.46), were calculated. Parallel experiments 
were performed with naltrindole and nor-binaltorphimine (nor-BNI); both compounds mimicked 
the inhibitory effect of naloxone and CTOP with pKB values of 8.24 (7.95-8.53) and 7.44 (7.07-
7.80) 
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Figure 10. Inhibition-response curves obtained by challenging 30 nM dermorphin with increasing 
concentrations of naloxone (left panel) and CTOP (right panel) in the calcium mobilization assay performed 
in CHOMOP cells stably expressing the Gαqi5 protein. Data are the mean ± sem of 4 separate experiments 
performed in duplicate. 
 
In order to evaluate the nature of the antagonism exerted by naloxone the classical Schild analysis 
was performed. The concentration-response curve to EM-1 was evaluated in absence and in 
presence of increasing concentrations of naloxone (10 nM - 1 µM). As shown in the left panel of 
Figure 11, the antagonist was able to rightward shift the concentration-response curve to the 
agonist in a concentration dependent and parallel manner without significantly affecting agonist 
maximal effect. The corresponding Schild plot (Figure 11, right panel) was linear with a slope not 
significantly different from unity (1.02 ± 0.1). A pA2 value of 8.27 was derived from these data. 
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Figure 11. Concentration-response curve to EM-1 obtained in the absence (vehicle) and in presence of 
increasing concentrations of naloxone (left panel). The corresponding Schild plot is shown in the right panel. 
Data are the mean of 4 separate experiments performed in duplicate. 
 
DOP receptor - The synthetic peptide DPDPE concentration dependently stimulated the calcium 
mobilization in CHO cells stably expressing the human DOP receptor and the Gαqi5 chimeric 
protein, reaching the maximal effect of 76 ± 2 % over the basal and a potency (pEC50) value of 
8.89 (8.16 - 9.63) (Table 2). The signal to noise ratio measured with CHODOP cells expressing the 
Gαqi5 chimeric protein was low and possibly not sufficient for performing antagonist type 
experiments. Thus, CHODOP cells were transfected with the GαqG66Di5 chimeric G protein that is 
reported in literature to be more efficient than Gαqi5 in forcing Gi receptors to couple with the 
calcium signaling (see introduction chapter). The effects of adenosine triphosphate (ATP) and 
DPDPE were then tested and compared in CHODOP expressing either Gαqi5 or GαqG66Di5. ATP, 
which interact with natively expressed Gq coupled purinergic receptors, was able to stimulate 
calcium mobilization generating superimposable concentration-response curves in the two cell 
lines (Figure 12). DPDPE displayed similar high potency in the two cell line while its maximal 
effects were significantly higher in GαqG66Di5 than in Gαqi5 cells (146 ± 23% and 70 ± 10% over 
the basal, respectively) (Figure 12). Based on these results all the subsequent experiments were 
performed with CHODOP expressing the GαqG66Di5 chimeric protein.  
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Figure 12. Concentration-response curve to ATP (left panel) and DPDPE (right panel) in calcium 
mobilization experiments performed on CHODOP cells stably expressing either the Gαqi5 or the GαqG66Di5 
chimeric G proteins. Agonist effects were expressed as % over the baseline. Data are the mean of 4 separate 
experiments performed in duplicate. 
 
Dermorphin and dynorphin A were also able to elicit similar maximal effects to that of DPDPE 
with potency values of 6.43 and 7.73, respectively. 
 
In a parallel series of experiments, a fixed concentration of DPDPE (30 nM) was challenged 
against increasing concentrations (10 pM - 10 μM) of naloxone and naltrindole. Naloxone and 
naltrindole were able to concentration dependently inhibits the stimulatory effect of DPDPE 
giving pIC50 values of 5.15 (4.88 - 5.42) and 9.14 (6.71 - 11.57), respectively (Figure 13). From 
these data the following pKB values 6.08 (5.56 - 6.60) and 10.18 (9.35 - 11.01), were calculated 
for naloxone and naltrindole, respectively. 
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Figure 13. Inhibition-response curves obtained by challenging 30 nM DPDPE with increasing concentrations 
of naloxone (left panel) and naltrindole (right panel) in the calcium mobilization assay performed in CHODOP 
cells stably expressing the GαqG66Di5 protein. Data are the mean ± sem of 4 separate experiments performed in 
duplicate. 
 
KOP receptor - The endogenous peptide dynorphin A stimulated the calcium mobilization in 
CHOKOP expressing the Gαqi5 chimeric protein in a concentration dependent manner with a pEC50 
value of 9.05 (8.90 - 9.20) and maximal effect 225 ± 16 % (Figure 14) (Table 2).  
6789101112
0
50
100
150
200
250
-log[dynorphin A]
F
IU
 (
%
 o
v
e
r 
th
e
 b
a
s
e
li
n
e
)
 
Figure 14. Concentration-response curve to dynorphin A in calcium mobilization experiments performed on 
CHOKOP cells stably expressing the Gαqi5 protein. Agonist effects were expressed as % over the baseline. Data 
are the mean of 4 separate experiments performed in duplicate. 
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Naloxone and nor-BNI were tested as antagonist in inhibition-response experiments against a 
fixed concentration of dynorphin A (30 nM) showing pIC50 values of 6.10 (5.74 - 6.46) and 8.23 
(8.12 - 8.34), respectively. The calculated pKB values are 7.59 (7.47 - 7.71) and 9.53 (8.78 - 
10.28), for naloxone and nor-BNI respectively (Figure 15). 
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Figure 15. Inhibition-response curves obtained by challenging 30 nM dynorphin A with increasing 
concentrations of naloxone (left panel) and nor-BNI (right panel) in the calcium mobilization assay performed 
in CHOKOP cells stably expressing the Gαqi5 protein. Data are the mean ± sem of 4 separate experiments 
performed in duplicate. 
 
 
In order to evaluate the nature of the antagonism exerted by nor-BNI, the classic Schild analysis 
was performed. The concentration-response curve to dynorphin A was evaluated in absence and 
in presence of increasing concentrations of nor-BNI (1 nM - 100 nM). As shown in the figure 
(Figure 16, left panel), dynorphin A potency and maximal effects were 9.31 (8.96 – 9.67) and 165 
± 12 % over the basal; the antagonist was able to rightward shift the concentration-response curve 
of the agonist in a parallel manner with a decrease of its maximal effect. The corresponding plot 
(Figure 16, right panel) was linear with a slope value corresponding to 0.9 ± 0.1 and a pA2 value 
of 9.33 was found, the pA2 value obtained from linear regression at low agonist response (Emax 
50% over the basal) was very similar to that from the Schild analysis (~ 3 fold higher, graph not 
shown). This value is also similar to that obtained in inhibition-response experiments (9.53). 
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Figure 16. Concentration-response curve to dynorphin A obtained in the absence (vehicle) and in presence of 
increasing concentrations of naloxone (left panel). The corresponding Schild plot is shown in the right panel. 
Data are the mean of 4 separate experiments performed in duplicate. 
 
Agonist potencies and maximal effects are summarized for each opioid receptor in Table 2, while 
antagonist potencies are summarized as summarized in Table 3. 
 
Table 2. Effects and potencies of standard opioid receptor agonists and ATP in CHO cells expressing either 
the human MOP, KOP, or DOP receptors, and Gαqi5 chimeric protein in the calcium mobilization assay 
 
MOP / Gαqi5 KOP / Gαqi5 DOP / Gαqi5 
 
pEC50 Emax pEC50 Emax pEC50 Emax 
ATP 6.18 270 ± 42% 5.91 252 ± 20% 5.80 176 ± 17% 
dermorphin 8.19 218 ± 1% Inactive 6.43 78 ± 3% 
dynorphin A 6.37 192 ± 17% 9.05 225 ± 16% 7.73 75 ± 4% 
DPDPE inactive Inactive 8.89 76 ± 2% 
Data in table are mean of at least 3 separate experiments performed in duplicate 
Inactive means the compound was found inactive up to 1 μM. 
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Table 3. Potencies (pKB) of standard opioid receptor antagonists in CHO cells expressing either the human 
MOP, KOP, or DOP receptors, and chimeric proteins in the calcium mobilization assay 
 
MOP/Gαqi5 KOP/Gαqi5 DOP/GαqG66Di5 
naloxone 8.34 6.93 6.14 
CTOP 7.70 inactive inactive 
nor-BNI 7.58 10.22 8.62 
naltrindole 8.24 7.42 9.54 
Data in table are mean of at least 3 separate experiments performed in duplicate. 
Inactive means the compound was found inactive up to 1 μM. 
 
 
With these experiments we investigated the possible impact of the use of chimeric G proteins on 
the pharmacological profile of MOP, DOP, and KOP opioid receptors. Cells co-expressing the 
human recombinant receptors and chimeric G proteins were used for measuring the calcium 
mobilization due to the stimulation evoked by a panel of standard opioid receptors agonists. 
Moreover, the effects of selective and non-selective antagonists for these receptors have been 
measured. Finally, it has been investigated the type of antagonism exerted by naloxone on the 
MOP receptor, and nor-BNI on the KOP receptor. The obtained results in which we applied the 
classical pharmacology criteria for receptor  characterization and classification, namely rank 
order of potency of  agonists and values of potency of selective and competitive antagonist, 
demonstrated that the aberrant signaling evoked by  chimeric G proteins does not cause 
significant modifications on the pharmacological profile of the opioid receptors.  
 
CHO cells expressing the human recombinant receptors MOP, KOP and DOP have been stably 
transfected with the chimeric G protein Gαqi5 (Conklin et al., 1993). Previous studies 
demonstrated that this protein is able to force the coupling of many GPCRs natively coupled to 
inhibitory Gα protein to the PLC/IP3 /Ca
2+
 pathway. This was confirmed in our laboratories for 
the NOP receptor with a large panel of ligands encompassing agonists with different efficacy and 
antagonists of both peptide and non-peptide nature (Camarda et al., 2009).  
The three cellular clones co-expressing the opioid receptors and the Gαqi5 protein were able to 
evoke similar high calcium mobilization levels when stimulated with ATP, that activates 
endogenously expressed Gq coupling purinergic receptors. Similar results were obtained in wild 
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type CHO, and in CHO transfected with only Gαqi5 or the opioid receptors (data not shown). 
These experiments demonstrated that i) ATP stimulates the calcium mobilization independently 
from both the Gαqi5 protein and the opioid receptors, ii) the maximal calcium mobilization levels 
achievable in the three cellular clones is comparable.  
 
A series of agonists acting at the opioid receptors has been evaluated. Small differences found in 
terms of affinity/potency (receptor binding > calcium mobilization > bioassay) of agonists may 
be easily discussed both in terms of accessibility of the receptor in the different preparations 
(membranes > cells > tissues) and in terms of efficiency of the stimulus/response coupling 
(recombinant > native). 
Dermorphin acts as a potent (pEC50 8.21) and selective (approximately 100 fold) MOP agonist, 
similar values of potency were found in the guinea pig ileum (e.g. 8.7 (Guerrini et al., 1998)) and 
also in line with binding affinity values (pKi 9.5, (Raynor et al., 1994)). Dynorphin A acts as a 
universal opioid agonist showing the highest potency value at the KOP receptor (pEC50 9.05). In 
fact this peptide is considered a KOP preferential agonist. Finally, the synthetic peptide DPDPE 
acts as a selective DOP agonist showing high potency (pEC50 8.89). This value of potency is 
similar to literature data, i.e. in the electrically stimulated mouse vas deferens its pEC50 value is 
8.07 (Dietis et al., 2012). In addition N/OFQ (data not shown) was completely inactive at the 
classical opioid receptors confirming its pharmacological profile of NOP receptor selective 
agonist (Calo et al., 2000c).  
The present experiments demonstrated the following rank order of potencies for standard opioid 
agonists.  
MOP receptor: dermorphin = EM-1 > dynorphin A >> DPDPE;  
DOP receptor: DPDPE > dynorphin A > dermorphin;  
KOP receptor: dynorphin A >>> dermorphin = DPDPE.  
These rank orders are in line with the data from the literature (Raynor et al., 1994; Toll et al., 
1998).  
As far as signal to noise ratios (S/N) are concerned, the stimulation of calcium mobilization was 
good enough for both agonism and antagonism studies in Gαqi5 expressing CHOKOP and CHOMOP 
cells (S/N ranging from 2 to 3), while in CHODOP cells the effects measurable were very low (S/N 
< 2). Basic fundamentals of assay development have taught that for those assays in which 
maximal effects are below 200% of the basal value, the study of antagonist properties of ligands 
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become very difficult if not impossible. For this reason CHODOP cells were transfected using a 
more efficient chimeric G protein, in which a substitution of the Gly66 residue in the αq subunit 
of G protein with an Asp residue, together with the αqi5 substitution, synergistically facilitate the 
forced coupling.. Further evidences of this enhancement have been described in the present study, 
DPDPE concentration dependently stimulates the calcium mobilization in CHODOP cells 
expressing the double engineered chimeric protein (GαqG66Di5) showing higher maximal effects 
than those obtained in CHODOP cells expressing the Gαqi5 protein. For this reason, antagonism 
type experiments have been performed in CHODOP cells expressing the GαqG66Di5 protein. 
In a separate series of experiments inhibition-response experiments were performed for a series 
of standard antagonists for classical opioid receptors, the universal antagonist naloxone and the 
selective antagonist CTOP (MOP), naltrindole (DOP), and nor-BNI (KOP). Naloxone behaves as 
antagonist over the three classical opioid receptors acting as universal antagonist. It is worth of 
mention that it is considered opioid mediated each naloxone sensitive biological action. The 
highest value of potency for naloxone has been measured on MOP (8.05), followed by KOP 
(7.59), and DOP (6.08). This rank order of selectivity is in line with published data, moreover 
these pKB values are similar to the binding affinity values at human recombinant receptors (MOP 
9.03, KOP 8.63, and DOP 7.77) (Raynor et al., 1994), and also similar to antagonist potencies in 
bioassay studies (MOP 8.8, KOP 8.0, DOP 7.5) (Calo et al., 1997). CTOP, naltrindole, and nor-
BNI exhibited high potency for the human MOP (7.56), DOP (10.18), and KOP (9.53), 
respectively. Again these values are in line with those from literature (CTOP 9.74, naltrindole 
10.69, and nor-BNI 10.56) (Raynor et al., 1994). 
 
Besides potency and selectivity of action, the type of antagonism exerted, competitive or non-
competitive,  is another important property of receptor antagonists. For evaluating this property, 
concentration-response curves to agonists were assessed in absence and in presence of increasing 
concentrations of antagonists. A competitive antagonist rightward shifts the concentration-
response curve to the agonist in a parallel and concentration dependent manner, without affecting 
the maximal effect elicited by the agonist. This is a typical surmountable behavior, if the Schild 
analysis of the curves produces a straight line with slope value not significantly different from 1, 
these antagonists are of competitive nature, and the potency (pA2) obtained as the abscissae 
intercept of the line is close to that derived in inhibition-response experiments (pKB). On the 
contrary, a non-competitive antagonist shows an insurmountable behavior by decreasing the 
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maximal effect of the agonist even after prolonged agonist incubation times. An intermediate 
condition is the one of slow dissociating competitive antagonists, these compounds similarly to 
non competitive ligands produce a depression of the agonist maximal, the real antagonist nature 
is evident only after prolonged exposures to the agonist, when equilibrium conditions occur. 
This type of experiment has been performed for naloxone and nor-BNI, for MOP and KOP 
receptors respectively. Naloxone rightward shifted the concentration-response curve to the 
agonist (EM-1) in a parallel and concentration dependent manner, without affecting its maximal 
effect, the Schild analysis confirmed the competitive nature of naloxone (slope ~ 1, pA2 8.27), 
close values of antagonist potency obtained by Schild analysis and by inhibition response 
experiments also confirmed the competitive nature of naloxone. This is in line with those 
obtained in classical bioassay experiments, namely a surmountable behavior of naloxone against 
morphine in the electrically stimulated guinea pig ileum (pA2 8.56 (Tallarida et al., 1982)).  
Similarly to naloxone, for evaluating the nature of the antagonism exerted by nor-BNI, the classic 
Schild analysis was applied. Nor-BNI produced a rightward shift of the concentration-response 
curve to dynorphin A in a parallel manner, producing however a decrease of its maximal effect. 
The pA2 value obtained from the Schild analysis was 9.33 (slope ~ 1), that is very similar to what 
derived in inhibition-response experiments (pKB 9.53) and to the literature data (recombinant rat 
receptor, pKi 9.59 (Meng et al., 1993)). Nor-BNI is described in the literature as a competitive 
antagonist, the insurmountable behavior found in the present experiments might be possibly due 
to assay artifacts. According to Charlton and Vauquelin, insurmountability will also be observed 
when pre-formed antagonist receptor complexes are reversible but dissociate so slowly that only 
part of the receptors can be liberated and, hence, occupied/stimulated by the subsequently added 
agonist before the response is measured. This situation will readjust with time until ultimately, 
both the agonist/ and the antagonist/receptor interactions reach equilibrium. Therefore, the 
insurmountability of slow dissociating antagonists is only apparent and can theoretically be 
overcome by measuring the response after a sufficient time lapse. Yet, this is not possible with 
calcium response measurements and, because of the much shorter delay between these 
measurements and the agonist administration when compared with other experimental paradigms 
(e.g. bioassays or GTPγS binding), quite fast dissociating competitive antagonists may display 
insurmountable behavior (Charlton & Vauquelin, 2010). According to what suggested by these 
authors the antagonist potency value was also calculated by computing concentration ratios at 
low agonist response (i.e. 50% over the basal, approximately the EC20 of the agonist in the 
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absence of antagonist), the antagonist potency obtained was very similar to that from the Schild 
analysis. Moreover, the calculation of antagonist potency at low agonist response is quite robust 
in the presence of high levels of stimulus/coupling efficiency (e.g. high levels of receptors and/or 
G proteins). 
Collectively, the rank order of agonists potency obtained for the MOP, DOP, and KOP receptors, 
indicate that the use of chimeric proteins for measuring the calcium mobilization and studying 
these receptors do not sustantially affect the pharmacological profile of classical opioid receptors. 
The use of the double mutated chimeric G-protein (GαqG66Di5) enhanced our ability to test both 
agonist and antagonist ligands at the DOP receptor. The values of potency obtained for 
competitive and selective antagonists at classical opioid receptors were similar to that already 
published in literature, confirming the ability of this method to accurately investigate the 
antagonist properties of ligands. The results obtained by studying the nature of antagonists 
suggest that this assay might produce misleading results for those antagonists characterized by 
slower kinetics of dissociation. This type of studies, calcium mobilization assay using chimeric G 
proteins, have been performed by independent groups on several GPCR, including the opioid 
field (Zhang et al., 2012), and it has been validated by our group for the NOP receptor (Camarda 
et al., 2009).  
Taken together our results extended the application of this assay to the study of opioid receptors 
and confirmed the validity of calcium mobilization as a useful primary screening assay.  
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3.1.2. Pharmacological profile of nociceptin/orphanin FQ receptors interacting with G-
proteins and β-arrestins 2 
 
Functional selectivity or biased agonism is emerging as an important and therapeutically relevant 
pharmacological concept in the field of G protein coupled receptors including opioids. To 
evaluate the relevance of this phenomenon in the NOP receptor, we used a BRET technology to 
measure the interactions of the NOP receptor with either G proteins or β-arrestin 2 in the absence 
and in presence of increasing concentration of ligands. 
 
Ligands effect on luciferase activity - NOP receptor ligands used in this study were tested for 
their effects over RLuc activity in cell membranes. At 1 µM the compounds did not modify RLuc 
activity . Similar results were obtained by testing the compounds at 10 µM with the only 
exception of Ro 65-6570 and PWT2-N/OFQ that produced a significant decrease in photons 
emitted by RLuc. Thus 1 µM was chosen as the highest concentration tested in concentration-
response curves to Ro 65-6570 and PWT2-N/OFQ (Table 4).  
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Table 4. Evaluation of CPS emitted in NOP/RLuc expressing membranes in presence of 1 or 10 μM of 
following compounds. 
 1 µM 10 µM 
PBS (and BSA 0.01%) 11330 ± 125 12022 ± 692 
PBS/DMSO (0.1 - 0.01%) 11244 ± 756 11381± 137 
N/OFQ 10482 ± 675 12315 ± 1833 
N/OFQ(1-13)-NH2 10662 ± 863 12767 ± 1737 
[Arg
14
Lys
15
]N/OFQ 9864 ± 456 11949 ± 1911 
UFP-112 13152 ± 436 13995 ± 843 
PWT2-N/OFQ 11406 ± 912 *6018 ± 543 
[F/G]N/OFQ(1-13)-NH2 12950 ± 322 13886 ± 936 
UFP-113 12496 ± 659 13455 ± 959 
Ac-RYYRIK-NH2 12746 ± 989 13555 ± 809 
[Nphe
1
]N/OFQ(1-13)-NH2 12844 ± 434 13410 ± 566 
UFP-101 12432 ± 851 11920 ± 512 
Ro 65-6570 12190 ± 356 *7792 ± 563 
SCH-221510 11616 ± 787 12012 ± 396 
J-113397 10810 ± 663 11791 ± 981 
SB-612111 10128 ± 846 11268 ± 1140 
C-24 12298 ± 366 12709 ± 411 
Naloxone 12146 ±1065 12591 ± 445 
GDP 11554 ± 1124 12601 ± 1012 
Data are mean ± sem of 3 separate experiments. * p < 0.05 vs. PBS according to one way ANOVA followed 
by the Dunnett test for multiple comparisons. 
 
 
Expression levels of RLuc/NOP receptor in Gβ1/RGFP and β-arrestin 2/RGFP expressing cells - 
In order to compare the expression levels of NOP receptor in the two cell lines we measured 
photons emitted by RLuc in response to 5 µM coelenterazine as a function of membrane protein 
concentrations. As shown in Figure 1 in both cell lines there was a linear increase in CPS with the 
increase of the membrane protein concentration. The slopes of the regression lines, 3.66 ± 
0.065·10
6
 and 4.09 ± 0.068·10
6
 CPS·10
6·μg-1 for Gβ1 and β-arrestin 2 cells, respectively, were 
not significantly different (Figure 17). 
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Figure 17. Light emitted (CPS) as function of the amount of protein (µg) in membranes prepared from 
NOP/RLuc cells expressing either Gβ1/RGFP or β-arrestin 2/RGFP membranes. 
 
Assessment of NOP/G-protein constitutive coupling - The GPCR/G-protein interaction assessed 
via BRET in cell membranes is abolished by the addition of guanine nucleotides. We thus 
examined the effect of GDP on NOP/ G-protein interaction to investigate the extent of 
constitutive activity in the NOP receptor under the present experimental conditions. GDP up to 
10 μM did not significantly modify the basal BRET ratio, and only a very weak inhibitory effect 
(5% of basal BRET) was detected by prolonging incubation time to 15 min (Figure 18). 
 
 
Figure 18. NOP receptor/G-protein interaction experiments - Concentration-response curves to N/OFQ and 
GDP following 15 minutes of incubation in membranes. Data are expressed as mean ± sem of 3 separate 
experiments performed in duplicate 
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Effect of Pertussis-toxin treatment - In order to elucidate the identity of the endogenous G 
subunits  mediating the NOP/Gβ1 interaction, and to evaluate their potential effects on NOP 
mediated β-arrestin 2 recruitment, HEK293 cells stably expressing the human NOP (NOP/RLuc) 
receptor and either the Gβ1 subunit (Gβ1/RGFP) or the β-arrestin 2 (β-arrestin 2/RGFP) were 
treated for 20 h with 10 ng PTX. As shown in Figure 2, right panel, PTX treatment abolished the 
ability of the agonist to stimulate NOP/G-protein interaction, but had negligible effects on the 
stimulation of NOP/β-arrestin 2 interactions (Figure 19). 
 
 
 
Figure 19. Concentration-response curves to N/OFQ - experiments performed in absence and in presence of 
PTX 10 ng 20 h treatment. NOP/G-protein (left panel) and NOP/β-arrestin 2 interaction experiments (right 
panel). Data are mean ± sem of 3 separate experiments performed in duplicate.  
 
 
Effect of ligands on NOP/G-protein interaction - Membrane extracts taken from HEK293 cells 
stably expressing both the human NOP (NOP/RLuc) receptor and the Gβ1 subunit (Gβ1/RGFP) 
were used to perform concentration-response curves to NOP ligands. The endogenous NOP 
receptor agonist N/OFQ promoted NOP/G-protein interaction in a concentration-dependent 
manner. N/OFQ displayed high potency (pEC50 8.44) and a maximal effect which corresponded 
to a stimulation of 0.42 ± 0.01 BRET ratio units over the baseline (Figure 20, Panel A). Under the 
same experimental conditions synthetic peptides such as, [Arg
14
Lys
15
]N/OFQ, PWT2-N/OFQ, 
UFP-112, and N/OFQ(1-13)-NH2 produced similar stimulatory effects, with Emax values 
comparable to those induced by the natural peptide. N/OFQ(1-13)-NH2 was equipotent with 
N/OFQ, while [Arg
14
Lys
15
]N/OFQ, PWT2-N/OFQ, and UFP-112 were 7, 5, and 8 fold more 
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potent than N/OFQ (Figure 20, Panel B). The non-peptide NOP ligands SCH-221510, Ro 65-
6570, J-113397, SB-612111, C-24, and the opioid receptor antagonist naloxone were also 
investigated. SCH-221510 and Ro 65-6570 exhibited maximal effect not significantly different 
from those of N/OFQ, but were 2 and 5 fold less potent then the natural peptide (Figure 3, Panel 
C). In contrast, J-113397, SB-612111, C-24, and naloxone did not modify the basal BRET ratio. 
In a separate series of experiments the peptides UFP-101, UFP-113, [Nphe
1
]N/OFQ(1-13)-NH2, 
Ac-RYYRIK-NH2, and [F/G]N/OFQ(1-13)-NH2 were tested. All such peptides exhibited  
maximal effects that were significantly lower than that of N/OFQ, ranging from 0.14 (UFP-101) 
to 0.72 ([F/G]N/OFQ(1-13)-NH2). As far as potency is concerned, all these ligands were less 
potent than the natural peptide, with the exception of UFP-113, which was 8 fold more potent 
than N/OFQ (Figure 20, Panel D). However, due to its very low Emax value, the potency of UFP-
101 could not be precisely estimated. All the data obtained in this series of experiments have 
been summarized in Table 5.  
Ligands with very weak or no agonist effects were assessed as antagonists. 
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Figure 20. NOP receptor/G-protein interaction experiments - Concentration-response curves to N/OFQ 
(Panel A); N/OFQ, UFP-112, PWT2-N/OFQ, N/OFQ(1-13)-NH2, and [Arg
14
Lys
15
]N/OFQ (Panel B); N/OFQ, 
SCH-221510, and Ro 65-6570 (Panel C); N/OFQ, UFP-113, UFP-101, [F/G]N/OFQ(1-13)-NH2, 
[Nphe
1
]N/OFQ(1-13)-NH2, and Ac-RYYRIK-NH2 (Panel D). Data are expressed as mean ± sem of at least 5 
separate experiments performed in duplicate. 
 
 
In a series of pilot experiments, UFP-101, SB-612111 and C-24 were tested at fixed 
concentrations against the concentration-response curve of N/OFQ. All ligands produced the 
expected shift of agonist EC50, however, unlike UFP-101, SB-612111 and C-24 also caused a 
depression of the maximal effect elicited by N/OFQ under such conditions. On repeating the 
experiments by increasing the time of incubation from 5 to 15 min, the decrease of N/OFQ Emax 
value was no longer evident (Figure 21). Thus, a longer incubation time was used to assess 
antagonist potency for both G protein interaction and arrestin interaction (see below). 
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Figure 21. NOP receptor/G protein interaction experiments - concentration-response curves to N/OFQ in the 
absence and in presence of SB-612111 (left panels), C-24 (middle panels), and UFP-101 (right panels). 
Antagonists were injected 15 min before N/OFQ and BRET ratio was measured 5 min (top panels) or 15 min 
(bottom panels) after agonist injection. Data are from a single representative experiment performed in 
duplicate. 
 
 
The ligands C-24 (10 nM), UFP-101 (1 µM), and J-113397 (30 nM) added to the concentration-
response curve of N/OFQ produced a rightward shift of the curve without significantly changing 
the maximal effect. From these experiments the following pKB values were derived: C-24, 9.11, 
UFP-101, 7.66, and J-113397, 7.95 (Figure 22). In similar experiments naloxone (1 μM) did not 
modify the concentration response curve to N/OFQ. 
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Figure 22. NOP receptor/G protein interaction experiments - concentration-response curves to N/OFQ in 
absence and in presence of C-24, UFP-101, and J-113397. Data are mean ± sem of 5 separate experiments 
performed in duplicate. 
 
 
Schild analysis was used to obtain a more detailed analysis of the antagonist properties of SB-
612111. Concentration-response curves of N/OFQ were generated in the absence and presence of 
increasing concentrations (1 - 100 nM) of the antagonist. SB-612111 produced a parallel 
rightward shift of the N/OFQ curves in a concentration dependent manner, without modifying the 
maximal effect elicited by the agonist (Figure 23, left panel). The resulting Schild plot was linear 
with a slope value of 1.16 ± 0.03; a pA2 value of 8.96 was derived from these experiments 
(Figure 23, middle panel). Finally, the antagonist potency of SB-612111 was also estimated from 
inhibition response curves. Increasing concentrations of SB-612111 (10 pM - 10 µM) were tested 
against a fixed concentration of N/OFQ (30 nM); the pKB derived from these experiments was 
9.13 (Figure 23, right panel). All the data obtained in this series of experiments are summarized 
in Table 6.  
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Figure 23. NOP receptor/G protein interaction experiments - concentration-response curves to N/OFQ in 
absence and in presence of increasing concentrations (1 - 100 nM) of SB-612111 (left panel). The 
corresponding Schild plot is shown in the middle panel. The inhibition response curve to SB-612111 vs. 
N/OFQ 30 nM is shown in the right panel. Data are mean ± sem of 4 separate experiments performed in 
duplicate. 
 
 
Effect of ligands on NOP/β-arrestin 2 interactions - HEK293 cells stably expressing both the 
human NOP (NOP/RLuc) receptor and the β-arrestin 2 (β-arrestin 2/RGFP) protein were used for 
performing concentration-response curves to NOP ligands. N/OFQ promoted receptor/arrestin 
interaction in a concentration dependent manner displaying high potency (pEC50 8.02), and 
maximal effects that corresponded to a stimulation of 0.07 ± 0.004 BRET ratio units over the 
baseline (Figure 24, Panel A). The synthetic peptides [Arg
14
Lys
15
]N/OFQ, UFP-112, and 
N/OFQ(1-13)-NH2 mimicked the stimulatory effect of N/OFQ and showed similar maximal 
effects. With regards to potency, UFP-112 was slightly more potent, whereas [Arg
14
Lys
15
]N/OFQ 
and PWT2-N/OFQ were 2 and 3 fold less potent than N/OFQ (Figure 24, Panel B). The non-
peptide compounds SCH-221510, Ro 65-6570, J-113397, SB-612111, C-24, and naloxone were 
also investigated for their ability to promote NOP receptor/β-arrestin 2 interactions. SCH-221510 
was 10 fold less potent than N/OFQ (Figure 24) and  Ro 65-6570 exhibited a similar decrease of 
potency, although we should note that the incomplete concentration-response curves of this 
compound did not allow an experimentally verified assessment of the asymptotic plateau, thus 
the pEC50 and Emax values obtained for this compound (6.3 and 0.84) are extrapolated from the 
fitting routine (Table 5). J-113397, SB-612111, C-24, and naloxone did not modify the basal 
BRET ratio. The synthetic peptides that are partial agonist at G protein coupling (i.e., 
[F/G]N/OFQ(1-13)-NH2, [Nphe
1
]N/OFQ(1-13)-NH2, UFP-101, UFP-113, [Nphe
1
]N/OFQ(1-13)-
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NH2, and Ac-RYYRIK-NH2) showed only a variable and weak stimulation of receptor / arrestin 
interaction (Figure 24, Panel D).  
 
 
Figure 24. NOP receptor/β-arrestin 2 interaction experiments - Concentration-response curves to N/OFQ 
(Panel A); N/OFQ, UFP-112, PWT2-N/OFQ, N/OFQ(1-13)-NH2 , [Arg
14
Lys
15
]N/OFQ (Panel B); N/OFQ, 
SCH-221510, and Ro 65-6570 (Panel C); N/OFQ, UFP-113, UFP-101, [F/G]N/OFQ(1-13)-NH2, 
[Nphe
1
]N/OFQ(1-13)-NH2, and Ac-RYYRIK-NH2 (Panel D). Data are expressed as mean ± sem of at least 5 
separate experiments performed in duplicate. 
 
 
All such ligands were thus analyzed as antagonists. They behaved as competitive antagonists, by 
producing a rightward shift in the concentration-response curve of N/OFQ for arrestin coupling 
without affecting the Emax value. The following pA2 values were computed from such 
experiments: [F/G]N/OFQ(1-13)-NH2, 7.52, Ac-RYYRIK-NH2, 7.11, [Nphe1]N/OFQ(1-13)-
NH2, 7.00, UFP-101, 9.42 (Figure 25). All the data obtained in this series of experiments have 
been summarized in Table 6. Of note, the antagonist potencies estimated for these ligands in 
inhibiting arrestin coupling are very close to their agonistic potency in stimulating G protein 
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coupling. This indicates that the lack of agonistic effect on arrestin is not due an insufficient 
concentration of ligand that was used in the assay. 
We also measured the inhibitory potency for arrestin coupling of the other antagonists, such as J-
113397, SB-612111, C-24, J-113397, and, naloxone. With the exception of the latter, which was 
inactive, all antagonists produced the expected competitive inhibition with a rightward shift of 
the concentration-response curve of N/OFQ, from which pA2 values were computed. All the data 
obtained in this series of experiments are summarized in Table 6. 
 
 
Figure 25. NOP receptor / β-arrestin 2 protein interaction experiments - concentration-response curves to 
N/OFQ in absence and in presence of SB-612111 (100 nM, panel A), C-24 (10 nM, panel B), [F/G]N/OFQ(1-
13)-NH2 (300 nM, panel C), Ac-RYYRIK-NH2 (300 nM, panel D), J-113397 (300 nM, panel E), UFP-101 (1 
μM, panel F), UFP-113 (30 nM, panel G), and [Nphe1]N/OFQ(1-13)-NH2 (1 μM, panel H). Data are mean ± 
sem of at least 3 separate experiments performed in duplicate. 
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Table 5. Potencies (pEC50), concentration ratio (CR), and maximal effects (Emax) of the compounds tested on 
the interaction of NOP with G protein and β-arrestin 2. 
 G protein β-arrestin 2 
 pEC50 
(CL95%) 
CR 
Emax 
± sem 
pEC50 
(CL95%) 
CR 
Emax 
± sem 
N/OFQ 8.44 
(8.33 - 8.56) 
1 1 
8.02 
(7.81 - 8.23) 
1 1 
N/OFQ(1-13)-NH2 8.46 
(7.94 - 8.99) 
0.95 1.00 ±0.03 
8.02 
(7.72 - 8.32) 
1 1.00 ±0.08 
[Arg
14
Lys
15
]N/OFQ 9.27 
(9.21 - 9.33) 
0.15 1.00 ±0.05 
7.83 
(7.63 - 8.03) 
1.55 1.10 ±0.04 
UFP-112 9.35 
(9.10-9.60) 
0.12 0.98 ±0.03 
8.37 
(8.18-8.57) 
0.45 0.89 ±0.07 
PWT2-N/OFQ 9.17 
(8.97-9.48) 
0.19 1.10 ±0.01 
7.53 
(7.30-7.77) 
3.09 1.3 ±0.07 
[F/G]N/OFQ(1-13)-NH2 7.85 
(7.75-7.96) 
3.89 0.72* ±0.03 inactive 
UFP-113 9.35 
(9.29 - 9.41) 
0.12 0.45* ±0.04 inactive 
Ac-RYYRIK-NH2 7.90 
(7.45 - 8.34) 
3.39 0.63* ±0.02 inactive 
[Nphe
1
]N/OFQ(1-13)-NH2 6.85 
(6.70-6.99) 
38.9 0.55* ±0.04 inactive 
UFP-101 7.01 
(6.79 - 7.24) 
26.9 0.14* ±0.04 inactive 
Ro 65-6570 7.77 
(7.35 - 8.18) 
4.68 0.96 ±0.05 
6.37 
(6.08-6.65) 
44.67 0.84 ±0.06 
SCH-221510 8.26 
(7.06 - 9.46) 
1.51 1.20±0.03 
6.96 
(6.43-7.48) 
11.48 0.75 ±0.10 
J-113397 inactive inactive 
SB-612111 inactive inactive 
C-24 inactive inactive 
naloxone inactive inactive 
Inactive means the compound did not stimulate BRET ratios up to 10 μM. *p < 0.05 vs. N/OFQ, according to 
one way ANOVA followed by the Dunnett test for multiple comparison. 
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Table 6. Effects on NOP/G protein and NOP/β-arrestin 2 interactions of NOP ligands showing reduced 
efficacy. 
 G protein β-arrestin 2 
 pEC50 Emax pKB pEC50 Emax pKB 
N/OFQ 8.44 1.00 - 8.02 1.00 - 
[F/G]N/OFQ(1-13)-NH2 7.85 
 
0.72* - inactive 
7.52  
(6.88-8.16) 
UFP-113 9.35 
 
0.45* - inactive 
9.42  
(8.44-10.40) 
Ac-RYYRIK-NH2 7.90 
 
0.63* - inactive 
7.11  
(6.85-7.38) 
[Nphe
1
]N/OFQ(1-13)-NH2 6.85 
 
0.55* - inactive 
7.00 
(6.33-7.66) 
UFP-101 7.01 
 
0.14* 
7.66 
(7.23-8.10) 
inactive 
7.34  
(6.73-7.94) 
J-113397 inactive 7.95 
(6.06-9.83) 
inactive 
7.27 
(6.24-8.30) 
SB-612111 inactive 8.96 
(8.84-9.08) 
inactive 
7.91 
(7.26-8.56) 
C-24 inactive 9.11 
(8.19-10.05) 
inactive 
9.09 
(8.56-9.63) 
Naloxone inactive Inactive inactive inactive 
Inactive means that the compound was inactive up to 1 μM. 
 
 
The pharmacological activity of ligands for promoting NOP receptor-G protein interaction was 
found to be in close agreement with the available data obtained in the [
35
S]GTPγS binding assay. 
In fact the potency of N/OFQ in evoking stimulation of BRET ratio (pEC50 8.44) is very similar 
to that previously reported for the stimulation of [
35
S]GTPγS binding (e.g. 8.95, (Fischetti et al., 
2009)). Moreover, compounds such as UFP-112, [Arg
14
Lys
15
]N/OFQ, PWT2-N/OFQ, and 
N/OFQ(1-13)-NH2 behaved as full agonists in both assays and in both exhibited an identical rank 
order of potency: UFP-112 > [Arg
14
Lys
15
]N/OFQ > PWT2-N/OFQ > N/OFQ(1-13)-NH2 = 
N/OFQ (Calo' & Guerrini, 2013; Rizzi et al., 2014). Likewise, the results observed for number of 
synthetic peptides, known as NOP partial agonists, were also in best agreement with 
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pharmacological activities characterized in [
35
S]GTPγS binding assays. The order of potency 
measured for these ligands (UFP-113 > Ac-RYYRIK-NH2 > [F/G]N/OFQ(1-13)-NH2 > 
[Nphe
1
]N/OFQ(1-13)-NH2) is in line with previously reported results (Calo' & Guerrini, 2013). 
The very high potency exhibited by UFP-113 in the BRET assay (pEC50 9.35) associated with a 
relative efficacy of 0.45, is also consistent with the similar profile reported in [
35
S]GTPγS 
binding experiments (pEC50 9.73, Emax 0.79, (Arduin et al., 2007)). Non-peptide ligands such as 
Ro 65-6570 and SCH-221510 displayed similar maximal effects but a reduced potency (5 and 2 
fold lower, respectively) compared to N/OFQ. The same results were observed previously using a 
[
35S]GTPγS binding assay (Varty et al., 2008). 
The correspondence between BRET and GTPS activities is also evident on comparing the 
estimates of antagonist potencies (pKB values). For example, the BRET assay potency of SB-
612111 estimated either using a classic Schild protocol (pA2 8.96) and from inhibition-response 
curves (pKB 9.13) was compatible with the previous estimate (9.70) obtained in [
35S]GTPγS 
binding studies (Spagnolo et al., 2007). 
 
In this study the pharmacological profile of the human NOP receptor was investigated using a 
BRET assay, which is based on the fusion of a RLuc donor to the receptor and a RGFP acceptor 
to the transduction protein. The same technology was employed to investigate the interaction of 
the NOP receptor with Gβ1 subunits (which is mediated by endogenous G subunits of the 
membrane) and with β-arrestin 2 (which is recruited to the membrane upon receptor activation). 
Thus, receptor/G-protein interactions were studied in isolated membranes while receptor/arrestin 
interactions were determined in whole cells. The pharmacological profile for NOP receptor 
coupling to the two transduction proteins was evaluated using a large panel of peptide and non-
peptide ligands, all of which are selective for the NOP receptor and enclose molecules that are 
known to display a broad range of receptor efficacy, from full agonism to inverse agonism. This 
allows an exhaustive and meaningful comparison of the molecular characterization of NOP 
receptor activity presented in this study with pharmacological results reported in a variety of 
previous investigations. 
 
Control experiments indicate that the BRET signals reported here represent an accurate 
determination of the ligand-induced changes of NOP receptor coupling to the two fluorescently-
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tagged transduction proteins, and that the comparison of such activities are not biased by large 
differences in receptor expression between the cell clones employed in this work. In fact, we 
found that within the range of concentrations used in this study ligands did not exert unspecific 
effects on the enzymatic activity of the Rluc used as BRET donor (Auld et al., 2008). Moreover, 
the analysis of the intrinsic luminescence of the cell membranes, which quantifies the abundance 
of Rluc-tagged receptor, indicated that the NOP receptors were expressed at comparable levels in 
the two cell clones. 
The NOP/G1 BRET signal measured in cell membrane preparations cannot be influenced by -
arrestin 2, since the amount of this transducer in the plasma membrane is negligible prior to 
ligand activation of the receptor. However, the NOP/G1 interaction may be mediated by a 
plurality of G subunits that can interact with the receptor. As shown here, PTX treatment 
abolished the BRET signal, indicating that the measured activity is primarily accounted for by the 
pertussis-sensitive family of G subunits (i.e., Gi/o). Thus the pharmacological parameters of 
NOP/G protein interaction reported here can be meaningfully compared with the results of 
pertussis toxin-dependent signalling studies of the NOP receptor (Cheng et al., 1997; Margas et 
al., 2008; McDonald et al., 2003). In contrast, the NOP/β-arrestin 2 signal measured in whole 
cells was resistant to the toxin, indicating that the interaction with G protein does not interfere 
with the measurement or receptor-arrestin interactions. In conclusion, unlike the results of studies 
based on measurements of signalling activities occurring downstream of the transduction 
proteins, the receptor-transducer coupling activities reported in this study represent 
determinations that are largely unaffected by the mutual antagonism existing between arrestin 
and G protein for complex formation with the receptor. Thus, these results are independent 
estimates of the ability of NOP receptor to associate with each of the two proteins.  
In the present study we found that GDP was not able to significantly inhibit the baseline of BRET 
ratio in membranes from cells expressing NOP-RLuc and Gβ1-RGFP. This indicates that the level 
of spontaneous coupling between the NOP receptor and G proteins is negligible in isolated 
membranes, and stands in contrast with data reported earlier on delta/RLuc or mu/RLuc opioid 
receptors using the same type of BRET assay (Vezzi et al., 2013). This result suggests that the 
NOP receptor has very low propensity to adopt a constitutively active conformation, particularly 
if compared to the delta receptor. Also in support of this suggestion is the observation that the 
ligand C-24, which was previously reported to behave as NOP inverse agonist (Mahmoud et al., 
Results and Discussion: Novel assays 
 
57 
 
2010), did not produce any significant inhibition of the basal BRET ratio. In agreement with such 
a conclusion, little evidence for NOP receptor constitutive activity has been described so far, at 
least under physiological conditions. Data suggesting NOP constitutive activity were only 
obtained by electrophysiological recording of neurons in which the over expression of the 
receptor was induced by microinjection of coding cDNA (Mahmoud et al., 2010). In another 
study, in which the ability to constitutively activate G-protein-coupled pathways was investigated 
in a series of NOP receptor point mutations, only the N133W mutant displayed increased ligand-
independent signalling (Kam et al., 2002). Interestingly, this mutated residue (N3.35) was 
recently found to contribute to the network of interactions that establish a sodium binding pocket 
in the structure of several GPCRs (Katritch et al., 2014), including the delta opioid receptor 
(Fenalti et al., 2014). It was suggested that sodium binding may favor the inactive conformation 
of the receptor (Katritch et al., 2014). Thus, additional comparative BRET experiments on the G 
protein interactions of delta and NOP receptors bearing cross-mutations in the residues that 
generate the sodium pocket will be necessary to evaluate if this structural domain is responsible 
for the large difference in constitutive activity observed between the two receptor subtypes. 
 
In the first part of this study we appraised the pharmacological profile of the ligands in promoting 
NOP receptor interaction with the pertussis toxin-sensitive family of G-protein. As detailed in the 
Results section, the pharmacological parameters derived from this investigation are in best 
agreement with the results previously reported from the analysis of GTPS binding data  (Calo' & 
Guerrini, 2013; Fischetti et al., 2009; Rizzi et al., 2014). This finding is not surprising, as both 
assays are performed in isolated membranes and both measure the same early event of the 
signalling cascade, i.e., receptor-mediated G-protein activation. Yet, the good correlation that we 
found in this study is important, because it suggests that there is no dissociation between ligand-
induced coupling to the G protein and ligand-promoted changes in the nucleotide-exchange 
properties of the G protein, within the studied ligands. In other words, we found no evidence for 
the existence of ligands that on promoting receptor-G protein coupling might produce a non 
proportional or even opposite effect on G protein activation. Moreover, this satisfactory 
agreement between NOP/G protein coupling and NOP stimulated GTPS binding further 
demonstrate that the BRET assay used in the study provides a robust and precise assessment of 
the ligand ability to activate the NOP receptor. 
Results and Discussion: Novel assays 
 
58 
 
On comparing the data with a wider range of pharmacological assays carried in vitro or in vivo, 
noticeable discrepancies are only apparent for a number of synthetic peptides that are known as 
NOP partial agonists. Such divergences are likely explained by the variations in 
stimulus/response coupling efficiency that characterize different pharmacological preparations. In 
fact, in accordance with classical receptor theory, the effect of a partial agonist can range from 
none to an almost full response, depending on the extent of amplification that the sensitivity of 
the signaling pathway exerts on the initial biological signal triggered by the receptor in complex 
with the transduction protein. For example, the peptide analog [F/G]N/OFQ(1-13)-NH2 that 
shows a significant level of partial agonism (Emax 0.72) in this study, was previously reported to 
behave as pure antagonist in a low-efficiency coupled preparation, such as the electrically 
stimulated mouse vas deferens (Guerrini et al., 1998). The same ligand displayed varying level of 
efficacy in other studies in vitro or in vivo (Calo' & Guerrini, 2013); it was also specifically 
shown that the relative response of this agonist can be varied on manipulating the levels of NOP 
receptor expression, which is a typical feature of partial agonism (McDonald et al., 2003). 
Analogous considerations apply to UFP-113, which shows weak and variable agonism in the 
mouse vas deferens (Arduin et al., 2007), or to the hexapeptide Ac-RYYRIK-NH2, for which 
conflicting and variable levels of efficacy were reported in the literature (Calo et al., 2000a; 
Dooley et al., 1997). Also consistent with this interpretation are the results obtained with the 
analog UFP-101. Although this peptide is known to behave as pure antagonist in a vast range of 
pharmacological tests (Calo' & Guerrini, 2013; Calo et al., 2005), it displayed a faint but 
detectable level of residual efficacy (Emax 0.14) in our assay. This is in line with the observation 
that a weak partial agonism in UFP-101 could only be revealed after receptor over-expression in 
neurons microinjected with plasmid coding for the NOP sequence (Mahmoud et al., 2010). 
In conclusion, we suggest that the rank order of relative effects that we measured for these partial 
agonists in the BRET assay (i.e. [F/G]N/OFQ(1-13)NH2 > Ac-RYYRIK-NH2 > 
[Nphe
1
]N/OFQ(1-13)-NH2 > UFP-113 >> UFP-101, see table 2 ) provides a more accurate 
description of the level of efficacy endowed in these ligands. 
Also the estimates of antagonist potency derived from BRET analysis were in substantial 
agreement with similar determinations made in a variety of different pharmacological studies. 
However, one interesting observation is that two of such antagonists, SB-612111 and C-24, 
displayed a pattern of agonist inhibition suggesting insurmountable behavior under some assay 
conditions (i.e. 5 min incubation with agonist); this is in contrast with a plurality of previous 
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studies, were the competitive nature of these compounds was demonstrated (Fischetti et al., 2009; 
Spagnolo et al., 2007; Zaratin et al., 2004). We found, however, that a 3-fold increase in 
incubation time was sufficient to restore an essentially competitive pattern of antagonism in these 
compounds, while other antagonists with lower potency, such as UFP-101 or J-113397, did not 
show similar time-dependent changes. Thus, it is conceivable that the very slow dissociation rate 
of these ligands and the consequent effect on the agonist ability to reach a steady-state level of 
receptor occupancy are responsible for the phenomenon. Also in line with these findings is the 
intriguing observation that the antagonist action of UFP-101 in the isolated mouse vas deferens is 
immediately reversible on washing, while the effect of SB-612111 remains unchanged even after 
3 hours of repeated washing (Spagnolo et al., 2007). 
 
In the second part of the study, we report the pharmacological profile of the same panel of 
ligands for the induction of NOP receptor interaction with β-arrestin 2. Although this is the first 
study in which a systematic assessment of the efficacy of NOP agonists for arrestin was made, 
previous results based on NOP receptor internalization show that agonists active in promoting 
internalization of the NOP receptor (Corbani et al., 2004; Spampinato et al., 2007) are among 
those that in this study display a robust effect on arrestin coupling. This supports the notion that 
NOP receptor internalization requires a clathrin-dependent rapid endocytosis mechanism that is 
mediated by arrestins (Zhang et al., 1996). 
The most prominent finding in our data is that the agonists showing relative Emax values  0.7 in 
G protein coupling produced negligible or no effects on arrestin recruiting. In fact, we also found 
that these inactive ligands behaved as virtually pure competitive antagonists in inhibiting the 
effect of the endogenous agonist N/OFQ on arrestin interaction. These results remind similar 
observations reported for delta and mu receptor interaction with arrestin, where the relationships 
between G protein and arrestin couplings for both receptors were strongly hyperbolic (Molinari et 
al., 2010). Perhaps this hyperbolic relation may be stronger in the NOP receptor, judging from 
the greater threshold of partial G protein agonism that is necessary in order to observe a 
measurable effect on arrestin interaction. In addition, our results indicate that the potencies of 
agonists for NOP/arrestin interaction were systematically lower that those measured for NOP/G 
protein interaction, by factors ranging between 0.4 – 1.6 log units.  
As far as pure antagonists are concerned, these compounds were similarly active at NOP/G 
protein and NOP/arrestin interaction and displayed an identical rank order of potency i.e. C-24 > 
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SB-612111 > J-113397 > UFP-101, with potency values that were only slightly lower at NOP/β-
arrestin 2 than NOP/G-protein.  
Altogether the comparison of the pharmacological profile of NOP receptor interacting with G-
protein or with β-arrestin 2 suggests minor differences for receptor antagonists, loss of efficacy 
for partial agonists and decrease of potency for synthetic full agonists. Collectively, these 
findings indicate that the activation induced by most NOP agonists is significantly biased towards 
promoting receptor-G protein interaction rather than receptor-arrestin interaction. Thus, the 
question is whether this preference is caused by system bias or reflects a true difference in 
agonist efficacy for driving the NOP receptor to interact with the two transduction proteins. 
Two common sources of system bias are the difference in the efficiency of the signalling pathway 
that couples the activation of each transducer to the measured biological signals, or the difference 
in the sensitivity of the assay methods employed to evaluate divergent transduction pathways. 
Yet, neither kind of system bias is likely to affect the results presented in this study. In fact, the 
BRET signals reported here quantify the extent of protein-protein interaction between receptor 
and transducer; this is not influenced, unlike biological responses, by the differences in efficiency 
of the signalling pathways. Furthermore, the methodology adopted in this study is based on 
exactly the same pair of donor/acceptor reporters that were used to both assess G protein and 
arrestin interactions. Thus, it is unlikely that major differences in the efficiency of the resonance 
energy transfer system may alter the sensitivity of the two determinations. 
However, there is a third source of system bias that may play a fundamental role in our results: 
i.e., the difference in binding affinity for the interaction of the two transduction proteins with the 
empty receptor. On comparing G protein vs. arrestin interactions, this difference is particularly 
difficult to evaluate, because under the generic term “affinity” one must factor additional 
biochemical events that regulate the ability of arrestin to associate to the receptor, such as GRK-
mediated phosphorylation and the intracellular process of translocation that brings arrestin to the 
receptor in the plasma membrane. Thus, it is possible that a globally lower susceptibility of the 
NOP receptor to be docked by arrestin than by G protein might generate the systematic reduction 
in agonist effects observed here, despite a conserved efficacy of the ligands in promoting the two 
interactions. 
A qualitative criterion that helps to distinguish between ligand and system bias is the rank of 
ligand effects at the two transduction systems; in fact, system bias, regardless of the source, 
cannot alter this ordering. An inversion in the rank order of potency was noted for some agonists. 
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For example, [Arg
14
Lys
15
]N/OFQ and PWT2-N/OFQ were more potent than the natural agonist 
in promoting G protein interaction, but less potent than N/OFQ in inducing arrestin interaction. In 
contrast, UFP-112 and the non peptide agonists (SCH-221510 and Ro-656570) maintained the 
same rank of potency at the two transduction proteins. 
To obtain a quantitative estimate of biased efficacy, approximate values for the difference in 
intrinsic efficacies of the agonists for the two transduction proteins (i.e. εGprotein/εarrestin) were 
computed as bias factors. Agonists such as Ro-656570 and PWT2-N/OFQ, displayed a 10-fold 
greater efficacy for G protein interaction. Smaller differences were observed in other agonists, 
such as UFP-112 and SCH-221510, whereas no biased efficacy was found in N/OFQ(1-13)-NH2 
(Table 7). Although the large propagated error in this calculation prevents an accurate assessment 
of the significance of the computed differences, the data suggest that several synthetic agonists, 
including perhaps those that behave as pure antagonists of receptor-arrestin interaction, may 
display significant losses of intrinsic efficacy at this transduction protein. This trend might result 
from the fact that these synthetic NOP analogs were designed and selected on the basis of SAR 
studies derived from G-protein-dependent signalling assays. Thus, it is possible that SAR studies 
focused on receptor/β-arrestin interaction will allow the discovery of arrestin biased agonist for 
the NOP receptor in the future. 
 
 
Table 7. Bias factors obtained from at least 5 independent Emax/EC50 values from both NOP/G-protein and 
NOP/arrestin experiments. 
 
 bias factor ± sem 
N/OFQ 0.00 
N/OFQ(1-13)-NH2 0.00 ± 0.40 
[Arg
14
,Lys
15
]N/OFQ 0.25 ± 0.46 
UFP-112 0.71 ± 0.37 
SCH 221510 0.77 ± 0.75 
Ro-65 6570 1.07 ± 0.38 
PWT2-N/OFQ 1.09 ± 0.28 
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Ligand bias has important implications in drug development. In principle, using biased agonists 
that selectively activate a single transduction pathway it might be possible to maximize 
therapeutically useful responses and minimize side effects. Some examples of this innovative 
strategy were already described in literature. G-protein biased agonists acting at the mu opioid 
receptor are under development as analgesics with higher tolerability (DeWire et al., 2013) while 
G-protein biased agonists at GPR109 may reduce serum fatty acids without inducing cutaneous 
flushing (Walters et al., 2009). Similarly, β-arrestin biased agonists acting at the AT1 receptor 
may be effective drugs for the treatment of heart failure (Violin et al., 2010), while biased β-
arrestin PTH receptor ligands are potential innovative drugs for promoting bone formation 
(Ferrari et al., 2005). 
N/OFQ via selective NOP receptor activation can control several biological functions, however 
the relative role of G-protein and arrestin in mediating these actions is presently unknown. 
Further studies are needed to identify new lead molecules that will help to understand the 
structural requirements underlying the difference in efficacy of NOP agonists for G-proteins and 
arrestins, and the potential therapeutic indications of G-protein or arrestin biased NOP agonists. 
N/OFQ can produce robust antinociceptive effects following spinal administration both in rodents 
and non human primates (Schroder et al., 2014). Thus, it is important to clarify whether the 
extent of G-protein bias, which is present in some NOP agonists as shown in this study, may be a 
crucial determinant for the antinociceptive response; this may lead to the discovery of innovative 
spinal analgesics. Interestingly, compounds such as UFP-112 and PWT2-N/OFQ demonstrated 
robust and extremely long acting antinociceptive properties after spinal administration in rodents 
and monkeys (Hu et al., 2010; Rizzi et al., 2014; Rizzi et al., 2007). It has been suggested that 
the long lasting action of these compounds may reflect reduced susceptibility to peptidase action 
(Rizzi et al., 2014; Rizzi et al., 2007). However, according to the present data, we may speculate 
that the G protein bias nature of these compounds could contribute to their persistent 
antinociceptive effect. Further studies and the use of mice knockout for the β-arrestin 2 gene are 
needed to validate this hypothesis.  
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3.2. Ligands for classical opioid receptors 
 
 
3.2.1. Pharmacological characterization of N-substituted derivatives of morphine and 
oxymorphone. 
 
Morphine and structurally related derivatives are highly effective analgesics, and the mainstay in 
the medical management of moderate to severe pain. Pharmacological actions of opioid 
analgesics are primarily mediated through agonism at the MOP receptor. Position 17 in morphine 
has been one of the most manipulated sites on the scaffold and intensive research has focused on 
replacements of the 17-methyl group with other substituents. Structural variations at the N-17 of 
the morphinan skeleton led to a diversity of molecules appraised as valuable and potential 
therapeutics and important research probes. Discovery of therapeutically useful morphine-like 
drugs has also targeted the C-6 hydroxyl group, with oxymorphone as one of the clinically 
relevant opioid analgesics, where a carbonyl substitutes an hydroxyl group at position 6 (Figure 
26). 
 
 
Figure 26. Structures of morphine, oxymorphone and N-substituted morphinans (compounds 1-6). 
 
In the present study, we tested derivatives 1, 4 and 6 in the calcium mobilization assay. In CHO 
cells expressing the human MOP receptor and the Gaqi5 chimeric protein, all compounds 
produced a concentration-dependent stimulation of calcium mobilization (Figure 27). DAMGO 
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was able to concentration dependently stimulate the calcium mobilization with high potency 
(EC50 42.7 nM) and maximal effects (217±21% over the basal value), all other effects are then 
expressed as intrinsic activities α, fraction of the DAMGO maximal effects. Morphine and 
oxymorphone were also tested for their ability to stimulate calcium mobilization displaying EC50 
values of 140 and 44.3 nM, respectively, with maximal effects being significantly lower than 
DAMGO (α 0.55 and 0.52, respectively). N-phenethylnoroxymorphone (6) was about 2-fold 
more potent than DAMGO. Among the two morphine derivatives, N-phenethylnormorphine (1) 
was about 3-fold more potent than morphine and equipotent to DAMGO, and about 3-fold more 
active than its 14-hydroxy analogue 4 in terms of potency at the MOP receptor. Among the two 
morphine derivatives, N-phenethylnormorphine (1) was about 3-fold more potent than morphine 
and equipotent to DAMGO, and about 3-fold more active than its 14-hydroxy analogue 4 in this 
assay (Table 8). As far as maximal effect is concerned, compounds 1, 4, and 6 displayed lower 
maximal effects to that of DAMGO (α 0.70, 0.70, and 0.78, respectively). The same compounds 
were tested in CHO cells expressing the human DOP receptor and the GαqG66Di5 chimeric protein, 
and in cells expressing the human KOP receptor and the Gαqi5 chimeric protein, compound 4 was 
inactive at both DOP and KOP receptors, compounds 1 and 6 both displayed a weak stimulation 
of calcium mobilization in CHODOP cells only in the high micromolar range of concentrations, 
while being completely inactive at the KOP receptor (Figure 27).  
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Figure 27. Concentration response experiments to morphine, oxymorphone, derivatives 1, 4, and 6, in 
calcium mobilization experiments performed in CHOMOP stably expressing the chimeric Gαqi5 chimeric 
protein. Agonists effects were expressed as FIU % over the basal value. Data are the mean ± sem of at least 3 
separate experiments performed in duplicate. 
 
 
Table 8. Potency and efficacy values at MOP, DOP, and KOP receptors in calcium mobilization assay. 
 MOP DOP KOP 
 EC50 (nM) α EC50 (nM) α EC50 (nM) α 
Morphine 140±31 0.55±0.03 inactive 2185±451 0.51±0.02 
Oxymorphone 44.3±9.7 0.52±0.05 inactive inactive 
1 48.8±14.0 0.70±0.04 crc incomplete inactive 
4 124±20 0.70±0.07 inactive inactive 
6 23.4±4.7 0.78±0.02 crc incomplete Inactive 
Data are mean ± sem of at least 3 separate experiments performed in duplicate. Inactive: the compound was 
inactive up to 10 µM. Crc incomplete: concentration response curve does not reach the maximal effect up to 
10 µM. α is expressed as a fraction of the maximal stimulation produced by DAMGO (MOP), DPDPE (DOP) 
or U69,593 (KOP). 
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The rank order of potency (6 > 1 > 4) and the high selectivity for the MOP receptor found, are in 
line with data obtained in the stimulation of [
35S]GTPγS binding assay (Table 9). Potency and 
efficacy values obtained in calcium mobilization assay and in the stimulation of [
35S]GTPγS 
binding, and receptor binding affinities at the MOP receptor (Table 10), together with previous in 
vivo data from the literature for compounds 1 (Winter et al., 1957) and 6 (Loew & Berkowitz, 
1978) were used for establishing an appropriate dose range for in vivo investigations.  
 
Table 9. Potency and efficacy values at MOP, DOP, and KOP receptors in the stimulation of stimulation of 
[
35S]GTPγS binding assay, performed in membranes from CHO cells stably expressing the human MOP, 
DOP, or KOP receptors. 
 MOP DOP KOP 
 EC50 (nM) α EC50 (nM) α EC50 (nM) α 
Morphine 34.4±5.1 0.89±0.17 668±65 1.09±0.14 710±23 0.76±0.02 
Oxymorphone 4.38±0.76 0.98±0.11 259±33 0.87±0.40 463±116 0.48±0.11 
1 10.3±0.9 1.13±0.08 712±86 1.38±0.17 1049±29 0.19±0.02 
4 46.3±7.1 1.19±0.03 1247±356 1.25±0.15 nd 
6 2.63±1.06 0.97±0.03 131±60 1.01±0.09 225±74 0.08±0.01 
Data are mean ± sem of at least 3 separate experiments performed in duplicate. ND, not determined due to 
very low binding affinity at the KOP receptor. α is expressed as a fraction of the maximal stimulation 
produced by DAMGO (MOP), DPDPE (DOP) or U69,593 (KOP). 
 
 
Table 10. Receptor binding assays were performed with membranes from rat brain (MOP and DOP receptors) 
and guinea pig brain (KOP receptors).  
 MOP DOP KOP 
 Ki (nM) Ki (nM) Ki (nM) 
Morphine 6.55±0.74 217±19 113±9 
Oxymorphone 0.97±0.05 80.5±5.5 61.6±1.2 
1 0.93±0.14 37.0±5.5 107±18 
2 79.5±1.1 869±171 565±24 
3 16.4±1.1 1081±271 789±77 
4 4.60±0.01 163±17 513±66 
5 359±31 1078±35 75.0±8.0 
6 0.54±0.03 12.8±0.2 84.2±7.2 
Data are mean ± sem of at least 6 separate experiments. 
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Antinociceptive properties of morphine derivatives 1 and 4, and oxymorphone analogue 6 were 
assessed in mice after subcutaneous (s.c.) administration using two nociceptive tests, hot-plate 
and tail-flick tests (Spetea et al., 2010). All three MOP agonists produced time- and dose-
dependent effects in both nociceptive assays with compounds 1 and 6 being the most effective 
against acute thermal nociception. The antinociceptive peak occurred generally 30 min after drug 
s.c. administration. Antinociceptive potencies expressed as ED50 values with 95% confidence 
limits are summarized in Table 9, and were compared with those of the reference opioids drugs, 
morphine and oxymorphone. In agreement with pivotal works in this field (Winter et al., 1957), 
the morphine derivative 1 elicits a stronger antinociceptive effect than morphine. In the hot-plate 
and tail-flick tests, it was 22- and 28-fold, respectively, more effective than morphine. First data 
on the antinociceptive effect of N-phenethyl-14-hydroxynormorphine (4) revealed that this MOP 
agonist is a potent antinociceptive agent with a 2- to 3-fold increased potency than morphine. 
Compound 6, the N-phenethyl analogue of oxymorphone, was found to be highly active with 
about 2-fold higher potency than oxymorphone, and comparable potency to 1. It was 8-fold more 
potent than its 6-hydroxy counterpart 4 in inducing an antinociceptive response, indicating that a 
6-keto substitution leads to improved analgesic properties. Besides analgesia, MOP agonists are 
well-known to induce other behavioral changes. In general, no major alterations in locomotor 
activity and no sedative effects were observed at any of the tested doses of compounds 1, 4 and 6, 
representing about 3- to 4-fold the analgesic ED50 dose, further investigations will be needed to 
establish the therapeutic index of these compounds (Ben Haddou et al., 2014a). 
 
In conclusion, position 17 in morphine has been one of the most manipulated sites on the scaffold 
and intensive research has focused on replacements of the 17-methyl group with other 
substituents. Structural variations at the N-17 of the morphinan skeleton have resulted in a 
diversity of compounds appraised as valuable and therapeutic agents and important research tools 
(Furst & Hosztafi, 2008; Pasternak & Pan, 2013; Spetea et al., 2013; Spetea & Schmidhammer, 
2012). Furthermore, discovery of therapeutically useful morphine-like drugs has also targeted the 
C-6 hydroxyl group, with oxymorphone as one example of the clinically relevant opioid 
analgesics, where a carbonyl instead of a hydroxyl group is present at position 6 (Furst & 
Hosztafi, 2008; Schmidhammer et al., 2013). Taken together, in the present study we highlight on 
the significant outcomes of N-substituent variation in morphine and oxymorphone on in vitro and 
in vivo biological properties and the emerging SAR. The presented data clearly reflect that a 
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Nphenethyl moiety in position 17 is highly favorable regarding enhanced affinity and selectivity 
at the MOP receptor, potent agonism and antinociceptive action. The increased lipophilicity of 
the N-phenethyl derivatives compared to the parent compounds may also contribute to the 
increased potency. Besides, it was also demonstrated that a carbonyl group at position 6 is 
preferable to a hydroxyl function in the N-phenethyl substituted molecules, augmenting MOP 
receptor affinity and agonist potency in vitro and in vivo. Though morphine derivatives, N-
phenethylnormorphine (1) and N-phenethyl-14-hydroxynormorphine (4), and the oxymorphone 
analogue N-phenethylnoroxymorphone (6) have been developed many years ago, this is the first 
report on their opioid receptor binding and signaling, and antinociceptive efficacy. This report 
clarifies the activity of these molecules at the opioid receptors for the first time, serving as a 
systematic study of understanding their mode of action and the link between agonist-induced G 
protein signaling events leading to the high analgesic efficacy. Moreover, these results reveal that 
targeting position 17 is a viable approach toward improving the pharmacological properties, and 
may be instrumental to the development of new opioids for therapeutic use in the clinic. 
Considering the interesting functional profile of these MOP agonists and their high efficacy as 
antinociceptive agents, it is of interest to investigate other intracellular signaling pathways (i.e. 
interactions with regulatory proteins such as β-arrestins) and their side-effect profile in future 
studies.   
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3.2.2. Exploring pharmacological activities of morphinans substituted in position 6 as 
potent MOP agonists 
 
A series of structurally related derivatives of morphine, substituted in position 6 with acrylonitrile 
and amid functions (Figure 28) were characterized for their pharmacological activities.  
 
 
Figure 28. Structures of N-methylmorphinans (compounds 1-6). 
 
Compounds 1-6 were tested in CHO cells stably expressing the human MOP receptor and the 
Gαqi5 chimeric protein. All compounds evoked a concentration-dependent stimulation of calcium 
mobilization (Figure 29). Compound 5 was the most potent with an EC50 value of 21.7 nM, being 
2-fold more potent than DAMGO, with lower maximal effects than the standard MOP agonist 
(intrinsic activity α 0.70, fraction of DAMGO maximal stimulation). Analogue 4 also showed 
high potency and maximal effect lower than that of DAMGO (EC50 56.1 nM, α 0.59). The other 
6-cyano substituted derivatives 1, 2, 3 and 6 exhibited up to 10 times higher potency than 
oxycodone and 14-OMC. In terms of efficacy, compounds 1–6 and 14-OMC showed 
intermediate maximal effects between oxycodone (α 0.38) and DAMGO (Table 11). Compounds 
1–6, oxycodone and 14-OMC were also functionally evaluated in the stimulation of [35S]GTPγS 
binding assay, their effects are reported as percentage of DAMGO maximal effects (Table 11).  
Compounds 1-6 concentration dependently stimulated the binding of [
35S]GTPγS, showing that 
the 6-cyano substituted 2, 3, 5 and 6, and their amido analogue 4 were approximately 10-fold 
more potent than oxycodone and 14- OMC, while the 4,14-dihydroxy-6-cyanomorphinan 1 
displayed similar potency. Similarly to calcium mobilization, derivative 5 was the most potent 
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agonist with an EC50 value of 1.64 nM. This 6-cyanomorphinan derivative was also 12-fold more 
potent than DAMGO (EC50 20.2 nM), while the analogues 1–4 showed similar or lower 
potencies. The 6-amido substituted 4 was 16 fold more potent than its 6-cyano analogue 5, but 
similar potency to the other two 6-cyanomorphinans 2, 3 and 6. The 4-methoxy analogue 2 had 
an about 6 times greater potency than its 4-hydroxy counterpart 1. A further increase in potency 
resulted upon methylation of the hydroxyl group in position 14, leading to compound 3 with 
about 10 fold lower EC50 value than its analogue 1.  
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Figure 29. Concentration response experiments to morphine, DAMGO, oxycodone, and 14-OMC (left panel), 
and derivatives 1-6 (right panel), in calcium mobilization experiments performed in CHOMOP stably 
expressing the chimeric Gαqi5 chimeric protein. Agonists effects were expressed as FIU% over the basal 
value. Data are the mean ± sem of at least 3 separate experiments performed in duplicate. 
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Table 11. Potency and efficacy values in the stimulation of [
35S]GTPγS binding assay, in membranes from 
CHO cells expressing the human MOP receptor, and in calcium mobilization assay in CHO cells expressing 
both the human MOP receptor and the chimeric G protein. 
 
 [
35S]GTPγS binding Calcium mobilization 
 EC50 (nM) α EC50 (nM) α 
Oxycodone 500±128 0.92±0.09 1176±347 0.38±0.03 
14-OMC 325±94 1.37±0.55 973±204 0.72±0.07 
1 273±24 0.98±0.04 957±233 0.57±0.04 
2 42.5±14.9 0.97±0.15 116±9 0.69±0.07 
3 26.2±1.7 0.85±0.03 140±21 0.61±0.06 
4 25.6±9.5 1.07±0.26 56.1±11.3 0.59±0.08 
5 1.64±0.19 1.33±0.07 21.7±5.5 0.70±0.08 
6 25.1±3.6 1.21±0.27 173±21 0.84±0.10 
DAMGO 20.2±5.6 1.00 42.7±7.6 1.00 
Data are mean ± sem of at least 3 separate experiments performed in duplicate. 
 
 
Binding affinities at MOP, DOP and KOP receptors of the new 6-acrylonitrile incorporated N-
methylmorphinans (5 and 6) and the corresponding amido derivative 4 were determined by 
radioligand binding assays in rat brain membranes. Data were reported as inhibition constant (Ki) 
values and summarized in Table 11. All three new derivatives 4-6 displayed a marked increase in 
MOP receptor affinity than the parental oxycodone. Compounds 4-6 showed high affinity for the 
MOP receptor, with derivative 5 showing a very high affinity (Ki 0.54 nM) and selectivity for the 
MOP receptor in rat brain membranes. Compound 4-6 showed 10/100 fold lower affinities at 
DOP and KOP receptors. The 6-amido substituted derivative 4 also showed high MOP receptor 
affinity in the low nanomolar range (Ki value of 1.61 nM), but reduced MOP selectivity. The 
presence of a 6-cyano group in 5 appears to be favorable for both affinity and selectivity for the 
MOP receptor, while a 6-amido substitution (4) leads to 3 to 9 fold lower MOP receptor affinity, 
and up to 5 and 7 fold reduced MOP receptor selectivity vs DOP and KOP receptors, 
respectively. In addition, the high affinity at the MOP receptor displayed by the 6-
cyanomorphinan 5 in the rat brain was also demonstrated at the recombinant rat MOP receptor 
expressed in C6 glioma cells (C6rMOP, Ki = 0.70 nM). In line with findings in the rat brain, low 
binding affinities were determined for this compound in C6 cells transfected with rat DOP 
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receptors (Ki = 56 nM) and Chinese hamster ovary (CHO) expressing human KOP receptors (Ki 
= 229 nM), thus extending the outcomes on the high MOP selectivity of 5 (80 fold vs DOP and 
327 times vs KOP). Comparison of the new 6-acrylonitrile 4,5-oxygen bridged 6 to the earlier 
developed non-bridged analogue 3 depicted no major changes in the MOP affinity and 
selectivity. It was also noted that methylation of the 4-hydroxy group in compounds 2, 4 and 5 
gives rise to an improved interaction with the MOP receptor. The comparison between 14-
methoxy and 6-cyano substituted 6 to its 6-keto counterpart 14-O-methyloxycodone (14-OMC), 
it was observed that the presence of a 6-acrylonitrile moiety increases binding to the MOP 
receptor by about 5 times (Table 12). Also, a similar increase was observed in the case of the 
other two new 14-methoxy substituted derivatives 4 and 5. The presence of a hydroxyl group in 
both 4 and 14 positions (compound 1) appears to largely affect binding at the MOP receptor. 
Compared to 6- cyano-N-methylmorphinans 1–3 described earlier (Spetea et al., 2005), the new 
analogues 4 and 5 had one order of magnitude lower Ki values at the DOP receptor, with the 6-
cyano derivative 6 showing comparable and reduced affinity. Also, like the 6-cyanomorphinans 
1–3, compounds 4– 6 retained the decreased binding at the KOP receptor (Table 12). 
 
 
Table 12. Receptor binding assays performed in membranes from rat brain. 
 MOP DOP KOP 
 Ki (nM) Ki (nM) Ki (nM) 
Oxycodone 43.6±1.5 1087±246 2658±367 
14-OMC 35.3±2.1 116±15 454±6 
1 31.7±2.1 498±79 1648±201 
2 2.44±0.13 107±5 364±7 
3 5.38±0.42 197±29 378±155 
4 1.61±0.05 28.8±2.3 105±45 
5 0.54±0.04 30.3±2.9 200±40 
6 7.39±0.34 239±40 194±68 
Data are mean ± sem of at least 3 separate experiments performed in duplicate. 
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The new derivatives 4–6 were evaluated in vivo for their antinociceptive effects in mice after 
subcutaneous (s.c.) administration using three well-established and commonly used tests, hot-
plate, tail-flick and PPQ abdominal stretching (Schutz et al., 2003). Both hot-plate and tail-flick 
assays are valuable models for acute thermal nociception. Activity in the hot-plate test suggests 
that a drug acts at the supraspinal level, whereas the tail-flick may reflect spinal activity (Le Bars 
et al., 2001). The PPQ assay evaluates chemical sensitivity, and is established as a model for 
visceral pain (Le Bars et al., 2001). Antinociceptive potencies expressed as ED50 values are listed 
in Table 13 from (Ben Haddou et al., 2014b), and were compared with those of the previously 
reported N-methyl-6-cyanomorphinans 1–3 (Spetea et al., 2005), oxycodone and 14-OMC. As 
shown in Table 13, compounds 4–6 produced potent antinociceptive effects in all three in vivo 
assays. The 6-cyano substituted 5 and 6 exhibited markedly higher antinociceptive potencies than 
the 6-amido analogue 4, and were up to 165 times more active than oxycodone. The 6-
acrylonitrile 4,5-oxygen bridged 6 showed comparable potency to its analogue 5 in the hot-plate 
and PPQ tests, and it was 3 times less potent in the tail-flick test. Compared to the earlier 
described derivatives 1–3 (Spetea et al., 2005), the new 6-cyanomorphinans 5 and 6 were overall 
more potent as antinociceptive agents in mice after s.c. administration being highly effective 
against thermal and chemical nociception. The 6-amido derivative 4 was as potent as compound 1 
in the tailflick and PPQ assays, while it was about 3 times less active in the hot-plate test (Table 
3). Antinociceptive potencies of compound 4 were also found to be comparable to those of 14-
OMC and oxycodone. The 14- methoxy-6-cyanomorphinan 6 was 11, 7, and 72 times more 
potent than its 6-keto counterpart 14-OMC in inducing an antinociceptive response in the hot-
plate, tailflick, and PPQ assays, respectively. In addition to antinociception, MOP agonists are 
well-recognized to elicit other behavioral changes in rodents. In the current study, there were no 
sedative effects observed at any of the tested doses. Some increase in locomotor activity was 
noticed in mice, however, this only occurred at doses in the upper end of the dose–response 
curve, i.e. 90% of analgesia. Further investigations will be needed to establish the side effect 
profile of these opioids. 
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Table 13. Antinociceptive activities in the hot-plate (HP), tail-flick (TF), and PPQ abdominal stretching test. 
 ED50 (mg/kg, s.c.) (CL95%) 
 HP TF PPQ 
Oxycodonea 1.37 (0.48-3.92) 0.94 (0.40-2.30) 0.38 (0.19-0.75) 
14-OMC 1.02 (0.52-2.01) 0.80 (0.32-2.04) 0.22 (0.12-0.41) 
1a 0.50 (0.12-2.02) 1.88 (1.25-2.83) 0.18 (0.076-0.42) 
2a 0.15 (0.054-0.41) 0.12 (0.061-0.23) 0.026 (0.012-0.055) 
3a 0.25 (0.11-0.59) 0.21 (0.11-0.40) 0.11 (0.072-0.16) 
4 1.30 (0.56-3.03) 1.34 (0.53-3.03) 0.18 (0.08-0.43) 
5 0.080 (0.011-0.61) 0.040 (0.020-0.090) 0.0023 (0.0009-0.0060) 
6 0.089 (0.037-0.21) 0.12 (0.070-0.20) 0.003 (0.0007-0.012) 
Antinociceptive potencies in mice after s.c. administration shown as ED50 values with 95% confidence limits 
(95% CL) (n = 6–10 mice per group). aData from (Ben Haddou et al., 2014b) 
 
 
Though natural opioid alkaloids such as morphine and codeine (Figure 1) contain a 6-hydroxyl 
group, synthetic approaches have uncovered that functionalizing position 6 gives rise to a wide 
range of diverse activities (Schmidhammer et al., 2013). Thus, position 6 of the morphinan 
skeleton has been a major target for successful drug developments over the years, leading to 
various opioid agonists and antagonists that are of importance both for clinical use and research. 
Oxycodone and oxymorphone, clinically used as opioid analgesics, are two representative 
examples of structural variation at C-6, where a carbonyl instead of a hydroxyl group is present in 
position 6. By targeting the chemically highly versatile 6-keto function of morphinan- 6-ones as 
in oxycodone, we have previously reported on a chemically innovative modification giving rise 
to a novel class of morphinans with acrylonitrile incorporated substructures (Greiner et al., 2001; 
Spetea et al., 2005). The resulted acrylonitrile incorporated 4,5-oxygen bridge-opened N-
methylmorphinans (1–3, Figure 1) emerged as high affinity and potent MOP antinociceptive 
agents, with a pharmacological profile comparable to that of their 6-keto counterparts (Spetea et 
al., 2005). The interesting approach to incorporate acrylonitrile substructures into morphinans 
was further explored by our group and resulted in new derivatives (Schutz et al., 2005).  
In the present study, combining in vitro ligand binding and functional assays and in vivo 
behavioral approaches, we show that the presence of a cyano group in position 6 in N-
methylmorphinans has a strong influence on opioid receptor binding and post-receptor molecular 
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events. In line with our previous findings, having a 6-cyano group in N-methylmorphinans (5 and 
6) results in increased MOP receptor activity compared to the lead molecule oxycodone both in 
vitro and in vivo. In the series of 6-cyanomorphinans, the new derivative 5 was consistently 
identified to exhibit the highest affinity and selectivity at the MOP receptor and to be the most 
potent MOP agonist. The design of compound 5 having a 4,14-dimethoxy substitution was 
attained based on our earlier observations, when a 4-methoxy group and/or a 14-methoxy group, 
like in compounds 2 and 3, is more favorable for binding and selectivity for the MOP receptor 
and antinociceptive activity than the corresponding hydroxy counterpart 1 (Spetea et al., 2005). 
Herein, we also establish that the presence of a methoxy group in both positions, 4 and 14, has a 
major impact not only on binding affinities to all three opioid receptor types, and MOP receptor 
selectivity, but also on agonist potencies and efficacies at this receptor. We have also examined 
how the combination of a C-6 cyano functionality together with a closed 4,5-oxygen bridge 
(compound 6) will affect in vitro and in vivo opioid activities. The two 6-cyanomorphinans 3 and 
6 show high and similar affinities at the MOP receptor, and low binding to DOP and KOP 
receptors. In both functional studies, [
35S]GTPγS binding and intracellular calcium mobilization, 
compounds 3 and 6 acted as potent MOP agonists with comparable EC50 values, and a somewhat 
reduced efficacy showed by derivative 3. In vivo, the 6- cyanomorphinan 6 with a closed 4,5-
oxygen bridge was more potent than its 4,5-oxygen bridge-opened analogue 3 in inducing an 
antinociceptive effect in mice after s.c. administration (ca. 3 times in the hot-plate, 2 times in the 
tail-flick and 37 times in the PPQ tests). Closing of the 4,5-oxygen bridge in the 6-acrylonitrile 
substituted 3 produces no major changes in interaction with the MOP receptor in vitro, but 
augmented antinociceptive potency. On the other hand, the 14-methoxy-6-cyanomorphinan 6 
showed greater MOP receptor affinity and agonist potency than 14-OMC and the 14-hydroxy 
substituted oxycodone, together with much better antinociceptive properties. It was of interest to 
assess the result of the conversion of the 6-acrylonitrile to a 6-amido group on the interaction 
with opioid receptors, signaling, and the link between antinociceptive efficacy and the mode of 
action. Since the presence of 4- and 14-methoxy groups was favorable in the case of the 6-cyano 
substituted N-methylmorphinan 5, the same substitution pattern was applied to the 6-amido 
analogue 4. It was remarkable to note that the presence of an amido group in position 6 resulted 
in high affinity at the MOP receptor and also good MOP selectivity. In the [
35S]GTPγS functional 
assay, the 6- amido substituted 4,5-oxygen bridge-opened 4 acted as a highly efficacious agonist 
at the MOP receptor with several times increased potency than oxycodone, 14-OMC and 4,14-
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dihydroxy substituted 6-cyanomorphinan 1. The same profile was depicted for compound 4 when 
stimulating G protein signaling and intracellular calcium release through MOP receptors. When 
compared to the 6-cyano analogue 5, the 6-amido group in 4 appears to largely affect agonist 
potency, leading to reduced activity, especially in antinociceptive potency. It is possible that 
differential metabolism of derivatives 4 and 5 may determine the differences in the in vivo 
activity. Primary aliphatic amides are known to be rapidly metabolically hydrolyzed (Testa & 
Mayer, 2006) whilst the nitrile group is more stable (Fleming et al., 2010). In this study, we 
described the in vitro functional activities of the previously reported 6-cyanomorphinans 1–3 and 
oxycodone based on the assessment of MOP receptor-mediated G protein activation and 
intracellular calcium mobilization. Replacement of the 4-hydroxy group in 6-cyanomorphinan 1 
with a 4-methoxy group in analogue 2, or substitution of 14-hydroxyl in compound 1 with a 14-
methoxy group in 3 results in 6 to 10 times enhanced agonist potencies and comparable 
efficacies, upon the test being used. Compared to the 6- ketomorphinans oxycodone and 14-
OMC, the 6-cyano substituted N-methylmorphinans 1–3 generally displayed higher agonist 
activity in vitro, which correlates well with the in vivo results on antinociceptive properties. 
Among all investigated N-methylmorphinans, derivative 5 is the most potent agonist in terms of 
G protein coupling and changes in intracellular calcium concentration. This MOP agonist potency 
enhancement of the new 6-cyanomorphinan 5 compared to the other derivatives established in the 
two functional assays is in agreement with the outcomes from in vitro binding assays and 
nociceptive tests, and supports the importance of the presence of both methoxy groups in 
positions 4 and 14 in this class of opioid morphinans (Spetea et al., 2005). The clinically relevant 
analgesic oxycodone was found as the MOP ligand with the lowest agonist potency in the series 
of the investigated morphinans. In CHOhMOP cell membranes, oxycodone stimulated [
35S]GTPγS 
binding with a EC50 value of 500 nM, which is lower than the EC50 value of 1.40 μM reported by 
Thompson et al. in the same cell line (Thompson et al., 2004). In the same work, a lower relative 
efficacy as percentage stimulation compared to DAMGO at the human MOP receptor in CHO 
cells was found for oxycodone (67%), while in this study a higher efficacy, i.e. 92% stimulation 
relative to DAMGO, was determined. Comparable potency (EC50 373 nM) and lower relative 
efficacy (66%) for oxycodone to our data was reported in C6rMOP cells (Peckham & Traynor, 
2006). Similarly, in CHOhMOP cells stably expressing the Gαqi5 chimeric protein, oxycodone 
exhibited low activity, by producing stimulation of calcium release with an EC50 value of 1,176 
nM and an efficacy of 38%. A recent study (Zhang et al., 2012) reported  on changes in 
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intracellular calcium levels produced by oxycodone in human embryonic kidney-293 (HEK293) 
cells co-expressing the human MOP receptor and Gαqi3 chimeric protein, with low potency (1.74 
μM) and high efficacy (100%). Although 14-OMC also displays low agonist potencies at the 
human MOP receptor in both functional systems, it shows a similar efficacy compared to 
oxycodone in [
35S]GTPγS binding and in calcium mobilization, that is also seen in 
antinociceptive potency. Mostly, compounds 1–6, oxycodone and 14-OMC were found to be 
more potent MOP agonists in the terms of G protein activation based on the lower EC50 values by 
one order of magnitude than the EC50 values for the calcium signaling, and with lesser efficacies 
measured in the latter. Presumably these differences may be due to variances in receptor reserve 
in the two cell lines, and/or possibly membranes vs. intact cells. Differences in signaling may 
also be regulated by the MOP receptor localization within the plasma membrane (Ge et al., 2009; 
Zheng et al., 2008). Receptor localization within the lipid rafts after agonist binding can promote 
G protein coupling or recruitment of other intracellular regulatory proteins (Levitt et al., 2009; 
Raehal et al., 2011). Over the past years, increased attention has been drawn to the understanding 
of intracellular signaling pathways that mediate the therapeutic and/or adverse effects of opioid 
agonists acting at the MOP receptor (Kelly, 2013; Pradhan et al., 2012; Raehal & Bohn, 2014). In 
vitro and in vivo studies demonstrate that different opioids can initiate distinct cellular and 
physiological responses downstream of receptor activation (Pradhan et al., 2012; Raehal et al., 
2011). The nature of MOP receptor signaling and regulation are functions not only of the type 
and structure of the agonist acting at the receptor but also of the cellular environment in which 
the receptor is expressed (Raehal et al., 2011). Moreover, the present understanding of MOP 
receptor function is persistently increasing, as the crystal structure is now available (Manglik et 
al., 2012). For a detailed discussion of these data see (Ben Haddou et al., 2014b). 
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3.2.3. Pharmacological characterization of endomorphin-2-based cyclicpentapeptides with 
methylated phenylalanine residues 
 
The cyclization of linear peptide sequences has been shown to result as a possible way to modify 
the pharmacological properties of opioid peptides (Piekielna et al., 2013). The aim of the present 
study was to pharmacologically characterize a panel of endomorphin-2 (EM-2, Tyr-Pro-Phe-Phe-
NH2) cyclic derivatives, modified from the previously described structure (compound 1) Dmt-
c[D-Lys-Phe-Phe-Asp]NH2 (Fichna et al., 2011). The derived compounds are: 2 (Dmt-c[D-Lys-
2’-MePhe-Phe-Asp]NH2), 3 (Dmt-c[D-Lys-3’-MePhe-Phe-Asp]NH2), 4 (Dmt-c[D-Lys-4’-
MePhe-Phe-Asp]NH2), 5 (Dmt-c[D-Lys-Phe-2’-MePhe-Asp]NH2), 6 (Dmt-c[D-Lys-Phe-3’-
MePhe-Asp]NH2), and 7 (Dmt-c[D-Lys-Phe-4’-MePhe-Asp]NH2). 
 
The in vitro biological activities of this series of compounds were evaluated at MOP, DOP, and 
KOP receptors, in the calcium mobilization assay. CHO cells stably expressing either the human 
MOP, DOP, or KOP, and chimeric G proteins were used to monitor calcium changes. 
Concentration response curves to EM-2 and compounds 1-6 are shown in Figure 30, the 
calculated agonist potencies (pEC50) and efficacies (α) are summarized in Table 14. Dermorphin, 
DPDPE, and dynorphin A were used as the reference agonists at the MOP, DOP, and KOP 
receptors, respectively. In general, all the analogs behaved as agonists displaying high potency at 
all three opioid receptors.  
In the CHOMOP cells both dermorphin and EM-2 evoked a concentration dependent stimulatory 
effect, displaying high potency (pEC50 8.11 and 7.81) and maximal effect of 221 ± 13% and 202 
± 7% over the basal value, respectively (Figure 30, panel A). The EM-2 analogs 1, 2, 5–7 
mimicked the stimulatory effect of dermorphin, showing similar potencies and maximal effects. 
Compounds 3 and 4 displayed high potencies associated with a significant reduction in efficacies. 
In the CHODOP cells, the DOP receptor selective ligand, DPDPE, showed high potency (pEC50 
8.20), while EM-2 did not stimulate calcium release up to 1 µM. All tested compounds were able 
to stimulate calcium mobilization, displaying moderate/high potency (pEC50 6.53-7.90) and low 
maximal effects (Figure 30, panel B). In the CHOKOP cells dynorphin A evoked a concentration 
dependent stimulation of calcium release displaying high potency (pEC50 8.88) and maximal 
effect (186 ± 10% over the basal values), while EM-2 did not stimulate calcium mobilization up 
to 1 µM (Figure 30, panel C). Analogs 3, 5, 6 and 7 exhibited high potencies; their maximal 
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effects were slightly but significantly lower than those evoked by dynorphin A. Compound 4 
showed lower maximal effect and potency as compared with dynorphin A. Compounds 1 and 6 
elicited maximal effects similar to those of dynorphin A but lower potencies.  
Collectively, analogs 5–7 with MePhe substitutions in position 4 displayed the highest potency at 
the MOP receptor (Figure 30, panel A). All cyclic analogs acquired agonist activity at the DOP 
receptor, where 2’-MePhe4 substitution produced the strongest effect (Figure 30, panel B). 
Additionally, analogs 1–7 showed very high potency for the KOP receptor (Figure 30, panel C). 
The highest potency at all three receptors was found for analog 5 with 2’-MePhe4, while analogs 
with 4’-MePhe3 were the least potent.  
 
 
 
Figure 30. Concentration response curves to EM-2, cyclic analogs and dermorphin
a
 (A), DPDPE
a
 (B) 
and dynorphin A
a
 (C) in calcium mobilization experiments performed in CHOMOP, CHODOP and 
CHOKOP cells, respectively. Data are mean ± sem of at least 4 separate experiments performed in 
duplicate. 
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Table 14. Effects of the cyclic pentapeptides at human recombinant opioid receptors coupled with calcium 
signaling via chimeric G proteins. 
 MOP DOP KOP 
 
pEC50 
(CL95%) 
α ± sem 
pEC50 
(CL95%) 
α ± sem 
pEC50 
(CL95%) 
α ± sem 
EM-2 
7.81 
(7.69-7.93) 
1.00 Inactive Inactive 
dermorphin 
8.11 
(7.95-8.27) 
0.99 ± 0.01 
6.43 
(6.04-6.82) 
1.03±0.07
a 
Inactive 
DPDPE Inactive 
8.20 
(7.78-8.61) 
1.00 Inactive 
dynorphin A 
6.67 
(6.17-7.17) 
0.83 ± 0.10
a
 
7.73 
(7.46-8.00) 
0.99 ± 0.04
a 8.88 
(8.58-9.17) 
1.00 
1 
7.76 
(7.38-8.14) 
0.84 ± 0.04 ≈ 6.7 0.34 ± 0.15* 
8.50 
(7.72-9.28) 
1.03 ± 0.19 
2 
8.25 
(8.11-8.39) 
0.94 ± 0.01 
7.94 
(7.81-8.07) 
0.46 ± 0.10
*
 
8.51 
(7.84-9.18) 
0.74 ± 0.04
*
 
3 
7.53 
(7.16-7.90) 
0.45 ± 0.02
*
 
7.57 
(6.81-8.33) 
0.26 ± 0.01
*
 
8.72 
(7.75-9.69) 
0.78 ± 0.02
*
 
4 
7.55 
(7.15-7.95) 
0.30 ± 0.01
*
 
7.34 
(6.62-8.06) 
0.39 ± 0.09
*
 
7.97 
(7.35-8.59) 
0.63 ± 0.05
*
 
5 
8.25 
(7.98-8.52) 
0.82 ± 0.03 
7.95 
(7.74-8.16) 
0.44 ± 0.02
*
 
8.92 
(8.16-9.68) 
0.74 ± 0.03
*
 
6 
7.96 
(7.50-8.42) 
0.87 ± 0.01 ≈ 7.1 0.55 ± 0.18* 
8.74 
(8.01-9.48) 
0.96 ± 0.10 
7 
8.11 
(8.04-8.18) 
0.90 ± 0.02 
7.34 
(6.78-7.90) 
0.21 ± 0.01
*
 
8.56 
(8.27-8.85) 
0.75 ± 0.04
*
 
Inactive means that the compound was inactive as agonist up to 1 µM.  
EM-2, DPDPE, and dynorphin A were used as reference agonists for calculating intrinsic activity at MOP, 
DOP, and KOP receptor, respectively. 
a
 these data are from Camarda and Calo’, 2013. * p < 0.05 according to 
one way ANOVA followed by the Dunnett test for multiple comparisons. 
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In receptor binding studies, parent compound 1 showed sub-nanomolar MOP receptor affinity 
and three rows of magnitude lower affinity for the DOP receptor (Fichna et al., 2011). Analogs 
2–4 with 2’-, 3’-or 4’-MePhe, respectively, in position 3 displayed also high but3–4-fold lower 
MOP binding affinity, increased DOP affinity and therefore decreased MOP versus DOP 
selectivity. The same modification (2’-, 3’-or 4’-MePhe) introduced into position 4 (analogs 5–7) 
resulted in the increased affinities for both, MOP and DOP receptors, as compared with the 
parent compound. The obtained results showed that introduction of methylated Phe residues 
generally enhanced binding to the DOP receptor. The effect of methyl groups on MOP binding 
depended on the position of MePhe. Introduction of the MePhe residue into position 3 resulted in 
a slight decrease, and into position 4, in a significant increase of MOP affinity. The position of 
the methyl group in the phenyl ring of Phe
4
 was also important: the rank order of affinity was 4’-
MePhe ≥ 2’-MePhe ≥ 3’-MePhe (data reported in (Perlikowska et al., 2014)). The resistance of 
cyclic analogs against protolithic degradation was evaluated in vitro, using rat brain 
homogenates. Cyclic pentapeptides and EM-2, were incubated with the homogenate for 90 min 
and then the mixtures were analyzed by RP-HPLC. All cyclic peptides displayed low 
degradation, not higher than 15%, while EM-2 was almost completely digested after 90 min of 
incubation (data reported in (Perlikowska et al., 2014)).  
 
The antinociceptive effects of the analogs were assessed in the hot-plate test in mice after i.c.v. 
administration. All cyclic analogs produced dose-dependent antinociceptive responses (Figure 
31). The incorporation of the MePhe residues into position 4 produced extremely potent analogs 
5–7, with ED50 values 4.9, 14.3 and 0.6 ng/animal, respectively (Table 15) (data are from 
(Perlikowska et al., 2014)). 
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Figure 31. Dose–response curves determined in the hot-plate test in mice for the inhibition of jumping 
induced by i.c.v. injection of cyclic analogs 1–7. Data are mean ± sem of 10 mice per group. 
 
 
Table 15. ED50 values for cyclic pentapeptides in the hot-plate test in mice. 
 
ED50 (jumping) 
ng/animal 
1 20.0 ± 3.1 
2 31.9 ± 1.2 
3 220.5 ± 13.7 
4 389.0 ± 23.0 
5 4.9 ± 0.2 
6 14.3 ± 0.9 
7 0.6 ± 0.05 
Data are mean ± SEM of 10 animals per group. Table is from (Perlikowska et al., 2014) 
 
 
It is generally accepted that the aromatic amino acids in the structure of EM-2 and other opioid 
peptides are essential structural elements for receptor binding and activation (Janecka et al., 
2007; Keresztes et al., 2010; Liu & Wang, 2012). The aromatic portions of the ligands can be 
positioned in close proximity to the hydrophobic pockets belonging to the receptor domains and 
exhibit significant non-covalent interactions in such areas. The introduction of substituents, 
especially methyl groups, into the aromatic rings of Tyr and Phe can influence the conformation 
of the opioid ligands because of the increased bulkiness of the side-chains. The development of 
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Dmt paved the way for achieving increased bioactivities in opioid peptides (Hansen et al., 1992; 
Li et al., 2005). The substitution of 2’,6’-dimethylphenylalanine (Dmp) into position 3 of EM-2 
produced analog with about 5-fold lower MOP receptor affinity (Sasaki et al., 2003).The 
combined introduction of Dmt1and alkylated analogs of Phe3(2’-ethyl-, 3’-,5’- and 2’-, 6’-
dimethyl-, 2’-ethyl- 6’-methyl-) into EM-2 structure did not produce potent MOP receptor 
agonists but was associated with DOP receptor antagonism (Li et al., 2007). Methylation of the 
Phe
4
 residue in EM-2 analogs was not explored so far. I was recently reported the synthesis and 
pharmacological activity of Dmt
1
-substituted cyclic analogs of EM-2 (Fichna et al., 2011). One 
of them, Dmt-c[D-Lys-Phe-Phe-Asp]NH2 (analog 1), showed high MOP receptor affinity and a 
strong, long-lasting MOP receptor-mediated antinociceptive effect after i.c.v. administration. 
 
In the present study, further modifications of analog 1, in particular the incorporation of bulkier, 
2’-, 3’- or 4’-methylated Phe residues in either the third or fourth position of the cyclic structures 
were studied. These modifications introduce an additional steric hindrance which may result in 
conformational changes. The more interesting is the series with MePhe substitutions in position 4 
(analogs 5–7). These analogs displayed extremely high affinities at the MOP receptor and 
simultaneously drastically enhanced affinities at the DOP receptor. The binding of the analogs to 
the KOP receptor was not tested, but the calcium mobilization functional assay was performed 
which, as opposed to the GPI/MVD assays, allows for the determination of the activity of 
peptides at all three types of opioid receptors. At the molecular level, opioids modulate calcium 
channel conductance through MOP, DOP and KOP receptors (Standifer & Pasternak, 1997). In 
the present study the pharmacological activities of the novel compounds have been evaluated by 
measuring calcium mobilization in cells expressing a recombinant human receptor and chimeric 
G proteins. This approach has been previously used and validated by investigating the 
pharmacological profile of non-peptide ligands of classical opioid receptors (Camarda & Calo, 
2013; Zhang et al., 2012) and of NOP receptor ligands (Camarda et al., 2009; Fischetti et al., 
2009; Marti et al., 2013; Trapella et al., 2009). Here, this functional assay was used for the first 
time to characterize and compare the potencies and efficacies of the novel cyclic analogs of a 
peptide structure. These analogs preferentially inter-acted with KOP and MOP receptors with the 
following order of potency: 5 > 6 > 3 > 7 (for the KOP receptor) and 2 ≥ 5 > 7 > 6 (for the MOP 
receptor), while potencies at the DOP receptor were following 5 > 2 > 3 > 4. In the past it was 
demonstrated that analogs that are KOP/MOP-receptor agonists may be effective for the 
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treatment of cocaine or other psychostimulant abuse (Greedy et al., 2013) which opens further 
possibilities for pharmacological testing of these analogs. In the in vivo hot-plate test, position 3 
substituted analogs 2–4 produced weaker – and position 4-substituted analogs 5–7 – much 
stronger antinociceptive effects than the parent compound 1 after i.c.v. injection. These results 
may suggest that the combined high agonist potency at both, the MOP and KOP receptors results 
in the great enhancement of the antinociceptive effect. The obtained data indicate that EM-2 
analogs cyclized through a side-chain to side-chain amide bond show in opioid bioassays 
preference for MOP and KOP receptors while EM-2 and many of its linear analogs are MOP 
receptor selective (Janecka et al., 2007). According to the accumulated data reviewed recently by 
Schiller (Schiller, 2010), it is now widely accepted that biological activity at a single receptor is 
often insufficient and ligands that bind to more than one receptor type may have much improved 
potency due to synergistic effects. Extremely high antinociceptive activity of the new cyclic 
analogs that activate MOP and KOP receptors with similar potency and show even some affinity 
to the DOP receptor open new possibilities in designing compounds with mixed opioid profile 
(Perlikowska et al., 2014). 
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3.3. Ligands for NOP receptor 
 
 
3.3.1. The nociceptin/orphanin FQ receptor antagonist NiK-21273 
 
The purpose of the present study was to characterize the in vitro pharmacological profile of the 
novel NOP receptor ligand NiK-21273 (2-[3-[4-(2-Chloro-6-fluoro-phenyl)-piperidin-1-
ylmethyl]-2-(morpholine-4-carbonyl)-indol-1-yl]-acetamide, Figure 32). The effects of this 
molecule were assessed in calcium mobilization studies performed with cells expressing the 
human recombinant NOP or the classical opioid receptors as well as in bioassay studies 
performed with isolated tissues expressing animal native NOP receptors. 
 
 
Figure 32. Chemical structure of NiK-21273 
 
N/OFQ concentration dependent stimulated the calcium signal in CHONOP cells stably expressing 
the Gαqi5 protein, displaying high potency (pEC50 9.19 (8.85–9.53)) and maximal effects of 
200±12% fluorescence over baseline. NiK-21273 inhibited the stimulatory effect of N/OFQ (10 
nM) in a concentration dependent manner with a pKB of 7.38, whereas naloxone was ineffective 
(Table 16). SB-612111 also inhibited N/OFQ effects in a concentration-dependent manner, with a 
pKB of 8.18 (not shown). NiK-21273 selectivity was then evaluated in CHO cells stably 
expressing classical opioid receptors (CHOMOP, CHOKOP and CHODOP cells) and the chimeric G 
proteins (Gαqi5 for MOP and KOP, GαqG66Di5 for DOP). In these cell lines, dermorphin, dynorphin 
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A and DPDPE evoked concentration-dependent stimulations of calcium mobilization showing 
different potencies (pEC50 8.26, 9.19 and 8.36, for MOP, KOP, and DOP, respectively) and 
efficacies (~189, ~226 and ~102% over baseline, respectively). Naloxone antagonized the 
stimulation evoked by 30 nM dermorphin (pKB 8.73), 30 nM dynorphin A (pKB 7.00) and 30 nM 
DPDPE (pKB 6.80) in a concentration-dependent manner, whereas NiK-21273 was ineffective 
(Table 16) (Figure 33).  
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Figure 33. Calcium mobilization experiments. Concentration response curves to agonists (left panels) and 
inhibition response curves to NiK-21273 (middle panels) and naloxone (right panels) in cells expressing the 
NOP (panels A, B, C), the MOP (panels D, E, F), the KOP (panels G, H, I), and the DOP (panels J, K, L) 
receptors. Data are mean ± sem of at least 3 separate experiments performed in duplicate. 
 
 
 
Results and Discussion: novel NOP receptor ligands 
 
88 
 
Table 16. Antagonist potencies of NiK-21273 and naloxone obtained in inhibition response experiments 
performed in CHO cells expressing NOP or classical opioid receptors and Gα chimeric proteins. 
 
 NOP MOP KOP DOP 
NiK-21273 7.38 
(7.06-7.70) 
< 6 < 6 < 6 
naloxone < 6 
8.73 
(8.38-9.08) 
7.00 
(6.68-7.32) 
6.80 
(6.09-7.51) 
Data are mean (CL95%) of at least 3 separate experiments performed in duplicate. 
 
 
In order to assess the nature of NiK-21273 antagonism at the NOP receptor, a classical Schild 
analysis was performed. NiK-21273 produced a concentration-dependent rightward shift of the 
N/OFQ curve without modifying its maximal effect (Figure 34, panel A). The corresponding 
Schild plot (Figure 34, panel B) was linear, yielding a pA2 of 7.77. SB-612111 (10 nM–1 µM) 
replicated this behavior (Figure 34, panel C), the corresponding Schild plot (Figure 34, panel D) 
yielding a pA2 of 7.74. 
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Figure 34. Concentration-response curve to N/OFQ obtained in the absence (control) and in presence of 
increasing concentrations of NiK-21273 (panel A) and SB-612111 (panel C). The corresponding Schild plots 
are shown in panels B and D. Data are the mean of at least 4 separate experiments performed in duplicate. 
 
 
NiK-21273 was also assessed in the electrically stimulated mouse and rat vas deferens. N/OFQ 
inhibited the twitch response in a concentration-dependent manner, both in the mouse (pEC50 
7.70; Emax -84 ± 3%; Figure 35, Panel A) and rat (pEC50 7.48; Emax -86±2%; Figure 35, Panel 
C) vas deferens. NiK-21273 alone was ineffective up to 1 µM in both preparations, but produced 
a concentration-dependent rightward shift of the N/OFQ curve without affecting its maximal 
effect (Figure 35, Panel A and C). Schild analysis (Figure 35, Panel B and D) yielded a pA2 value 
of 7.74 and 7.75 in the mouse and rat tissues respectively. SB-612111 (100 nM) replicated this 
behavior with pKB values of 8.77 (mouse) and 8.05 (rat) (data not shown). 
In functional washout experiments performed in the electrically stimulated mouse vas deferens, 
the reversibility of NiK-21273 and SB-612111 action at equieffective concentrations (1 and 0.1 
µM, respectively) was evaluated. The concentration–response curves to N/OFQ performed 1, 2 
and 3 h after washing were superimposable to the control curve. The antagonist effect of 1 µM 
NiK-21273 (CR 30, where CR is the ratio between the EC50 of the agonist in the presence and in 
the absence of the antagonist) was easily, although not completely, reversed by washing the 
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tissues for 1 h (CR 3). On the contrary, the antagonist effect exerted by 0.1 µM SB-612111 (CR 
30) could not be reversed even after 3 h of washing (CR 10). 
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Figure 35. Concentration-response curve to N/OFQ obtained in the absence (control) and in presence of 
increasing concentrations of NiK-21273 in the electrically stimulated mouse (panel A) and rat (panel C) vas 
deferens. The corresponding Schild plots are shown in panels B and D. Data are the mean of at least 4 
separate experiments. 
 
 
The present results demonstrated that NiK-21273 behaves in vitro as a pure, fairly potent and 
highly selective NOP receptor antagonist. This molecule represents a novel and useful tool for 
investigating the role played by the N/OFQ – NOP receptor system in physiology and pathology. 
For results and discussion of the in vivo activity of NiK-21273 in animal models of Parkinson’s 
disease see (Marti et al., 2013). 
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3.3.2. Spiroxatrine derivatives, pharmacological activity for the NOP receptor 
 
Spiroxatrine (Figure 36) is an alpha2-adrenoceptor and 5-HT1A receptor antagonist able to bind 
the NOP receptor with moderate affinity (pKi ~ 7, (Zaveri et al., 2001)). 
 
 
Figure 36. Spiroxatrine (1). 
 
It was known that the 1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one portion of 1, due to its chemical 
features, is responsible for the NOP affinity of this class of compounds. The resulting 
spiropiperidine analogues exhibited high affinity for the NOP receptor. In particular, the 
spiropiperidine series developed by Roche and Pfizer demonstrated high affinity associated with 
moderate selectivity for the NOP receptor (Largent-Milnes & Vanderah, 2010). 
 
Herein this study reports the results of three different SAR studies aimed at identifying a series of 
triazaspirodecanone derivatives as NOP receptor ligands.  
 
The first SAR development plan was to investigate possible substitutions of the chromane core of 
8-(chroman-4-yl)-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one. 
Compounds 1-18, S-4 and R-4 were tested in the calcium mobilization assay in CHO cells stably 
expressing the human NOP receptor and the Gαqi5 chimeric protein. The compounds were tested 
as agonists together with N/OFQ as standard (Figure 37). Under the present experimental 
conditions, N/OFQ produced a concentration-dependent stimulatory effect showing high potency 
(pEC50 9.68) and maximal effect (254±16% over the basal value), in line with previously 
published data (Fischetti et al., 2009; Trapella et al., 2009). Spiroxatrine (1) behaved as a low 
potency NOP full agonist (pEC50 6.49 and α 0.81). Compounds 4 and 18 produced a 
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concentration-dependent calcium mobilization with pEC50 values of 6.80 and 6.37, respectively. 
Compounds 5–10, 13–15 and 17 produced a weak stimulation of the NOP receptor, generating 
incomplete concentration response curves. Thus these molecules behaved as very low potency 
NOP agonists. Differently, compounds 11, 12 and 16 did not stimulate calcium mobilization up 
to 10 µM. 
These compounds were further evaluated in antagonist-type experiments. In these studies SB-
612111 was used as a positive control. Inhibition response curves were performed against a fixed 
concentration of N/OFQ, approximately corresponding to its EC80. As shown in Figure 37, right 
panel, under the present experimental conditions SB-612111 elicited a complete and 
concentration-dependent inhibition of the N/OFQ stimulatory effect, with a pKB value of 8.10. 
This value is in line with previously reported findings (Camarda et al., 2009; Fischetti et al., 
2009). Compounds 11, 12, and 16 up to 10 µM did not modify the stimulatory effect of N/OFQ. 
In addition, compounds 7 and 13, which displayed a weak stimulatory effect only at 10 µM, were 
also evaluated as NOP antagonists up to 1 µM. These compounds produced a weak inhibitory 
effect only at the highest concentration tested.  
All the data were summarized in Table 17. 
 
 
 
Figure 37. Calcium mobilization experiments performed in CHONOP cells stably expressing the Gαqi5 protein. 
Concentration response curve to N/OFQ (left panel) and inhibition response curve to SB-612111 vs 1 nM 
N/OFQ (right panel). Data are the mean ± sem of at least 4 separate experiments performed in duplicate. 
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Table 17. Effects of standard and novel ligands in calcium mobilization experiments performed in CHO cells 
coexpressing the human NOP receptor and the Gαqi5 chimeric protein. 
 
 
 
agonist antagonist 
pEC50 (CL95%) α±sem pKB (cl95%) 
N/OFQ 9.68 (9.59–9.78) 1.00 nd 
SB-612111 inactive 8.10 (7.95–8.24) 
1 
 
6.49 (5.95-7.03) 0.81±0.03 nd 
4 
 
6.80 (5.79–7.63) 1.02±0.04 nd 
5 
 
crc incomplete nd 
6 
 
crc incomplete nd 
7 
 
crc incomplete <6 
8 
 
crc incomplete nd 
9 
 
crc incomplete nd 
10 
 
crc incomplete nd 
11 
 
inactive inactive 
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12 
 
inactive inactive 
13 
 
crc incomplete <6 
14 
 
crc incomplete nd 
15 
 
crc incomplete nd 
16 
 
inactive inactive 
17 
 
crc incomplete nd 
18 
 
6.37 (6.31–6.43) 1.00±0.09 nd 
S-4 
 
6.68 (6.57–6.80) 0.95±0.04 nd 
R-4 
 
7.34 (7.29–7.39) 0.98±0.04 nd 
Data are mean of at least 3 separate experiments performed in duplicate. n.d.: not determined. Inactive: 
inactive up to 10 µM. Crc incomplete: the concentration response curve could not be completed because of 
the low potency of the agonist. <6: the pKB could not be precisely determined because the ligand produced a 
weak inhibitory effect only at the highest concentration tested, i.e. 1 µM. 
 
 
The introduction of the chromane core on the piperidine nitrogen of 1-phenyl- 1,3,8-triazaspiro 
[4.5]decan-4-one, as in compound 4, moderately increases the agonist activity with respect to 1. 
Introduction of a halogen atom at position 5 of compound 4, to give 18, leads to a slight decrease 
in potency. The presence of a steric hindrance at position 3 of the chromane moiety as in 
compound 17 decreases the ligand potency. A similar trend was observed for the introduction of 
alkyl and aromatic substituents on position 2 of the chromane as in compounds 5 and 15. By 
increasing the steric hindrance at position 2 of the chromane core, compounds 6 and 15 did not 
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show promising activity, suggesting very low steric tolerance on the chromane ring. The 
homologation of the spiro structure of 6, to give 7, seems to convert the compound into a weak 
antagonist. However, the very low potency of this compound does not allow a detailed 
characterization of its pharmacological activity. Further homologation of the spiro alkyl 
substituents (8) led to a decrease in activity both as agonist and antagonist. The same behavior 
was observed for the isosters of 7, compounds 9, 10 and 16. Indeed the latter was completely 
inactive as its methyl and ethyl derivatives (11 and 12, respectively), probably because at 
physiological pH the nitrogen atom is protonated and the positive charge may negatively interfere 
with the binding process. Compound 13, with a non-protonable sulfonamidic nitrogen which also 
carries the hindered substituent such as the methanesulfonyl group, showed a weak antagonist 
activity similar to compound 7. However, this is not observed with compound 14 which has a 
similar nitrogen atom (acetamidic), indicating the relevant and discriminating role of steric 
interactions in the antagonist activity.  
 
 
Single enantiomers (S-4 and Z-4) of the most potent spiroxatrine derivative i.e. compound 4, 
were also tested in calcium mobilization assay. (+)-(R)-4 and (-)-(S)-4 produced a concentration-
dependent stimulation of NOP receptor with pEC50 values of 7.34 and 6.68, respectively (Table 
17 and Figure 39). Thus the results identified the (R)-enantiomer as the most active component 
being 5-fold more potent than the (S)-enantiomer. Moreover, in order to demonstrate the direct 
involvement of the NOP receptor in the biological action of (+)-(R)-4 and (-)-(S)-4 inhibition  
response experiments were performed by testing increasing concentrations of SB-612111 against 
fixed concentrations of (+)-(R)-4 and (-)-(S)-4 (1 µM), approximately corresponding to their 
EC80. The pKB values obtained for SB-612111 vs. (+)-(R)-4 and (-)-(S)-4 were 8.67 and 8.58, 
respectively (Figure 38), indicating that the latter compounds behaved as full agonists interacting 
with the NOP receptor at the orthosteric binding site.  
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Figure 38. Calcium mobilization experiments performed in CHONOP cells stably expressing the Gαqi5 protein. 
Concentration response curve to N/OFQ and S-4 (left panel), and R-4 (right panel). Data are the mean ± sem 
of at least 4 t experiments performed in duplicate. 
 
 
 
Figure 39. Inhibition response experiments performed in CHONOP cells stably expressing the Gαqi5 protein. 
Inhibition response curve to SB-612111 vs 1 µM S-4 (left panel), or 1 µM R-4 (right panel). Data are the 
mean ± sem of at least 4 t experiments performed in duplicate. 
 
 
This first series of spiroxatrine derivatives, led to characterize several small molecule ligands for 
their ability to bind and stimulate the NOP receptor, among them compound 4 demonstrated a 
good activity as a NOP receptor agonist. Then an enantioseparative method led to obtain single 
enantiomers of 4. Further biological studies have shown (R)-4 as the eutomer, indicating a clear 
stereospecific interaction. Docking studies were performed on the NOP receptor crystal structure 
in order to understand the binding mode of the two stereoisomers of 4. These results would help 
guide further developments of N-substituted spiropiperidine-based NOP agonists (Battisti et al., 
2014).   
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For the second SAR, a new series of spiroxatrine derivatives was characterized in the calcium 
mobilization assay, in CHO cells coexpressing the human NOP receptor and the Gαqi5 chimeric 
protein. N/OFQ produced a concentration dependent stimulation of calcium mobilization with a 
pEC50 of 9.27 and maximal effects of 157 ± 19 % over the basal value. Compound 1 mimicked 
the stimulatory effect of N/OFQ showing similar maximal effects but lower potency (pEC50 
6.49). Similar results were obtained with compounds 21 and 23 that were slightly less potent than 
compound 1. Compound 22 also behaved as a full agonist showing, however, a further decrease 
in potency (pEC50 5.91). Compounds 21, 22 and 23 were also tested in CHO cells expressing the 
Gαqi5 protein but not the human NOP receptor. In these cells, ATP produced concentration 
dependent stimulatory effect with a pEC50 value of 6.94 and Emax of 278 ± 44 %, while 21, 22 and 
23 were inactive up to 10 µM. These findings demonstrate that the stimulatory effects of 21, 22, 
and 23 are due to NOP receptor activation. Compounds 23, 24 and 25, isosters of 21, produced 
weak stimulatory effects only at micromolar concentrations thus generating incomplete 
concentration response curves (Table 18). Compound 29 did not stimulate calcium mobilization 
up to 10 µM suggesting a complete loss of agonist activity. The same results were obtained with 
all azaspiro derivatives 26, 28, 30–32. In order to investigate putative NOP antagonist properties 
of these compounds, inhibition response curves were performed against a fixed concentration of 
N/OFQ (10 nM). The NOP antagonist J-113397 was used as positive control (Kawamoto et al., 
1999). As shown in Figure 40 right panel, under the above presented experimental conditions, J-
113397 elicited a complete and concentration-dependent inhibition of the N/OFQ stimulatory 
effect. A pKB value of 7.73 was derived from these experiments; this value is in line with 
previously reported findings (Camarda et al., 2009). In parallel experiments compounds 26, 28–
32 did not modify up to 10 µM the stimulatory effects induced by 10 nM N/OFQ (Table 18). 
Thus, these compounds were found inactive also as NOP antagonists. 
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Figure 40. Calcium mobilization experiments performed in CHONOP cells stably expressing the Gαqi5 protein. 
Concentration response curve to N/OFQ (left panel) and inhibition response curve to J-113397 vs 10 nM 
N/OFQ (right panel). Data are the mean ± sem of at least 4 separate experiments performed in duplicate. 
 
 
Table 18. Effects of standard and spiroxatrine derivatives in calcium mobilization experiments performed on 
CHO cells co-expressing the human NOP receptor and the Gαqi5 chimeric protein. 
 
agonist antagonist 
pEC50 (CL95%) α±sem pKB (CL95%) 
N/OFQ 9.27 (8.98–9.55) 1.00 nd 
J-113397 inactive 7.73 (7.45–8.01) 
Spiroxatrine (1)  6.49 (5.95-7.03) 0.81±0.03 nd 
20 
 
crc incomplete nd 
21 
 
6.29 (6.02–6.56) 0.87±0.04 nd 
22 
 
5.91 (5.83–6.00) 1.17±0.11 nd 
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23 
 
6.23 (5.93–6.53) 1.01±0.09 <6 
24 
 
crc incomplete nd 
25 
 
crc incomplete nd 
26 
 
inactive nd 
28 
 
inactive inactive 
30 
 
inactive inactive 
31 
 
inactive inactive 
32 
 
inactive inactive 
Inactive: compound inactive up to 10 µM. 
Crc incomplete: the concentration response curve could not be completed because of the low potency of the 
agonist tested. 
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The analysis of these biological results suggests different molecular effects of these ligands on 
calcium release in CHONOP cells stably expressing the Gαqi5 chimeric protein. Replacement of 
1,4-benzodioxane fragment with 2,2-diphenyl-1,3-dioxolane moiety as in compound 20 caused a 
slight decrease of agonist activity. When the geminal phenyl rings were replaced by a spiro 
group, as in 21, the agonist activity is maintained both in terms of potency and efficacy. 
Compound 21 was taken as a new starting point in order to further explore a possible structure-
activity relationship. Homologation of the spiro structure, as in compound 22 and 23, produced a 
decrease in ligand potency; this was more pronounced for 22 with respect to compound 23. 
Moreover, it was observed that the polarity of the atom at position 8 of the 1,4-
dioxaspiro[4.5]decane derivatives has a critical influence. Indeed increasing the polarity of that 
atom led to a decrease (24 and 25, incomplete concentration response curves) or even to a 
complete loss of activity (29). For compound 29, another parameter may be responsible of the 
observed loss of activity: at physiological pH, the nitrogen atom is protonated, and the positive 
charge may interfere with the binding process. The same explanation may be put forward in order 
to interpret the inactivity of compound 28 and 30 which in addition carry hydrophobic sterically 
hindered substituents such as benzyl and ethyl groups respectively. Steric hindrance may also be 
a negative factor in the case of compounds 26, 31, and 32 (in these cases the nitrogen atom is not 
protonated at physiological pH), obtained by the introduction of hydrogen bond acceptor or 
electron donor/ acceptor moieties on the nitrogen atom of compound 29. Compounds inactive as 
agonists were further evaluated as NOP antagonists. The azaspiro derivatives 26–32 did not 
affect the stimulatory effects of N/OFQ up to 10 µM. This evidence suggests that these 
compounds are not able to bind NOP receptor. As a conclusion of these studies, 1,4-dioxolane-
triazospirodecanone derivatives showed unique and significant SAR as NOP receptor agonists. In 
particular, the present study demonstrated that 1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one 
portion, together with an appropriate 1,4-dioxolane substituent might represent a new promising 
class of NOP receptor ligands.  
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The third series of SAR studies on spiroxatrine molecule has been pharmacologically evaluated at 
the NOP receptor in the calcium mobilization assay using again, the endogenous peptide N/OFQ 
as standard agonist (Figure 41, left panel). Under the present experimental conditions N/OFQ 
produced a concentration dependent stimulation of calcium mobilization with a pEC50 of 9.55 
and maximal effects of 198 ± 29% over the basal values. Results obtained with the novel 
compounds are summarized in Table 19. Spiroxatrine (compound 1), taken as lead compound for 
the present study, mimicked the stimulatory effect of N/OFQ, showing similar maximal effect 
with 1000-fold lower potency (pEC50 6.49). Compounds cis-4, cis-18 and cis-22 produced a 
concentration-dependent calcium mobilization with pEC50 values of 6.67, 6.57 and 6.38 
respectively. The maximal effects elicited by these compounds were not significantly different 
from that of N/OFQ (Table 19). Compound 6 also behaved as a full agonist showing however 
lower potency (pEC50 5.97). Compound trans-4 stimulated calcium mobilization in a 
concentration dependent manner with a potency value of 6.45. However the maximal effect 
induced by this compound was significantly lower than those produced by the standard agonist 
N/OFQ (Table 19 and Figure 42, Panel A). Thus, trans-4 behaved as a partial NOP agonist 
(Figure 42, Panel A). These compounds were inactive up to 10 μM when assayed in CHO cells 
expressing the Gαqi5 protein but not the NOP receptor. Thus the stimulatory effects of 
compounds 6, trans-4, cis-4, cis-18 and cis-22 are due to the ability of these molecules to bind 
and activate the NOP receptor. trans-22 produced an incomplete concentration response curve at 
10 μM, stimulating calcium mobilization to 39 ± 14% over the basal value. Similar results were 
obtained testing compounds 5, 10, 17 and 23. Thus these molecules behaved as low potency NOP 
agonists. On the contrary, compounds 3, 14 and 21 did not modify calcium levels up to 10 μM. 
Therefore these compounds were further evaluated in antagonist-type experiments. In these 
studies SB-612111 was used as positive control (30). Inhibition response curves were performed 
against a fixed concentration of N/OFQ, approximately corresponding to its EC80. As shown in 
Figure 41, right panel, under the present experimental conditions, SB-612111 elicited a complete 
and concentration-dependent inhibition of the N/OFQ stimulatory effect. A pKB value of 8.50 
was derived from these experiments. This value is in line with previously reported findings 
(Camarda et al., 2009; Fischetti et al., 2009). In parallel experiments, compound 3 did not modify 
the N/OFQ stimulatory effect up to 10 μM. Compound 14 and 21 displayed weak antagonist 
activity only at the higher concentration tested, i.e. 10 μM.  
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Figure 41. Calcium mobilization experiments performed in CHONOP cells stably expressing the Gαqi5 protein. 
Concentration response curve to N/OFQ (left panel) and inhibition response curve to SB-612111 vs 10 nM 
N/OFQ (right panel). Data are the mean ± sem of at least 4 separate experiments performed in duplicate. 
 
 
Finally the selectivity of compounds trans-4, cis-4 was evaluated measuring calcium mobilization 
in CHO cells stably expressing the Gα chimeric protein and either the MOP, DOP or KOP 
receptors. The results obtained are summarized in Table 19 and Figure 42. Compounds trans-4, 
and cis-4 did not modify calcium levels up to 10 μM in agonist-type experiment for KOP and 
DOP receptors highlighting a fine NOP/DOP and NOP/KOP selectivity (Figure 42 panel C and D 
respectively). Differently trans-4 and cis-4 produced a concentration-dependent calcium 
mobilization for the MOP receptor with pEC50 values of 6.21 and 6.17 respectively, with a low 
NOP/MOP selectivity ratio (<0.6 and 3.2 respectively, Table 20). Notably, a reversed behaviour 
in selectivity was observed in comparison to NOP agonist activity and trans-4 proved to be the 
most active isomer suggesting complete different stereointeractions with the two NOP/MOP 
receptors. 
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Figure 42. Calcium mobilization experiments performed in CHO cells coexpressing the chimeric G proteins 
and the human NOP, MOP, KOP, and DOP receptors (panels A, B, C, and D, respectively). Concentration 
response curves to standard agonists, cis-4 and trans-4. Data are the mean ± sem of at least 3 separate 
experiments performed in duplicate. 
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Table 19. Effects of standard and novel NOP ligands in calcium mobilization assays, performed in CHO cells 
coexpressing the human NOP receptor and the Gαqi5 protein. 
 
 
 
agonist antagonist 
pEC50 (CL95%) α±sem pKB (CL95%) 
N/OFQ 9.55 (9.07–10.04) 1.00 nd 
SB-612111 inactive 8.50 (8.03–8.97) 
1 
 
6.49 (5.95-7.03) 0.81±0.03 nd 
6 
 
5.97 (5.78–6.17) 1.09±0.05 nd 
5 
 
crc incomplete nd 
23 
 
crc incomplete nd 
3 
 
inactive inactive 
17 
 
crc incomplete nd 
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21 
 
inactive <6 
cis-4 
 
6.67 (6.43-6.91) 0.83±0.04 nd 
trans-4 
 
6.45 (5.77-7.13) 0.70±0.02* nd 
cis-22 
 
6.38 (5.51-7.25) 1.01±0.41 nd 
trans-22 
 
crc incomplete nd 
cis-18 
 
6.57 (6.06-7.08) 1.08±0.32 nd 
10 
 
crc incomplete nd 
14 
 
inactive <6 
Agonist efficacy is expressed as intrinsic activity (α) using the maximal effect elicited by N/OFQ as internal 
standard (α = 1.00).  
* p < 0.05 according to Anova followed by the Dunnett test for multiple comparisons. 
inactive: inactive up to 10 μM. 
crc incomplete: the concentration response curve could not be completed because of the low potency of the 
agonist. 
< 6: the pKB could not be precisely determined because the ligand produced a weak inhibitory effect only at 
the highest concentration tested, i.e. 10 μM. 
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Table 20. Effects of trans-4, cis-4 and standard NOP, MOP, KOP, and DOP ligands in calcium mobilization. 
 
NOP MOP KOP DOP 
pEC50 
(CL95%) 
α 
±sem 
pEC50 
(CL95%) 
α 
±sem 
pEC50 
(CL95%) 
α 
±sem 
pEC50 
(CL95%) 
α 
±sem 
N/OFQ 
9.35 
(8.86–9.83) 
1.00 < 5 < 6 < 5 
dermorphin < 5 
8.43 
(7.98-8.87) 
1.00 < 5 < 6 
dynorphin A < 6 
6.67 
(6.17-7.17) 
0.99 
±0.05
a
 
8.29 
(7.45-9.12) 
1.00 
7.16 
(7.07-7.25) 
1.10 
±0.20 
DPDPE inactive Inactive inactive 
8.73 
(8.39–9.07) 
1.00 
trans-4 < 6 
6.21 
(6.00-6.42) 
0.87 
±0.06 
inactive  inactive 
cis-4 
6.68 
(5. 96-7.41) 
0.85 
±0.08 
6.17 
(5.88-6.45) 
0.73 
±0.05 
inactive inactive 
Agonist efficacy is expressed as intrinsic activity (α) using the maximal effect elicited by N/OFQ as internal 
standard (α = 1.00) 
Inactive: inactive up to 10 μM. 
< 5 and < 6: the concentration response curve could not be completed because of the low potency of the 
agonist; the estimated pEC50 obtained by constraining the maximal effects were less than 5 or 6.  
 
 
The isosteric substitution O-1/CH2 in the 1,4-benzodioxane nucleus of spiroxatrine (1) as 
represented by compound 6, results in a 3 fold decrease of agonist potency. A further decrease in 
potency was observed with the unsaturated benzopyran-derivative 5 and with the tetralin 
derivative 23 with respect to 6. These results indicate that both oxygen atoms are necessary for 
spiroxatrine activity at NOP receptors and the one at position 1 is probably more sensitive to 
isosteric replacement. By alternatively dislocation out of the ring the oxygen at position 1 and 4 
of the 1,4-benzodioxane core of 1 produced the chroman-4-one derivatives 3 and 17 and it was 
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possible to determine that the introduction of a carbonyl group led to a severe loss of activity. 
These findings suggest that the introduction of an H-bond acceptor is not well tolerated. In 
addition, the replacement of oxygen at position 1 of the chroman-4-one derivative 3 provided the 
inactive α-tetralone derivative 21, confirming the role of this oxygen. Compounds 3, 17 and 21 
proved to be inactive also in antagonist-type experiments; these data suggest that these 
compounds do not bind NOP receptor. 
One moiety of 3, which gave chroman-4-ols cis- and trans-4, allowed the recovery of agonist 
activity, especially in the case of cis isomer that showed a pEC50 value of 6.67, higher than that of 
spiroxatrine (6.49). The favorable effect of carbonyl reduction was also observed for compound 
22 obtained from the other chromanone derivative 21. Also in this case the cis isomer was more 
potent than the trans isomer, with a pEC50 value of 6.38. Further confirmation of the positive role 
of the hydroxyl group in this position came from the comparison of the activities of chromanone 
17, regional isomer of chromanone 3, and its carbonyl-reduced derivative cis-18 which showed a 
pEC50 value of 6.57. Unfortunately, in the case of this 4-hydroxyl-derivative, only the cis isomer 
was obtained. We did not made any further effort to obtain the trans isomer since the same 
isomer of the alcohols 4 and 22 was less active than the cis one. For this reason, most likely also 
in the case of trans-18 it would have been obtained the same result.  
 
Finally we wanted to investigate the effect of the introduction of a double bond in the 
chromanone structure of regional isomers 3 and 17 with the synthesized chromones 10 and 14. 
Proceeding from 3 to 10, a small and barely detectable agonist efficacy was seen, while the 
contrary seems to be true going from 17 to 14, since in this case the already weak activity 
disappears. Certainly such consideration is based on a very small variation of activity and might 
be speculative. However it is suggested that the more constrained structure of these chromones, 
that makes therefore planar this part of the molecule, does not favor agonist activity. This 
indirectly seems to confirm the importance first of a certain distortion of the lateral chain and 
secondly of the oxygenated function in position 4, indicating that the interaction at NOP receptor 
site is highly stereoselective. 
 
In conclusion, this third panel of spiroxatrine derivatives also shown that these ligands might 
represent novel tools for better understanding the structural requirements necessary for NOP 
receptor binding and activation. Moreover with this last part of SAR studies we demonstrated that 
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by introducing specific group on the chromane core of this type of molecules it is possible to 
modulate the agonist activity notwithstanding the lipophilic portion is attached to the piperidine 
nitrogen by a 1-carbon linker. Since the majority of the agonists reported in literature are 
connected directly to the piperidine nitrogen these evidences could be useful for the development 
of new NOP ligands. 
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3.3.3. Structure activity studies of nociceptin/orphanin FQ(1-13)-NH2 
derivatives modified in position 5 
 
N/OFQ and Dynorphin (Dyn) share some similarities, in particular the same length, the N-
terminal part with two aromatic residues linked by a Gly-Gly spacer and a C-terminal part rich in 
basic residues. Despite these structural homologies, N/OFQ is highly selective for the NOP and 
Dyn for the KOP receptor. The systematic replacement in the C-terminus of the Dyn sequence 
with residues of the C-terminus of N/OFQ slightly increased affinity but did not affect potency at 
the NOP receptor. In contrast, further replacement of position 6 (Arg/Gly) and 5 (Lue/Thr) 
substantially increased affinity and produced a dramatic enhancement of NOP potency (Lapalu et 
al., 1997). An important role of N/OFQ Thr
5
 for NOP occupation/activation is also suggested by 
classical Ala scan studies that demonstrated a substantial loss of affinity and an even greater loss 
of potency of [Ala
5
]N/OFQ (Dooley & Houghten, 1996; Reinscheid et al., 1996). 
This study was aimed to investigating the structure activity relationship of the Thr residue in 
position 5 of the N/OFQ sequence. To this aim N/OFQ(1-13)-NH2 was used as chemical template 
and 28 [X
5
]N/OFQ(1-13)-NH2 derivatives, in which Thr was substituted with natural and 
unnatural residues (Figure 43), were synthesized, purified and characterized for their 
pharmacological action at the NOP receptor.  
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Figure 43. Chemical structure of the unnatural amino acids employed in the present study. 
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[
35S]GTPγS binding studies - N/OFQ was able to concentration dependently stimulate the 
[
35S]GTPγS binding to membranes from CHO cells stably expressing the human NOP receptor, 
in a concentration dependent manner showing a maximal effect of 210 ± 17 % over the basal 
value and a pEC50 of 8.45. This stimulatory effect of N/OFQ was mimicked by N/OFQ(1-13)-
NH2 that produced a superimposable concentration response curve (Emax 199 ± 16 %, pEC50 
8.57). Under the same experimental conditions, [X
5
]N/OFQ(1–13)-NH2 analogues in which Thr 
was substituted with natural amino acids (compounds 1-13) stimulated [
35S]GTPγS binding in a 
concentration dependent manner showing maximal effects similar to those evoked by the 
reference compound N/OFQ(1–13)-NH2 (Table 1). As far as potency is concerned, compounds 5 
and 10 displayed potency values similar to that of N/OFQ(1–13)-NH2, while all the other 
analogues showed lower potency. In particular compounds 4, 8, 9 and 12 had EC50 values from 3 
to 10 fold lower than the reference peptide, compounds 1, 2, 6, 7, 11 and 13 had EC50 values 
from 10 to 100 fold lower than N/OFQ(1–13)-NH2, while compound 3 was 117 fold less potent 
than the standard.  
In a second series of experiments the effects of [X
5
]N/OFQ(1–13)-NH2 analogues in which Thr 
was substituted with unnatural amino acids (compounds 14-28) were investigated. All 
compounds stimulated [
35S]GTPγS binding in a concentration dependent manner with maximal 
effects similar to those evoked by N/OFQ(1–13)-NH2 (Table 1). As far as potency is concerned, 
compounds 16 and 23 displayed similar potency to that of N/OFQ(1–13)-NH2, while all the other 
analogues displayed lower potency. In particular compounds 15, 19-22, and 26 showed EC50 
values from 3 to 10 fold lower than the reference peptide, compounds 18, 24, 25, 27, and 28 had 
EC50 values from 10 to 100 fold lower than N/OFQ(1–13)-NH2, while compounds 14 and 17 
were more than 100 fold less potent than the standard.  
 
Calcium mobilization studies - N/OFQ stimulated calcium mobilization in a concentration 
dependent manner with a maximal effect of 238 ± 17 % over the basal values and a pEC50 of 
8.74. The stimulatory effect of N/OFQ was mimicked by N/OFQ(1-13)-NH2 that produced a 
superimposable concentration response curve (Emax of 232 ± 13, pEC50 9.07). Under the same 
experimental conditions, the effects of [X
5
]N/OFQ(1–13)-NH2 analogues in which Thr was 
substituted with natural amino acids were evaluated. All compounds stimulated calcium 
Results and Discussion: novel NOP receptor ligands 
 
112 
 
mobilization with maximal effects similar to those evoked by the reference compound N/OFQ(1–
13)-NH2 (Table 2). As far as potency is concerned, compound 5 and 10 displayed potency similar 
to that of N/OFQ(1–13)-NH2, while all the other analogues showed lower potency. In particular 
compounds 9 and 12 had EC50 values from 3 to 10 fold lower than the reference peptide, 
compounds 1, 4, 6-8, and 11 had EC50 values from 10 to 100 fold lower than N/OFQ(1–13)-NH2, 
while compound 2 and 13 were 159 and 760 fold less potent than the standard, respectively. 
Finally the potency of compound 3 could not be estimated because the compound produced an 
incomplete concentration response curve. 
In the last series of experiments the effects of [X
5
]N/OFQ(1–13)-NH2 analogues in which Thr 
was substituted with unnatural amino acids (compounds 14-28) were investigated. All 
compounds stimulated calcium mobilization in a concentration dependent manner showing 
maximal effects similar to those evoked by N/OFQ(1–13)-NH2 (Table 2). As far as potency is 
concerned, compounds 21-23 displayed potency similar to that of N/OFQ(1–13)-NH2, while all 
the other analogues showed lower potency. In particular, compound 16 was 4 fold less potent 
than the reference peptide, compounds 15, 19, 20, and 26-28 had EC50 values from 10 to 100 fold 
lower than N/OFQ(1–13)-NH2, while compounds 14, 17, 18, 24 and 25 were more than 100 fold 
less potent than the standard.  
The results obtained in the [
35S]GTPγS binding and in the calcium mobilization assay have been 
compared in Figure 44: a determination coefficient (r
2
) of 0.82 and a value of p<0.01 were 
derived from these data.  
  
Results and Discussion: novel NOP receptor ligands 
 
113 
 
Table 21. Effects of N/OFQ, N/OFQ(1-13)-NH2 and its [X
5
] derivatives in [
35S]GTPγS binding 
experiments in membranes of CHOhNOP cells.  
 Compound pEC50 (CL95%) CR α ± sem 
 N/OFQ 8.45 (8.18-8.73) 1 1.04 ± 0.15 
 N/OFQ(1-13)-NH2 8.57 (8.28-8.86) 1 1.00 
1 [Asp
5
]N/OFQ(1-13)-NH2 7.15 (6.69-7.62) 26 0.72±0.12 
2 [Arg
5
]N/OFQ(1-13)-NH2 6.92 (5.95-7.90) 44 0.96 ±0.25 
3 [Lys
5
]N/OFQ(1-13)-NH2 6.50 (5.23-7.77) 117 0.81 ±0.09 
4 [Ser
5
]N/OFQ(1-13)-NH2 7.70 (6.28-9.12) 7 1.01 ±0.25 
5 [Asn
5
]N/OFQ(1-13)-NH2 8.41 (7.87-8.96) 1 0.78 ±0.11 
6 [His
5
]N/OFQ(1-13)-NH2 7.36 (6.59-8.12) 16 0.94 ±0.14 
7 [Phe
5
]N/OFQ(1-13)-NH2 7.38 (6.69-8.08) 15 0.84 ±0.19 
8 [Tyr
5
]N/OFQ(1-13)-NH2 7.75 (6.91-8.59) 7 0.85 ±0.14 
9 [Leu
5
]N/OFQ(1-13)-NH2 7.88 (7.11-8.66) 5 0.88 ±0.11 
10 [Val
5
]N/OFQ(1-13)-NH2 8.15 (7.31-8.99) 3 0.79 ±0.11 
11 [Ala
5
]N/OFQ(1-13)-NH2 7.24 (6.30-8.18) 22 0.84 ±0.13 
12 [Gly
5
]N/OFQ(1-13)-NH2 7.57 (7.19-7.94) 10 0.90 ±0.15 
13 [Pro
5
]N/OFQ(1-13)-NH2 6.88 (6.51-7.25) 49 0.84 ±0.14 
14 [Aib
5
]N/OFQ(1-13)-NH2 6.47 (5.66-7.28) 126 0.91 ±0.21 
15 [AlloThr
5
]N/OFQ(1-13)-NH2 7.81 (6.97-8.65) 6 0.88 ±0.15 
16 [Ac-Lys
5
]N/OFQ(1-13)-NH2 8.21 (7.80-8.61) 2 0.87 ±0.15 
17 [HoLys
5
]N/OFQ(1-13)-NH2 6.36 (5.34-7.38) 163 0.94 ±0.11 
18 [Orn
5
]N/OFQ(1-13)-NH2 6.61 (6.04-7.18) 92 0.82 ±0.11 
19 [Dab
5
]N/OFQ(1-13)-NH2 7.87 (7.46-8.28) 5 1.01 ±0.16 
20 [Dap
5
]N/OFQ(1-13)-NH2 7.66 (7.38-7.95) 8 1.08 ±0.14 
21 [Nle
5
]N/OFQ(1-13)-NH2 7.90 (7.05-8.75) 5 0.77 ±0.15 
22 [Nva
5
]N/OFQ(1-13)-NH2 8.01 (7.58-8.45) 4 0.94 ±0.09 
23 [Abu
5
]N/OFQ(1-13)-NH2 8.44 (8.06-8.82) 1 0.98 ±0.14 
24 [S-PipGly
5
]N/OFQ(1-13)-NH2 7.18 (6.87-7.50) 25 0.89 ±0.14 
25 [PipAla
5
]N/OFQ(1-13)-NH2 6.65 (6.24-7.06) 84 1.07 ±0.14 
26 [2-Pal
5
]N/OFQ(1-13)-NH2 7.79 (7.38-8.20) 6 0.91 ±0.17 
27 [3-Pal
5
]N/OFQ(1-13)-NH2 7.45 (6.89-8.01) 13 0.75 ±0.18 
28 [4-Pal
5
]N/OFQ(1-13)-NH2 7.31 (7.03-7.60)   18 0.90 ±0.17 
CR: concentration ratio, N/OFQ(1-13)-NH2 used as standard.  
α: maximal effect expressed as fraction of that of N/OFQ(1-13)-NH2 
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Table 22. Effects of N/OFQ, N/OFQ(1-13)-NH2 and its [X
5
] derivatives in calcium mobilization assay 
performed in CHOhNOP cells coexpressing the Gαqi5 protein. 
 Compound pEC50 (CL95%) CR α ±sem 
 N/OFQ 8.74 (8.57-8.92) 2 0.95 ±0.05 
 N/OFQ(1-13)-NH2 9.07(8.74-9.40) 1 1.00 
1 [Asp
5
]N/OFQ(1-13)-NH2 7.37 (7.18-7.55) 35 0.99 ±0.05 
2 [Arg
5
]N/OFQ(1-13)-NH2 7.02 (6.71-7.33) 159 0.75 ±0.03 
3 [Lys
5
]N/OFQ(1-13)-NH2 crc incomplete 
4 [Ser
5
]N/OFQ(1-13)-NH2 8.44 (7.79-9.09) 30 0.87 ±0.11 
5 [Asn
5
]N/OFQ(1-13)-NH2 8.72 (8.53-8.91) 2 1.03 ±0.06 
6 [His
5
]N/OFQ(1-13)-NH2 7.87 (7.45-8.29) 22 0.79 ±0.05 
7 [Phe
5
]N/OFQ(1-13)-NH2 7.24 (6.94-7.54) 48 0.99 ±0.00 
8 [Tyr
5
]N/OFQ(1-13)-NH2 7.60 (7.37-7.82) 21 0.94 ±0.06 
9 [Leu
5
]N/OFQ(1-13)-NH2 8.03 (7.17-8.88) 8 0.96 ±0.02 
10 [Val
5
]N/OFQ(1-13)-NH2 8.65 (7.81-9.50) 2 0.79 ±0.13 
11 [Ala
5
]N/OFQ(1-13)-NH2 7.71 (7.30-8.13) 16 0.90 ±0.08 
12 [Gly
5
]N/OFQ(1-13)-NH2 8.01 (7.83-8.19) 8 0.97 ±0.06 
13 [Pro
5
]N/OFQ(1-13)-NH2 6.04 (5.53-6.55) 760 0.85 ±0.05 
14 [Aib
5
]N/OFQ(1-13)-NH2 6.44 (6.09-6.79) 300 0.90 ±0.04 
15 [AlloThr
5
]N/OFQ(1-13)-NH2 7.13 (6.75-7.51) 62 0.96 ±0.01 
16 [Ac-Lys
5
]-N/OFQ(1-13)-NH2 8.61 (7.44-9.78) 4 0.74 ±0.14 
17 [HoLys
5
]N/OFQ(1-13)-NH2 6.61 (6.28-6.94) 406 0.71 ±0.03 
18 [Orn
5
]N/OFQ(1-13)-NH2 6.44 (6.18-6.70) 597 0.66 ±0.10 
19 [Dab
5
]N/OFQ(1-13)-NH2 7.82 (7.43-8.21) 25 0.64 ±0.05 
20 [Dap
5
]N/OFQ(1-13)-NH2 7.86 (7.33-8.39) 23 0.67 ±0.06 
21 [Nle
5
]N/OFQ(1-13)-NH2 8.91 (8.74-9.07) 2 0.86 ±0.01 
22 [Nva
5
]N/OFQ(1-13)-NH2 8.78 (8.35-9.21) 3 0.88 ±0.04 
23 [Abu
5
]N/OFQ(1-13)-NH2 8.80 (8.55-9.05) 3 0.90 ±0.13 
24 [S-PipGly
5
]N/OFQ(1-13)-NH2 6.95 (6.26-7.63) 187 0.95 ±0.08 
25 [PipAla
5
]N/OFQ(1-13)-NH2 6.33 (6.11-6.56) 773 0.74 ±0.05 
26 [2-Pal
5
]N/OFQ(1-13)-NH2 7.65 (7.35-7.95) 37 0.81 ±0.05 
27 [3-Pal
5
]N/OFQ(1-13)-NH2 7.57 (6.85-8.29) 45 0.80 (±0.06) 
28 [4-Pal
5
]-N/OFQ(1-13)-NH2 8.05 (7.64-8.46) 15 0.69 (±0.05) 
CR: concentration ratio, N/OFQ(1-13)-NH2 used as standard.  
α: maximal effect expressed as fraction of that of N/OFQ(1-13)-NH2 
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Figure 44. Correlation between agonist potency (pEC50) of N/OFQ, N/OFQ(1-13)-NH2 and its [X
5
] 
derivatives at the human NOP receptor obtained in the [
35S]GTPγS binding and the calcium mobilization 
assays. 
 
This study investigated the structure activity relationships of N/OFQ Thr
5
. The shortest sequence 
maintaining the same potency and efficacy of the natural peptide namely N/OFQ(1-13)-NH2 
(Calo et al., 1996; Guerrini et al., 1997) has been used as chemical template. 13 [X
5
]N/OFQ(1-
13)-NH2 derivatives were synthesized by substituting Thr
5
 with natural amino acid residues. A 
further 17 [X
5
]N/OFQ(1-13)-NH2 derivatives were obtained using unnatural amino acids. All 
these compounds were assessed pharmacologically for their activity at human NOP receptors 
using two different functional assays: [
35
S]GTPS binding in cell membranes and calcium 
mobilization in whole cells co-expressing a chimeric G protein. 
 
All the 28 [X
5
]N/OFQ(1-13)-NH2 derivatives produced maximal effects similar to those of the 
standard peptide in both the [
35
S]GTPS binding and the calcium mobilization assay, thus 
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consistently behaving as NOP receptor full agonists. This finding suggests that Thr
5
 is important 
for receptor binding but not for receptor activation. Moreover the rank order of agonist potency 
obtained in [
35
S]GTPS binding and the calcium mobilization assay was virtually superimposable 
(determination coefficient of the correlation is r
2
 = 0.82). This demonstrated that the 
pharmacological profile of the NOP receptor interacting with native Gi proteins and that of the 
same receptor artificially coupled with calcium signaling via the chimeric G protein is 
superimposable. In other words this result corroborates literature findings (Camarda et al., 2009) 
demonstrating that the artificial coupling does not affect the ligand recognition features of the 
NOP receptor.  
[X
5
]N/OFQ(1-13)-NH2 derivatives in which Thr
5
 was substituted with natural residues displayed 
very different potencies. In particular, the most detrimental results were obtained using charged 
amino acids either with acid (compound 1) or basic (compounds 2 and 3) side chains. In contrast 
the best results were obtained using hydrophilic non charged residues such as Asn (compound 5) 
or aliphatic branched side chain such as Val (compound 10). In addition, the replacement of the 
secondary alcoholic function of Thr with the primary alcoholic function of Ser (compound 4) 
caused a significant loss of potency. These findings suggest that the oxydryl group of Thr side 
chain is not crucial for receptor binding. However the spatial disposition of the alcoholic moiety 
of Thr may affect receptor binding. This is suggested by the loss of potency of compound 4 in 
which the primary alcoholic function is not chiral and of compound 15 in which the chirality of 
the side chain has been inverted. The replacement of Thr with aromatic residues as in compounds 
6-8 caused a loss of potency. Similar results were obtained using the smallest chiral residue Ala 
(compound 11). This confirms previous data obtained in classical Ala-scan studies (Dooley & 
Houghten, 1996; Reinscheid et al., 1996). The increase in peptide flexibility obtained using the 
non chiral residue Gly produced a moderate loss of potency. In contrast replacement of position 5 
with conformational inducer residues (the beta bend inducer Pro and the alpha helix inducer Aib) 
caused an important loss of potency. A similar conformational perturbation can be induced by 
using D residues and in line with the present findings it has been reported that [D-Thr
5
]N/OFQ 
shows an important loss of affinity and a dramatic loss of potency compared to the natural 
peptide sequence (Reinscheid et al., 1996). The huge effect of conformation inducing residues 
may probably be due to their interference with the formation of the beta bend centered on Gly
6
-
Ala
7
 sequence which has been reported to play an important role for N/OFQ biological activity 
(Amodeo et al., 2002). 
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Collectively these results suggest that the size of X
5
 side chain as well as its lipo / hydrophilic 
balance and hydrogen bond capability are not crucial for receptor binding. In contrast the 
presence of an ionizable side chain, particulary in the case of Lys, produced a dramatic loss of 
potency.  
In order to investigate in detail the reasons underlying the loss of potency induced by Thr/Lys 
replacement a series of [X
5
]N/OFQ(1-13)-NH2 derivatives generated using Lys analogues has 
been synthesized and assayed. The elimination of basic character of Lys by acetylation as in 
compound 16 restored ligand potency. This finding demonstrates that primary amino function of 
Lys side chain plays a crucial role in hindering receptor binding. Then we investigate the 
importance of the distance between the primary amino function and the peptide backbone. 
Increasing this distance as in compound 17 does not substantially affect ligand potency. 
However, reducing this distance by 1 to 3 carbon atoms (compounds 18-20) caused a progressive 
recovery of potency. In addition the elimination of the primary amino function from the side 
chain of Lys, Orn and Dab as in compounds 21-23 produced NOP ligands almost as potent as the 
standard peptide. Interestingly, the presence of a secondary amino function obtained by 
cyclization of the side chain of Orn and Lys, and as in compounds 24 and 25, respectively, 
generated ligands showing the same rank order of potency 24 > 25 displayed by their linear 
analogs 18 > 3. Collectively these findings demonstrated that both the presence of the basic 
amino function and its distance from the peptide backbone play a very important role in 
disrupting peptide receptor binding.  
Finally modulation of the distance from the peptide backbone of the nitrogen atom obtained with 
aromatic derivatives as in compounds 26-28 does not substantially affect ligand potency. This 
result is similar to that obtained with the natural aromatic residues Phe, Tyr and His. Thus, these 
findings corroborate the proposal that NOP receptor binding is sensitive to the spatial disposition 
of the positive charge of the basic nitrogen atom of the X
5
 residue.  
 
In conclusion this study investigated the structure activity relationship of the position 5 of N/OFQ 
sequence. The major findings of this investigation can be summarized as follows: i) position 5 
does not play a pivotal role in receptor activation; ii) the secondary alcoholic function of Thr is 
not important for receptor binding; iii) side chain size, lipo / hydrophilic balance as well as 
hydrogen bond capability are also not crucial for receptor binding; iv) an aliphatic amino function 
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positively charged with at least 3 carbon atom distance from the peptide backbone has a huge 
disrupting effect on receptor binding. 
This study in addition to extending our knowledge on the structure activity relationship of 
N/OFQ allowed the identification of N/OFQ(1-13)-NH2 derivatives (i.e. compound 23) as potent 
as the natural sequence. The presence of unnatural residues e.g. Abu in the peptide sequence may 
at least partially prevent enzymatic degradation thus generating longer lasting effects in vivo. 
Further studies are needed to validate this proposal.  
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3.3.4. Pharmacological characterization of nociceptin/orphanin FQ tetrabranched 
derivatives 
 
The present study was aimed to deeply investigate the pharmacological profile of three recently 
developed tetrabranched derivatives of N/OFQ (Guerrini et al., 2014). These synthetic peptides 
were generated with  an innovative chemical approach, named peptide welding technology 
(PWT), that allows the synthesis of multibranched peptides with extraordinary high yield, purity 
and reproducibility. The three N/OFQ derivatives have been named PWT1-N/OFQ, PWT2-
N/OFQ, and PWT3-N/OFQ. These compounds differ exclusively in the core used: (Lys)2-Lys-
NH2 for PWT1-N/OFQ, Cyclam for PWT2-N/OFQ, and (Lys)2-ethylendiamine for PWT3-
N/OFQ (Figure 45). The PWT N/OFQ derivatives activities were compared with those of the 
naturally occurring peptide in receptor binding, stimulation of [
35S]GTPγS binding, calcium 
mobilization, and electrically stimulated mVD assays. Results of the in vivo pharmacological 
activities of PWT derivatives of N/OFQ have been previously reported (Rizzi et al., 2014) 
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Figure 45. Chemical structures of PWT derivatives of N/OFQ. 
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Receptor binding - In CHONOP cell membranes N/OFQ displaced [
3
H]UFP-101 binding in a 
concentration depend manner showing high affinity (pKi 9.42). Similar results were obtained 
with PWT derivatives of N/OFQ that displayed however increased affinity by 5 (PWT3-N/OFQ) 
up to 15 (PWT1-N/OFQ) fold (Table 23). To investigate selectivity over classical opioid 
receptors similar experiments were performed using membranes obtained from CHO cells 
expressing the MOP, KOP and DOP human receptors and [
3
H]DPN as radioligand. N/OFQ up to 
1 µM did not bind KOP and DOP sites while displayed micromolar affinity at MOP (pKi 6.06). 
All PWT derivatives showed higher affinity than N/OFQ at classical opioid receptors, however 
their NOP selectivity (range 2570 – 14125 fold) was never inferior to that displayed by the 
natural peptide (2291 fold). In parallel experiments standard ligands for classical opioid receptors 
displayed the expected high affinity (morphine pKi 8.57 for MOP, Dmt-Tic pKi 8.87 for DOP, 
and norbinaltorphimine pKi 10.69 for KOP). 
 
Table 23 - Affinities of N/OFQ and its PWT derivatives in membranes of CHO cells expressing the human NOP or 
classical opioid receptors. 
 NOP MOP KOP DOP 
 pKi (CL95%) pKi (CL95%) pKi (CL95%) pKi (CL95%) 
N/OFQ 9.42 (9.23 - 9.57) 6.06 (5.80 - 6.32) < 6 < 6 
PWT1-N/OFQ 10.60 (10.10 - 11.10) 6.45 (6.21 - 6.69) 6.40 (6.01 - 6.79) 6.38 (6.07 - 6.69) 
PWT2-N/OFQ 10.30 (9.99 - 10.61) 6.60 (6.31 - 6.89) 6.36 (5.80 - 6.92) < 6 
PWT3-N/OFQ 10.10 (9.74 - 10.46) 6.69 (6.19 - 7.19)  6.33 (5.98 - 6.68) < 6 
Data are the mean of 3 separate experiments performed in duplicate. 
 
 
Stimulated [
35
S]GTPS binding - In CHONOP cell membranes N/OFQ stimulated [
35
S]GTPS 
binding in a concentration dependent manner with maximal effects equal to 3.5 ± 0.2 and pEC50 
of 8.84 (Figure 45, top panel). PWT derivatives of N/OFQ mimicked the stimulatory effect of the 
natural peptide showing similar maximal effects but higher potency (7-19 fold more potent than 
N/OFQ). In fact the pEC50 of PWT compounds were in the range 9.71 - 10.12 (Figure 45, top 
panel). 
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Calcium mobilization assay - In CHONOP cells stably expressing the Gαqi5 chimeric protein and 
human NOP recombinant receptor, N/OFQ and its PWT derivatives evoked a concentration 
dependent stimulation of calcium release (Figure 45, bottom panel). N/OFQ displayed high 
potency (pEC50 9.39) and maximal effects (237 ± 15% over the basal values). PWT derivatives of 
N/OFQ mimicked the peptide stimulatory effects showing similar maximal effects but slightly 
lower potency (pEC50 8.75 – 9.16) (Figure 45, bottom panel). Inhibition response experiments 
were performed by testing increasing concentrations (10 pM – 10 µM) of the standard NOP 
antagonist SB-612111 against a fixed concentration of agonist approximately corresponding to its 
EC80 (10 nM for N/OFQ and 30 nM for all PWT derivatives). SB-612111 concentration 
dependently inhibited the stimulatory effect of N/OFQ, displaying a pKB value of 8.01. Similar 
results were obtained challenging the antagonist against the stimulatory effect of PWT1-N/OFQ, 
PWT2-N/OFQ and PWT3-N/OFQ. pKB values of SB-612111 vs PWT compounds were in the 
range 7.82 – 8.23. 
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Figure 45 - Concentration response curves to N/OFQ and its PWT derivatives in [
35
S]GTPS 
binding experiments performed in CHONOP cell membranes (top panel) and in calcium mobilization 
experiments performed on CHO cells coexpressing the NOP receptor and the Gαqi5 chimeric protein 
(bottom panel). Data are mean ± sem of 4 experiments performed in duplicate.  
 
 
In order to assess the selectivity of action of PWT derivatives of N/OFQ, calcium mobilization 
experiments were also performed in cells expressing chimeric G protein and the classical opioid 
receptors MOP, DOP and KOP. In this series of experiments dermorphin, DPDPE and dynorphin 
A were used as standard agonists for MOP, DOP and KOP, respectively. Opioid ligands were all 
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inactive up to 1 µM in CHONOP cells (Table 23). In cells expressing the MOP receptor 
dermorphin evoked concentration dependent stimulatory effects with pEC50 of 9.29 and maximal 
effects of 135 ± 21 %. The stimulatory effects of dermorphin were mimicked by dynorphin A that 
was however approx. 300 fold less potent. In these cells DPDPE, N/OFQ and its PWT 
derivatives, were found inactive up to 1 µM. In cells expressing the DOP receptor DPDPE 
evoked concentration dependent stimulatory effects with pEC50 of 9.57 and maximal effects of 86 
± 14 %. Dynorphin A was also able to elicit calcium mobilization in these cells producing similar 
maximal effects but being approximately 100 fold less potent. All the other agonists were 
inactive up to 1 µM. Finally, in KOP cells dynorphin A stimulated calcium release in a 
concentration dependent manner with very high potency (pEC50 of 10.04) and maximal effects of 
225 ± 10 %. All other agonists were inactive in these cells.  
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Table 23 - Calcium mobilization studies. Potencies of N/OFQ, its PWT derivatives, and standard 
opioid agonists in CHO cells expressing the human NOP or classical opioid receptors and chimeric 
proteins. 
 NOP MOP DOP KOP 
 pEC50 (CL95%) pEC50 (CL95%) pEC50 (CL95%) pEC50 (CL95%) 
N/OFQ 9.39 (9.23 - 9.57) < 6 < 6 < 6 
PWT1-N/OFQ 8.75 (8.35 - 9.15) < 6 < 6 < 6 
PWT2-N/OFQ 8.83 (8.47 - 9.18) < 6 < 6 < 6 
PWT3-N/OFQ 9.16 (9.08 - 9.24) < 6 < 6 < 6 
Dermorphin < 6 9.29 (9.19 - 9.38) < 6 < 6 
DPDPE < 6 < 6 9.57 (9.03 - 10.11) < 6 
Dynorphin A < 6 6.76 (6.50 - 7.02) 7.63 (7.38 – 7.88) 10.04 (9.93 – 10.16) 
Data are the mean of 3 separate experiments performed in duplicate. 
 
 
Electrically stimulated isolated tissue experiments - PWT1-N/OFQ mimicked the inhibitory 
effect of N/OFQ producing similar maximal effects but showing approximately 3 fold higher 
potency (pEC50 7.85). Similar results were obtained by testing PWT2-N/OFQ and PWT3-
N/OFQ: both molecules elicited maximal effects similar to those of N/OFQ being more potent 
than the natural peptide (Figure 46). Interestingly enough, the inhibitory effect induced by 
N/OFQ takes place immediately after adding the peptide to the bath and was immediately 
reversible after washing the tissue (Figure 47). On the contrary, PWT1-N/OFQ induced a slower 
inhibitory effect which was rather resistant to washing (Figure 47). Superimposable results both 
in terms of slow kinetic and washing resistant effects were obtained with PWT2-N/OFQ and 
PWT3-N/OFQ (not shown).  
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Figure 46. Concentration response curves to N/OFQ, PWT1-N/OFQ, PWT2-N/OFQ and PWT3-
N/OFQ in the electrically stimulated mouse vas deferens. The values are means ± SEM of 4 separate 
experiments 
 
 
 
Figure 47. Typical tracings showing concentration response curves to N/OFQ and to PWT1-N/OFQ. 
Note the slow kinetic of PWT1-N/OFQ action and slow and incomplete reversal after washing 
 
Results and Discussion: novel NOP receptor ligands 
 
127 
 
The inhibitory effects elicited by equieffective concentrations of N/OFQ and PWT1-N/OFQ, that 
is, 30 and 10 nM, respectively was challenged versus the NOP antagonist SB-61211123 using a 
curative protocol. As shown in Figure 48 SB-612111 1 μM rapidly and fully reversed the 
inhibitory effect of N/OFQ and PWT1-N/OFQ. 
 
 
Figure 48. Typical tracings showing the curative effect of SB-612111 1 µM vs. the inhibitory action of 
equieffective concentrations of N/OFQ and to PWT1-N/OFQ. The bar graph summarizes the results obtained 
in 5 separate experiments.  
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In a separate series of experiments, concentration response curves to N/OFQ, PWT1-N/OFQ, 
PWT2-N/OFQ, and PWT3-N/OFQ were performed in the absence and presence of SB-612111. 
SB-612111 100 nM did not modify per se the control twitches but produced a rightward shift of 
the concentration response curve to N/OFQ without modifying the maximal effect induced by the 
agonist (Figure 49, top left panel). A pKB value of 8.48 was derived from these data. Similar 
findings were obtained by challenging SB-612111 versus PWT compounds. Of note the pKB 
value obtained for SB-612111 against PWT1-N/OFQ (8.02) was slightly lower than those 
obtained against N/OFQ or the other PWT compounds (Figure 49 and Table 24).  
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Figure 49. Concentration-response curve to N/OFQ (top left panel), PWT1-N/OFQ (top right panel), PWT2-
N/OFQ (bottom left panel) and PWT3-N/OFQ (bottom right panel) obtained in the absence (control) and in 
the presence of SB-612111 (100 nM) in the electrically stimulated mouse vas deferens. The values are means 
± SEM of at least 4 separate experiments. 
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Table 24. Agonist effects of N/OFQ and its PWT derivatives and antagonist potency of SB-612111 in the 
electrically stimulated mouse vas deferens. 
 Emax ± sem pEC50 (CL95%) 
pKB (CL95%) 
SB-612111 
N/OFQ 88±1 7.37 (7.29-7.45) 8.48 (8.19-8.77) 
PWT1-N/OFQ 89±1 7.85 (7.73-7.97) 8.02 (7.84-8.20) 
PWT2-N/OFQ 93±2 7.78 (7.57-7.99) 8.22 (7.61-8.83) 
PWT3-N/OFQ 85±2 8.08 (7.99-8.17) 8.33 (8.17-8.49) 
Data are mean of at least 4 separate experiments. 
 
 
In tissues taken from NOP(-/-) the inhibitory effects elicited by the natural peptide N/OFQ were 
no longer evident (Figure 50). In contrast the three PWT derivatives of N/OFQ maintained the 
ability to inhibit the electrically induced contractions in NOP(-/-) tissues showing however 
reduced potency by more than 10 fold for PWT1-N/OFQ and approximately 100 fold for PWT2-
N/OFQ and PWT3-N/OFQ (Figure 50). The selective DOP receptor agonist DPDPE produced 
similar inhibitory effects in NOP(+/+) and NOP(-/-) tissues showing high potency (pEC50 ≈ 8.5) 
and maximal effects (≈ 95 %) (data not shown). 
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Figure 50. Concentration response curve to N/OFQ and its PWT derivatives in electrically stimulated 
mouse vas deferens taken from NOP(+/+) and NOP(-/-) animals. Data are mean ± sem of 4 
experiments. 
 
 
The in vivo effects of PWT derivatives of N/OFQ have been evaluated on spontaneous locomotor 
activity and in food intake studies in mice (Guerrini et al., 2014; Rizzi et al., 2014). Without 
going into details, PWT derivatives showed, compared to N/OFQ, an increase in terms of potency 
in inhibiting the mice locomotor activity and in the orexigenic effects, and exhibited a prolonged 
duration of action, i.e. PWT2-N/OFQ showed a significant inhibitory effects after 24 hours of 
i.c.v. injection while N/OFQ was no more active. 
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Collectively, in this study we investigated the pharmacological profile of tetrabranched 
derivatives of N/OFQ generated using the PWT technology. In vitro experiments demonstrated 
that PWT compounds bound the NOP receptor with high affinity and behaved as full agonists 
both at human recombinant and animal native receptors. While NOP selectivity over classical 
opioid receptors was not affected, knockout studies in isolated tissues documented, compared to 
N/OFQ, a decline in selectivity of the PWT compounds, which was modest or moderate 
depending on the type of core. In vivo studies have confirmed the ability of PWT compounds to 
mimic the effects of N/OFQ and their higher potency. In addition the in vivo duration of action of 
PWT derivatives is far longer than that of N/OFQ. The results obtained in the present study, 
together with those published, demonstrated that the PWT technology can be successfully applied 
to the N/OFQ peptide sequence to generate novel NOP ligands that display compared to the 
natural peptide similar biological activity but extremely prolonged duration of action.  
In receptor binding studies performed on membranes obtained from cells stably expressing the 
human NOP receptor N/OFQ displayed subnanomolar affinity (pKi 9.42) in line with previous 
studies (9.62, (Camarda et al., 2009), 9.68, (Spagnolo et al., 2007)). PWT derivatives of N/OFQ 
concentration dependently displaced [
3
H]N/OFQ binding displaying higher affinity than N/OFQ 
by 3 to 10 fold. This result is in line with previous findings that showed that N/OFQ dendrimers 
displaced [
3
H]N/OFQ binding from rat brain membranes with 4.5 fold higher affinity than 
N/OFQ (Bracci et al., 2003). Similar results were also reported with multibranched derivatives of 
other peptide sequences including Leu-enkephalin (9 fold), Met-enkephalin (4 fold), and 
neurotensin(8-13) (12 fold) (Bracci et al., 2003). Even larger increases in affinity of 
multibranched peptides compared to the native peptide sequence, from 20 to 350 fold depending 
on the linker unit used, was reported in the case of melanocyte stimulating hormone (Brabez et 
al., 2011). However no differences were found when the full sequence of neurotensin was used 
(Bracci et al., 2003). Thus an increase in binding affinity of multibranched peptides compared to 
the natural sequences seems to be a rather general rule even if there are significant differences 
depending on the specific peptide sequence and the linker used. 
In functional assays performed on the human recombinant NOP receptor ([
35
S]GTPS binding 
and calcium mobilization) and at native NOP receptors expressed in the mouse vas deferens PWT 
compounds mimicked the actions of N/OFQ producing similar maximal effects. Thus PWT 
compounds always behave as NOP receptor full agonists. This applies to PWT1-N/OFQ, PWT2-
N/OFQ and PWT3-N/OFQ and therefore we can suggest that the different cores used for 
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generating these compounds have negligible if any impact on the ability of the peptide sequence 
to adopt the biologically active conformation responsible for full agonist pharmacological 
activity. 
As far as potency is concerned the following rank order of potency has been measured in the 
[
35
S]GTPS binding assay and mouse vas deferens assay PWT1-N/OFQ = PWT2-N/OFQ = 
PWT3-N/OFQ > N/OFQ. These results are in line with the increased affinity displayed by PWT 
compounds in binding studies. However an opposite result has been obtained in calcium 
mobilization studies where N/OFQ displayed a value of potency higher than those of PWT 
compounds. Since the rank order of agonist potency is considered the receptor fingerprint this 
discrepant result deserves attention. The calcium mobilization assay is based on the aberrant 
signaling generated by the chimeric Gαqi5 protein that forces the NOP receptor to signal via the 
calcium pathway. Therefore it is possible that the aberrant signaling may cause modifications of 
the pharmacological profile of the receptor. However the following considerations argue against 
this proposal. In a previous systematic study a large panel of NOP ligands, including full and 
partial agonists as well as antagonists, has been evaluated in the calcium assay and the results we 
obtained were superimposable to those of classical Gi based assays and tissues studies (Camarda 
et al., 2009). Moreover it is reasonable to assume that N/OFQ and PWT compounds interact with 
the binding pocket of the NOP receptor (whose 3D structure is now available (Thompson et al., 
2012)) with the same chemical structures i.e. the N/OFQ N-terminal tetrapeptide FGGF (Calo & 
Guerrini, 2013). Thus other reasons may account for the discrepant result. As mentioned in the 
results section, PWT compounds displayed in the mouse vas deferens slow kinetic of action 
compared to N/OFQ. Camarda and colleagues showed that the calcium mobilization assay tends 
to underestimate the potency of agonists characterized by a slow interaction with the NOP 
receptor (Camarda et al., 2009) such the peptides UFP-112 (Rizzi et al., 2007), UFP-113 (Arduin 
et al., 2007) and ZP120 (Rizzi et al., 2002) and the non peptide Ro 64-6198 (Rizzi et al., 2001). 
This phenomenon may derive from the non equilibrium conditions which characterize the 
calcium assay. In fact the relatively long time needed to obtain the full activation of the NOP 
receptor by slowly equilibrating agonists is not compatible with the rapid and transient nature of 
the calcium response. This may likely explain the underestimation of the potency of N/OFQ PWT 
derivatives in this assay. Interestingly Charlton and Vauquelin made simulations in two different 
experimental systems modeled to mimic the [
35
S]GTPS binding and the calcium assay with two 
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different agonists: a high affinity slowly associating ligand (L1) and a lower affinity fast onset 
ligand (L2). The simulation displayed an opposite rank order of potency of agonists in the two 
assays with L1 > L2 in the system mimicking the [
35
S]GTPS assay and L2 > L1 in the system 
mimicking the calcium assay (see for details Figure 4 of (Charlton & Vauquelin, 2010)). Thus the 
results of this simulation perfectly match our experimental data obtained with N/OFQ and its 
PWT derivatives; this suggests that the reversal of the rank order of agonist potency measured in 
the calcium assay may likely derive from kinetic artifacts.  
As far as receptor selectivity is concerned receptor binding and calcium mobilization studies 
demonstrated that the high selectivity of N/OFQ over classical opioid receptors is maintained by 
PWT derivatives. The molecular basis for the selectivity of action of NOP ligands over classical 
opioid receptors have been recently documented comparing the 3D crystal structure of these 
receptors (Filizola & Devi, 2013). In the NOP receptor binding pocket the N-terminal 
tetrapeptide of the N/OFQ related peptide UFP-101 (Nphe-Gly-Gly-Phe) make the same 
hydrophobic interactions as the aromatic rings of C-24 (the ligand used to generate the NOP 
crystal), and the N-terminal amino group forms a salt bridge with Asp 130 thus supporting a close 
similarity in the binding poses between small molecules and peptides (Thompson et al., 2012). 
Although this information is relative to the inactive form of these receptors (i.e. in complex with 
antagonists) most likely similar mechanisms regulate the interaction of N/OFQ with the NOP 
receptor and its selectivity over classical opioid receptor as discussed in detail in (Calo & 
Guerrini, 2013). These same molecular mechanisms are not affected by applying the PWT 
technology to the N/OFQ sequence since tetra branched derivatives of N/OFQ displayed similar 
selectivity over classical opioid receptor as N/OFQ itself.  
SB-612111 counteracted the inhibitory effect exerted by N/OFQ in the electrically stimulated vas 
deferens producing a rightward shift of the concentration response curve to N/OFQ without 
modifying its maximal effects and showing a pKB value of 8.48; this value of antagonist potency 
is superimposable to that previously reported in literature (8.50 (Spagnolo et al., 2007)). Similar 
results were obtained by challenging SB-612111 against PWT-N/OFQ compounds both in terms 
of competitive interaction and antagonist potency. This result demonstrated that the action of 
PWT-N/OFQ compounds derives from their ability to bind and activate the NOP receptor. In 
other words, these findings suggest that PWT-N/OFQ compounds do not lose the high selectivity 
of action of the natural peptide N/OFQ. Of note the potency of SB-612111 against PWT1-N/OFQ 
was slightly lower. This may suggest that the NOP selectivity of this derivative is lower than that 
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of N/OFQ and the other PWT compounds. Thus PWT2 and PWT3 seem to be better than PWT1 
in terms of maintaining the high selectivity of action of the natural peptide sequence. 
For further clarifying the selectivity of action of PWT compounds, N/OFQ and its PWT 
derivatives were tested in tissues taken from NOP(+/+) and NOP(-/-) mice. The inhibitory effect 
exerted by N/OFQ in the electrically stimulated vas deferens of NOP(+/+) mice was no longer 
evident in tissues taken from NOP(-/-) animals. This is in line with findings previously obtained 
in NOP(-/-) mice (Carra et al., 2005; Rizzi et al., 2007) and in NOP(-/-) rats (Rizzi et al., 2011). 
In parallel experiments PWT derivatives of N/OFQ were still active in NOP(-/-) tissues although 
showing reduced potency from 20 (PWT1-N/OFQ) to more than 100 fold (PWT2-N/OFQ and 
PWT3-N/OFQ). These findings, together with the antagonism results, indicate that the absolute 
selectivity of N/OFQ seems to be affected by the application of the PWT technology and 
tetrabranched derivatives of N/OFQ are able to interact in this preparation at relatively high 
concentrations with an undefined receptor to inhibit the twitch response. Interestingly the loss of 
selectivity of tetrabranched peptides is moderate for PWT1-N/OFQ and modest for PWT2-
N/OFQ and PWT3-N/OFQ; thus it seems that the PWT2 and PWT3 cores are superior to PWT1 
in maintaining the selectivity of action of the natural sequence. Further studies are needed to 
investigate if this is a general phenomenon of if it depends on the specific peptide sequence used 
to generate the PWT derivatives. However the partial loss of selectivity displayed by PWT 
derivatives in the mouse vas deferens should not be overemphasized. In fact in this assay off 
target effects were reported for different non peptide NOP agonists. For instance Ro 64-6198 
(Jenck et al., 2000), the most extensively published non peptide NOP agonist (Shoblock, 2007), 
mimicked N/OFQ inhibitory effect in the mouse vas deferens. However in this preparation the 
effects of Ro 64-6198 could not be antagonized by selective NOP antagonists ([Nphe
1
]N/OFQ(1-
13)-NH2, J-113397) even in the presence of naloxone (Rizzi et al., 2001). Other molecules such 
as Ro 65-6570 (Wichmann et al., 2000) or SCH 221510 (Varty et al., 2008) were also able to 
inhibit the twitch response of the mouse vas deferens however their effects were not sensitive to 
the NOP antagonist J-113397 and their concentration response curves in NOP(+/+) and in NOP(-
/-) tissues were superimposable (Molinari et al., 2012).  
 
For evaluating the in vivo pharmacological activities of PWT derivatives of N/OFQ, the mouse 
locomotor activity (LA) assay was used in our laboratories. In the original article reporting its 
identification, N/OFQ was shown to inhibit LA after supraspinal administration (Reinscheid et 
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al., 1995). This was later confirmed in mice and rats in different laboratories (Lambert, 2008). 
However, some studies have reported biphasic effects of N/OFQ on LA with low doses 
producing stimulation and high doses producing inhibition (Florin et al., 1996). The exclusive 
involvement of the NOP receptor in this action of N/OFQ has been firmly demonstrated in both 
receptor antagonism and knockout studies (Calo and Guerrini, 2013). In the present study, in the 
first series of experiments we performed dose–response curves to N/OFQ and to its PWT 
derivatives by measuring the animal behaviour for 120 min. N/OFQ produced biphasic effects 
depending upon the dose and time. In particular, relatively low doses of peptide produced 
stimulatory effects, whereas high doses produced robust inhibitory effects during the first hour 
after administration and stimulatory effects during the second hour. A similar pattern of effects 
was measured in response to the supraspinal administration of PWT derivatives of N/OFQ, with 
the following major differences: agonist potency and onset and duration of action. The biphasic 
effect of N/OFQ on LA associated with the very different onset and duration of action of the 
natural peptide versus PWT derivatives makes the comparison of the dose–response curves and 
the calculation of agonist potency quite difficult. However, the profound inhibition of locomotor 
behavior obtained immediately after the injection of 10 nmol of N/OFQ and after 2 h (PWT2-
N/OFQ) or more (PWT1-N/OFQ and PWT3-N/OFQ) from the injection of PWT compounds 
suggests an approximate dose-ratio of 40. This increase in agonist potency is larger than that 
observed in in vitro studies. This may possibly derive from the lower susceptibility to peptidase 
action reported for multibranched peptides compared with the free peptide sequence. In fact, 
Bracci et al. (2003) demonstrated that N/OFQ was degraded within 2 h of incubation with serum 
or rat brain membranes, whereas a tetrabranched derivative of N/OFQ was still detectable after 
24 h. Interestingly, a structure-based hypothesis of branched peptide resistance to proteolysis has 
been proposed previously (Falciani et al., 2007b). Since peptide metabolism is likely to be more 
relevant in vivo than in vitro, it is reasonable to assume that the lower susceptibility to peptidase 
action contributes to the increased agonist potency displayed by these compounds in vivo. 
Another major difference between N/OFQ and PWT-N/OFQ action is the kinetic of action. The 
onset of PWT-N/OFQ action is delayed compared with that of N/OFQ and the duration of action 
seems to be longer. In fact, the inhibitory effects exerted by PWT compounds at the higher dose 
tested were more pronounced during the second than the first hour after injection. Interestingly, 
these in vivo differences parallel the kinetic of action of these compounds in vitro in the mVD 
where they mimicked N/OFQ actions but showed slower kinetic and wash-resistant effects. To 
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further investigate the duration of action of PWT derivatives of N/OFQ, an overnight experiment 
was performed where the effects of equieffective doses of N/OFQ and PWT derivatives were 
compared. The results of this experiment clearly demonstrate that N/OFQ produces short lasting 
effects, whereas those elicited by PWT derivatives lasted for the whole period of observation. To 
further investigate possible differences in the duration of action of PWT derivatives, animals 
were injected with the same doses and their LA was measured 24 h after injection. Mice treated 
with N/OFQ and PWT1-N/OFQ displayed a locomotor behaviour similar to that of saline treated 
animal, whereas mice treated with PWT3-N/OFQ displayed reduced LA, although the differences 
did not reach a statistical level of significance. In contrast, even after 24 h from the injection, 
mice treated with PWT2-N/OFQ displayed a statistically significant reduction in the horizontal 
and vertical activities and increase in immobility time. Collectively, these in vivo studies 
demonstrated that PWT compounds mimic the effects of N/OFQ on LA, but with higher potency 
and much longer duration of action. In particular, PWT2-N/OFQ was found to be the PWT 
derivative showing the longest duration of action. Thus, the PWT2 seems to be the best core in 
terms both of retaining the selectivity of action of the native peptide sequence and of increasing, 
by several fold, the in vivo duration of action. To investigate the involvement of the NOP 
receptor in the in vivo action of PWT2-N/OFQ, the effect of this compound on LA was assessed 
in NOP(+/+) and NOP(−/−) mice. PWT2-N/OFQ 250 pmol induced a robust inhibitory effect on 
LA of NOP(+/+) mice while being completely inactive in NOP(−/−) animals. This result clearly 
demonstrates that the action of PWT2-N/OFQ on LA, similar to what has previously been 
reported for N/OFQ (Nishi et al., 1997; Carra et al., 2005), is exclusively due to stimulation of 
NOP receptors. Collectively, the results from the in vitro and in vivo studies demonstrate that 
PWT2-N/OFQ is a full agonist of the NOP receptor characterized by high potency, good 
selectivity and remarkable in vivo duration of action. Among available ligands, the most potent 
and selective agonist for the NOP receptor is the peptide UFP-112, which was designed using a 
combination of several chemical modifications that increase NOP receptor affinity/potency 
and/or reduce susceptibility to enzymatic degradation (Rizzi et al., 2007; Calo et al., 2011). 
Compared with UFP-112, PWT2-N/OFQ displays slightly lower potency and selectivity of 
action. However, the duration of action of PWT2-N/OFQ is longer than that of UFP-112. In fact, 
the inhibitory effects of UFP-112 on LA lasted for about 6 h (Rizzi et al., 2007), whereas those 
elicited by PWT2-N/OFQ were still evident after 24 h from injection. In conclusion, the present 
study showed that the PWT can be successfully applied to the peptide sequence of N/OFQ to 
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generate tetrabranched derivatives characterized by a pharmacological profile similar to the 
native peptide, but associated with a higher potency and a marked prolongation of action in vivo. 
The compound PWT2-N/OFQ displayed good selectivity and the longest duration of action in 
vivo. This NOP receptor ligand is therefore proposed as a novel research tool particularly to 
investigate those conditions in which a prolonged activation of the NOP receptor may evoke 
beneficial effects. More generally, the PWT strategy may be easily used to generate innovative 
and interesting ligands for peptide GPCRs. Using the PWT2 core, we are planning to generate 
and study several PWT derivatives obtained with different peptide sequences characterized by 
diverse pharmacological activity (antagonist, partial and full agonists). The information coming 
from these studies will allow us to firmly establish the value of the PWT strategy for the 
generation of innovative ligands for peptide receptors. 
 
In conclusion, the in vitro studies demonstrated that PWT derivatives of N/OFQ behave as potent 
full agonists at human recombinant and animal native NOP receptors and display a profile of 
NOP selectivity which is inferior to that of N/OFQ but clearly superior to that of the available 
non peptide NOP agonists. In vivo results demonstrated confirmed high NOP selectivity and 
demonstrated high potency associated to extremely prolonged duration of action. In summary this 
study provide evidence that the PWT technology can be successfully applied to the peptide 
sequence of N/OFQ to generate tetrabranched derivatives characterized by a pharmacological 
profile similar to the native peptide associated with an higher potency and a marked prolongation 
of action in vivo. The compound PWT2-N/OFQ displayed good selectivity and the longest 
duration of action in vivo. PWT2-N/OFQ is therefore proposed as a novel research tool 
particularly to investigate those conditions in which a prolonged activation of the NOP receptor 
may evoke beneficial effects. 
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4. General conclusions  
 
This thesis summarized an intensive work aimed to a twofold aim: pharmacologically 
characterize novel ligands and set-up and validate innovative in vitro assays for investigating 
NOP and classical opioid receptors.  
 
In the frame of these studies both peptide and non peptide ligands have been investigated. 
Innovative ligands of peptide nature for targeting NOP and classical opioid receptors are certainly 
useful because of the well known pharmacodynamic advantages of peptides such as high potency 
associated to extraordinary selectivity of action. On the other hand peptides have poor 
pharmacokinetic properties due to their high molecular weight and low metabolic resistance. 
Thus, these compounds are extremely useful pharmacological tools but, at least in most of the 
cases, poor candidates as drug prototypes. Opposite considerations can be done for small 
molecules. In fact non peptide compounds display in general good pharmacokinetic properties 
such as capability to cross biological membranes including the blood brain barrier, high 
metabolic stability, good bioavalability, etc. On the other hand in most of the cases is difficult 
with small molecules to get high potency associated with high selectivity and this is often the 
reason underling off target side effects. However small molecules have been and still are the 
standard source for generating drug candidates.  
The calcium mobilization assay performed on cells expressing chimeric G proteins was used for 
investigating the pharmacological profile of several molecules acting as NOP or classical opioid 
receptor ligands. As far as opiates molecules are concerned, an intensive SAR work has been 
performed on morphine and oxymorphone, targeting position 17 and position 6 of morphine. 
These SAR studies led to the discovery of a novel and interesting MOP selective ligand (i.e. 14- 
methoxy-6-cyanomorphine) and contributed to increase the knowledge of morphine SAR within 
the three classical opioid receptors. Another SAR study has been conducted on endomorphin-2 
related cyclic pentapeptides. This study let to the identification of interesting mixed opioid 
receptor ligands based on the structure p-MePhe
4
 substituted cyclic EM-2 that displayed 
remarkable antinociceptive activity after supraspinal administration. As far as NOP ligands are 
concerned, it has been demonstrated that the non peptide compound NiK-21273 behaves as a 
highly potent, competitive, and selective NOP receptor antagonist. In addition this compound has 
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been used to confirm and extend evidence that NOP antagonist have therapeutic potential as 
novel drug for treating Parkinson disease. Always in the field non peptide NOP ligands three 
SAR studies were performed on spiroxatrine derivatives. These studies identified the role of 
different substituents in different positions for NOP receptor binding and activation. Some of 
these compounds displayed moderate potency acting as NOP receptor agonists. SAR studies were 
also performed on N/OFQ related peptides. In this field a systematic study of position Thr
5
 was 
performed by substituting this residue with natural and unnatural aminoacids. The results of this 
study suggest that position 5 does not play a pivotal role in receptor activation; the secondary 
alcoholic function of Thr is not important for receptor binding; side chain size, lipo/hydrophilic 
balance as well as hydrogen bond capability are also not crucial for receptor binding; an aliphatic 
amino function positively charged with at least 3 carbon atom distance from the peptide 
backbone has a huge disrupting effect on receptor binding. In conclusion this study demonstrated 
that a simple ethyl side chain is sufficient in N/OFQ position 5 for maintaining bioactivity. 
Always in the field of novel peptide ligands for the NOP receptor, in the present thesis we deeply 
investigated three tetrabranched derivatives of N/OFQ synthesized with an innovative chemical 
approach named PWT. PWT1-N/OFQ, PWT2-N/OFQ, and PWT3-N/OFQ are very interesting 
NOP ligands that maintain in vitro the same pharmacological profile of the natural peptide. 
Interestingly enough PWT derivatives mimicked the in vivo effects of N/OFQ on locomotor 
activity being more potent and displaying an extraordinary long lasting duration of action. 
Similar results were recently obtained by testing PWT2-N/OFQ as spinal analgesic in mice and 
non human primates (Rizzi et al., personal communication). A similar in vitro pharmacology 
associated with an increased in vivo potency and particularly duration of action seems to be a 
general feature of PTW derivative of peptide ligands. This is suggested by results obtained 
applying the PWT modification to different peptide sequences including natural tachykinins 
(substance P, neurokinin A and B) REF and neuropeptide S REF. Studies are under way to 
investigate the in vitro and in vivo pharmacology of PWT derivatives of other biologically active 
peptides including the DOP preferring agonist Leu-enkephalin, the MOP selective agonist 
dermorphin, the NOP selective antagonist UFP-101, and the universal opioid receptor agonist 
[Dmt
1
]N/OFQ(1-13)NH2. When the results of these ongoing studies will be available we may 
draw well grounded conclusions on the general value of PWT derivatives as innovative ligands 
for peptidergic receptors.   
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A parallel aim of the present thesis was to extend and validate the use of calcium mobilization 
assay performed on cells expressing chimeric G proteins for studying the classical opioid 
receptors. Cells expressing either MOP or KOP receptors and the Gαqi5 chimeric G protein, 
displayed satisfactory signal to noise ratios, while cells expressing the DOP receptor and the 
Gαqi5 have been put aside for cells expressing the most efficient GαqG66Di5 chimeric protein. A 
quite large panel of standard opioid ligands including full agonists and pure antagonists have 
been pharmacologically characterized in calcium mobilization experiments. Despite few cases 
where artifacts have been recognized (i.e. underestimation of the potency of  slow interacting 
agonists and unsurmountable behavior of slow dissociating competitive antagonists), the data 
obtained are robust and perfectly in line with literature results. This corroborate the validity of the 
calcium mobilization assay as primary screening test. The usefulness and convenience of the 
calcium mobilization assay applied to the field of NOP and classical opioid receptor 
pharmacology is convincingly demonstrated by the large list of compounds of different chemical 
nature evaluated in the present thesis and by the good match obtained by comparing the results of 
the calcium assay with those obtained with classical methods for investigating Gi coupled 
receptors. 
 
A BRET based assay was setup for investigating the ability of a panel of NOP receptor ligands of 
different pharmacological activity to promote or block NOP/G protein and NOP/arrestin 
interaction. NOP/G protein interaction studied in cell membranes allows a precise estimation of 
ligand potency and efficacy with values highly consistent with the known pharmacological 
profile of this receptor as determined with classical biochemical assays for Gi coupled receptors 
as well as with bioassay studies on animal tissues. The same panel of ligands displayed marked 
differences in the ability to promote NOP/β-arrestin 2 interactions. Full agonists displayed in 
general lower potency and some of them an inverted rank order of potency. This reversal in 
agonist order of potency strongly suggest biased agonism. Compounds acting as partial agonist at 
NOP/G-protein behaved as competitive antagonists at NOP/β-arrestin 2 and similar values of 
potency in the two assays. Antagonists displayed similar values of potency for NOP/Gβ1 and 
NOP/β-arrestin 2 interaction and perfectly the same rank order.  Thus this study represents the 
first attempt to investigate NOP receptor functional selectivity. Accumulating evidence in the 
field of GPCR including opioids suggests that functional selectivity and biased agonists might be 
a completely innovative strategy to dissociate the biological actions elicited by a selective ligand. 
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In other words biased agonists by maximizing beneficial effects and/or reducing side effects can 
be proposed as entirely novel class of more effective / safer drugs. N/OFQ via selective 
stimulation of the NOP receptor exerts multiple biological actions and several therapeutic 
indications has been proposed for NOP selective agonists (i.e. spinal analgesia, anxiolysis, cough, 
urinary incontinence) and antagonists (i.e. depression, Parkinson, sepsis). Clearly such a large 
panel of biological functions controlled by the N/OFQ/NOP receptor system may represents and 
important drawback in terms of drug development. Thus the identification of G protein and 
arrestin NOP receptor biased agonists together with the knowledge of which biological functions 
depend on NOP/G protein or NOP/arresting signaling may allow the scientific community to 
activate rational programs for the development of NOP biased agonist as innovative drugs. In this 
perspective our laboratory is going to activate SAR studies aimed at identify arresting biased 
agonists and to investigate the phenotype and the response to N/OFQ of β-arrestin 2 knockout 
mice in several behavioral assays.  
 
In summary the studies performed in the frame of my PhD project extend our knowledge on the 
pharmacological profile of NOP and classical opioid receptors, provided to the scientific 
community novel compounds, pharmacologically characterized in detail, to be used as research 
tools and possibly as drug prototypes, and made available novel pharmacological assays useful 
for selecting fully innovative drugs such as NOP receptor biased agonists. 
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